Results B-Claim
of I-Claim
this I-Claim
randomized I-Claim
study I-Claim
incorporating I-Claim
prospective I-Claim
QOL I-Claim
measurements I-Claim
suggested I-Claim
that I-Claim
in I-Claim
patients I-Claim
with I-Claim
locally I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
analyzing I-Claim
QOL I-Claim
data I-Claim
by I-Claim
either I-Claim
gender I-Claim
or I-Claim
performance I-Claim
status I-Claim
alone I-Claim
may I-Claim
not I-Claim
accurately I-Claim
reflect I-Claim
how I-Claim
these I-Claim
factors I-Claim
depend I-Claim
upon I-Claim
each I-Claim
another I-Claim
. I-Claim

Policy B-Claim
makers I-Claim
should I-Claim
consider I-Claim
the I-Claim
inclusion I-Claim
of I-Claim
exercise I-Claim
opportunities I-Claim
in I-Claim
cancer I-Claim
rehabilitation I-Claim
services I-Claim
. I-Claim

In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
who I-Claim
develop I-Claim
disease I-Claim
progression I-Claim
after I-Claim
treatment I-Claim
with I-Claim
nonsteroidal I-Claim
aromatase I-Claim
inhibitors I-Claim
, I-Claim
EVE I-Claim
+ I-Claim
EXE I-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
longer I-Claim
TDD I-Claim
in I-Claim
global I-Claim
HRQOL I-Claim
versus I-Claim
PBO I-Claim
+ I-Claim
EXE I-Claim
. I-Claim

Grade B-Claim
2 I-Claim
or I-Claim
higher I-Claim
acute I-Claim
toxicity I-Claim
was I-Claim
more I-Claim
common I-Claim
in I-Claim
the I-Claim
4 I-Claim
day I-Claim
group I-Claim
, I-Claim
approaching I-Claim
statistical I-Claim
significance I-Claim
. I-Claim

Quality B-Claim
of I-Claim
life I-Claim
during I-Claim
maintenance I-Claim
therapy I-Claim
with I-Claim
pemetrexed I-Claim
is I-Claim
similar I-Claim
to I-Claim
placebo I-Claim
, I-Claim
except B-Claim
for I-Claim
a I-Claim
small I-Claim
increase I-Claim
in I-Claim
loss I-Claim
of I-Claim
appetite I-Claim
, I-Claim
and I-Claim
significantly I-Claim
delayed I-Claim
worsening I-Claim
of I-Claim
pain I-Claim
and I-Claim
haemoptysis I-Claim
. I-Claim

Compared B-Claim
with I-Claim
the I-Claim
EP I-Claim
regimen I-Claim
, I-Claim
the I-Claim
PCDE I-Claim
regimen I-Claim
yielded I-Claim
higher I-Claim
response I-Claim
rates I-Claim
and I-Claim
better I-Claim
survival I-Claim
rates I-Claim
in I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
SCLC I-Claim
without I-Claim
affecting I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
of I-Claim
the I-Claim
patients I-Claim
during I-Claim
chemotherapy I-Claim
. I-Claim

For B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
SFI I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim

At B-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
women I-Claim
in I-Claim
all I-Claim
treatment I-Claim
groups I-Claim
report I-Claim
good I-Claim
emotional I-Claim
functioning I-Claim
but I-Claim
report I-Claim
decreased I-Claim
physical I-Claim
functioning I-Claim
, I-Claim
particularly I-Claim
among I-Claim
women I-Claim
who I-Claim
have I-Claim
a I-Claim
mastectomy I-Claim
or I-Claim
receive I-Claim
chemotherapy I-Claim
. I-Claim

Epoetin B-Claim
alfa I-Claim
administered I-Claim
at I-Claim
40,000 I-Claim
U I-Claim
once I-Claim
weekly I-Claim
( I-Claim
qw I-Claim
) I-Claim
to I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
receiving I-Claim
chemotherapy I-Claim
increases I-Claim
hemoglobin I-Claim
levels I-Claim
, I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
, I-Claim
and I-Claim
reduces I-Claim
transfusions I-Claim
. I-Claim

DC/CIK B-Claim
treatment I-Claim
is I-Claim
a I-Claim
safe I-Claim
and I-Claim
effective I-Claim
method I-Claim
for I-Claim
maintenance I-Claim
therapy I-Claim
of I-Claim
advanced I-Claim
non-small I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
. I-Claim

Although B-Claim
TMZ I-Claim
( I-Claim
both I-Claim
arms I-Claim
combined I-Claim
) I-Claim
did I-Claim
not I-Claim
show I-Claim
a I-Claim
clear I-Claim
benefit I-Claim
compared I-Claim
with I-Claim
PCV I-Claim
, I-Claim
comparison I-Claim
of I-Claim
the I-Claim
TMZ I-Claim
schedules I-Claim
demonstrated I-Claim
that I-Claim
the I-Claim
21-day I-Claim
schedule I-Claim
was I-Claim
inferior I-Claim
to I-Claim
the I-Claim
5-day I-Claim
schedule I-Claim
in I-Claim
this I-Claim
setting I-Claim
. I-Claim

It B-Claim
is I-Claim
a I-Claim
safe I-Claim
, I-Claim
effective I-Claim
and I-Claim
durable I-Claim
treatment I-Claim
for I-Claim
vasomotor I-Claim
symptoms I-Claim
secondary I-Claim
to I-Claim
long-term I-Claim
antiestrogen I-Claim
hormone I-Claim
use I-Claim
in I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Amenorrhea B-Claim
rates I-Claim
differed I-Claim
significantly I-Claim
by I-Claim
treatment I-Claim
arm I-Claim
, I-Claim
with I-Claim
the I-Claim
AT I-Claim
arm I-Claim
having I-Claim
the I-Claim
lowest I-Claim
rate I-Claim
. I-Claim

FJD B-Claim
combined I-Claim
chemotherapy I-Claim
could I-Claim
effectively I-Claim
improve I-Claim
the I-Claim
QOL I-Claim
of I-Claim
solid I-Claim
tumor I-Claim
children I-Claim
patients I-Claim
, I-Claim
elevate I-Claim
their I-Claim
survival I-Claim
rate I-Claim
, I-Claim
and I-Claim
prolong I-Claim
their I-Claim
life I-Claim
spans I-Claim
. I-Claim

The B-Claim
superiority I-Claim
of I-Claim
combination I-Claim
therapy I-Claim
over I-Claim
monochemotherapy I-Claim
has I-Claim
not I-Claim
been I-Claim
demonstrated I-Claim
convincingly I-Claim
. I-Claim

The B-Claim
incidence I-Claim
and I-Claim
development I-Claim
of I-Claim
cancer I-Claim
are I-Claim
closely I-Claim
related I-Claim
to I-Claim
dysfunction I-Claim
of I-Claim
immune I-Claim
function I-Claim
. I-Claim

The B-Claim
IMPACT I-Claim
collaborative I-Claim
care I-Claim
program I-Claim
appears I-Claim
to I-Claim
be I-Claim
feasible I-Claim
and I-Claim
effective I-Claim
for I-Claim
depression I-Claim
among I-Claim
older I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
diverse I-Claim
primary I-Claim
care I-Claim
settings I-Claim
. I-Claim

Hormone B-Claim
replacement I-Claim
therapy I-Claim
is I-Claim
often I-Claim
either I-Claim
undesirable I-Claim
or I-Claim
contraindicated I-Claim
. I-Claim

Monthly B-Claim
infusion I-Claim
of I-Claim
pamidronate I-Claim
30 I-Claim
mg I-Claim
should I-Claim
be I-Claim
the I-Claim
recommended I-Claim
dose I-Claim
for I-Claim
prevention I-Claim
of I-Claim
bone I-Claim
disease I-Claim
in I-Claim
patients I-Claim
with I-Claim
multiple I-Claim
myeloma I-Claim
. I-Claim

Morbidity B-Claim
associated I-Claim
with I-Claim
wound I-Claim
complications I-Claim
may I-Claim
translate I-Claim
into I-Claim
disability I-Claim
and I-Claim
quality-of-life I-Claim
disadvantages I-Claim
for I-Claim
patients I-Claim
treated I-Claim
with I-Claim
radiotherapy I-Claim
( I-Claim
RT I-Claim
) I-Claim
for I-Claim
soft I-Claim
tissue I-Claim
sarcoma I-Claim
( I-Claim
STS I-Claim
) I-Claim
of I-Claim
the I-Claim
extremities I-Claim
. I-Claim

There B-Claim
was I-Claim
no I-Claim
significant I-Claim
difference I-Claim
between I-Claim
the I-Claim
two I-Claim
schedules I-Claim
examined I-Claim
in I-Claim
terms I-Claim
of I-Claim
improvement I-Claim
in I-Claim
KP I-Claim
or I-Claim
QOL I-Claim
, I-Claim
but I-Claim
there I-Claim
seemed I-Claim
to I-Claim
be I-Claim
a I-Claim
trend I-Claim
in I-Claim
favor I-Claim
of I-Claim
the I-Claim
3w4 I-Claim
schedule I-Claim
. I-Claim

In B-Claim
fatigued I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
nurse-led I-Claim
monitoring I-Claim
and I-Claim
protocolized I-Claim
treatment I-Claim
of I-Claim
physical I-Claim
symptoms I-Claim
is I-Claim
effective I-Claim
in I-Claim
alleviating I-Claim
fatigue I-Claim
. I-Claim

Some B-Claim
studies I-Claim
have I-Claim
also I-Claim
suggested I-Claim
that I-Claim
gemcitabine I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
in I-Claim
such I-Claim
patients I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
the I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
by I-Claim
nurses I-Claim
should I-Claim
be I-Claim
seriously I-Claim
considered I-Claim
on I-Claim
oncology I-Claim
units I-Claim
. I-Claim

Vinorelbine B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

GC B-Claim
is I-Claim
as I-Claim
effective I-Claim
as I-Claim
PE I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression-free I-Claim
survival I-Claim
and I-Claim
has I-Claim
a I-Claim
toxicity I-Claim
profile I-Claim
more I-Claim
acceptable I-Claim
to I-Claim
patients I-Claim
. I-Claim

The B-Claim
clinical I-Claim
efficacy I-Claim
of I-Claim
pemetrexed I-Claim
and I-Claim
gemcitabine I-Claim
combined I-Claim
with I-Claim
cisplatin I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
previously I-Claim
untreated I-Claim
advanced I-Claim
NSCLC I-Claim
was I-Claim
roughly I-Claim
the I-Claim
same I-Claim
, I-Claim
but B-Claim
the I-Claim
adverse I-Claim
reactions I-Claim
decreased I-Claim
significantly I-Claim
in I-Claim
the I-Claim
PP I-Claim
group I-Claim
compared I-Claim
with I-Claim
those I-Claim
in I-Claim
the I-Claim
GP I-Claim
group I-Claim
. I-Claim

Short-term B-Claim
postoperative I-Claim
morbidity I-Claim
was I-Claim
similar I-Claim
in I-Claim
the I-Claim
two I-Claim
groups I-Claim
. I-Claim

Relapse B-Claim
after I-Claim
completing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
therapy I-Claim
is I-Claim
a I-Claim
persistent I-Claim
threat I-Claim
for I-Claim
women I-Claim
with I-Claim
hormone-responsive I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Nevertheless B-Claim
, I-Claim
both I-Claim
community I-Claim
settings I-Claim
were I-Claim
acceptable I-Claim
to I-Claim
and I-Claim
preferred I-Claim
by I-Claim
patients I-Claim
compared I-Claim
with I-Claim
hospital I-Claim
, I-Claim
were I-Claim
safe I-Claim
, I-Claim
with I-Claim
no I-Claim
detrimental I-Claim
impact I-Claim
on I-Claim
overall I-Claim
health-care I-Claim
costs I-Claim
. I-Claim

Patients B-Claim
given I-Claim
targeted I-Claim
intervention I-Claim
following I-Claim
a I-Claim
detailed I-Claim
clinical I-Claim
algorithm I-Claim
had I-Claim
better I-Claim
improvements I-Claim
in I-Claim
radiotherapy-induced I-Claim
gastrointestinal I-Claim
symptoms I-Claim
than I-Claim
did I-Claim
patients I-Claim
given I-Claim
usual I-Claim
care I-Claim
. I-Claim

It B-Claim
can I-Claim
be I-Claim
concluded I-Claim
that I-Claim
the I-Claim
tailored I-Claim
Pain I-Claim
Education I-Claim
Program I-Claim
is I-Claim
effective I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
in I-Claim
chronic I-Claim
pain I-Claim
. I-Claim

Older B-Claim
adult I-Claim
patients I-Claim
who I-Claim
received I-Claim
a I-Claim
multidisciplinary I-Claim
intervention I-Claim
to I-Claim
improve I-Claim
QOL I-Claim
while I-Claim
undergoing I-Claim
advanced I-Claim
cancer I-Claim
treatments I-Claim
benefited I-Claim
differently I-Claim
in I-Claim
some I-Claim
QOL I-Claim
domains I-Claim
, I-Claim
compared I-Claim
to I-Claim
younger I-Claim
adult I-Claim
patients I-Claim
. I-Claim

Oral B-Claim
doxifluridine I-Claim
with I-Claim
leucovorin I-Claim
shows I-Claim
a I-Claim
comparable I-Claim
therapeutic I-Claim
efficacy I-Claim
to I-Claim
intravenous I-Claim
5-FU I-Claim
regimen I-Claim
with I-Claim
high I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
postoperative I-Claim
adjuvant I-Claim
therapy I-Claim
. I-Claim

Distress B-Claim
reduction I-Claim
is I-Claim
highlighted I-Claim
as I-Claim
an I-Claim
important I-Claim
mechanism I-Claim
by I-Claim
which I-Claim
health I-Claim
can I-Claim
be I-Claim
improved I-Claim
. I-Claim

The B-Claim
two I-Claim
schedules I-Claim
are I-Claim
equivalent I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
response I-Claim
rate I-Claim
, I-Claim
median I-Claim
time-to-progression I-Claim
and I-Claim
overall I-Claim
survival I-Claim
. I-Claim

Of B-Claim
the I-Claim
three I-Claim
regimens I-Claim
tested I-Claim
, I-Claim
the I-Claim
combination I-Claim
of I-Claim
LV5FU2-irinotecan I-Claim
is I-Claim
the I-Claim
most I-Claim
promising I-Claim
and I-Claim
will I-Claim
be I-Claim
assessed I-Claim
in I-Claim
a I-Claim
phase I-Claim
III I-Claim
trial I-Claim
. I-Claim

Using B-Claim
video I-Claim
and I-Claim
print I-Claim
materials I-Claim
, I-Claim
with I-Claim
brief I-Claim
individualized I-Claim
training I-Claim
, I-Claim
effectively I-Claim
improved I-Claim
pain I-Claim
management I-Claim
over I-Claim
time I-Claim
for I-Claim
cancer I-Claim
patients I-Claim
of I-Claim
varying I-Claim
diagnostic I-Claim
and I-Claim
demographic I-Claim
groups I-Claim
. I-Claim

Therefore B-Claim
, I-Claim
this I-Claim
regimen I-Claim
is I-Claim
not I-Claim
recommended I-Claim
as I-Claim
standard I-Claim
of I-Claim
care I-Claim
treatment I-Claim
for I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Incorporating B-Claim
MRI-based I-Claim
dose-volume I-Claim
histogram I-Claim
analysis I-Claim
into I-Claim
the I-Claim
treatment I-Claim
planning I-Claim
process I-Claim
may I-Claim
reduce I-Claim
acute I-Claim
urinary I-Claim
morbidity I-Claim
after I-Claim
brachytherapy I-Claim
. I-Claim

There B-Claim
is I-Claim
no I-Claim
consensus I-Claim
on I-Claim
an I-Claim
accepted I-Claim
intervention I-Claim
that I-Claim
significantly I-Claim
reduces I-Claim
its I-Claim
severity I-Claim
. I-Claim

The B-Claim
observation I-Claim
that I-Claim
longer I-Claim
infusion I-Claim
produces I-Claim
more I-Claim
myelosuppression I-Claim
but I-Claim
does I-Claim
not I-Claim
yield I-Claim
higher I-Claim
response I-Claim
rates I-Claim
should I-Claim
lead I-Claim
to I-Claim
further I-Claim
studies I-Claim
to I-Claim
determine I-Claim
the I-Claim
optimal I-Claim
dose I-Claim
and I-Claim
schedule I-Claim
of I-Claim
this I-Claim
interesting I-Claim
new I-Claim
agent I-Claim
. I-Claim

Our B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
switching I-Claim
patients I-Claim
to I-Claim
adjuvant I-Claim
exemestane I-Claim
treatment I-Claim
after I-Claim
at I-Claim
least I-Claim
2 I-Claim
years I-Claim
of I-Claim
tamoxifen I-Claim
therapy I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
an I-Claim
advantage I-Claim
over I-Claim
continuing I-Claim
adjuvant I-Claim
tamoxifen I-Claim
treatment I-Claim
in I-Claim
terms I-Claim
of I-Claim
body I-Claim
composition I-Claim
. I-Claim

Erlotinib B-Claim
maintenance I-Claim
therapy I-Claim
significantly I-Claim
extends I-Claim
progression-free I-Claim
survival I-Claim
without I-Claim
compromising I-Claim
patient I-Claim
HRQoL I-Claim
in I-Claim
comparison I-Claim
with I-Claim
placebo I-Claim
, I-Claim
with I-Claim
some I-Claim
improvement I-Claim
in I-Claim
symptoms I-Claim
. I-Claim

Capecitabine/docetaxel B-Claim
was I-Claim
a I-Claim
cost-effective I-Claim
treatment I-Claim
in I-Claim
patients I-Claim
with I-Claim
anthracycline-pretreated I-Claim
advanced I-Claim
breast I-Claim
carcinoma I-Claim
, I-Claim
and I-Claim
had I-Claim
an I-Claim
incremental I-Claim
cost-effectiveness I-Claim
ratio I-Claim
that I-Claim
compares I-Claim
very I-Claim
favorably I-Claim
with I-Claim
that I-Claim
of I-Claim
many I-Claim
other I-Claim
oncology I-Claim
therapies I-Claim
. I-Claim

Dose-intensified B-Claim
EC I-Claim
does I-Claim
not I-Claim
provide I-Claim
a I-Claim
measurable I-Claim
therapeutic I-Claim
benefit I-Claim
over I-Claim
CEF I-Claim
as I-Claim
neoadjuvant I-Claim
chemotherapy I-Claim
for I-Claim
unselected I-Claim
locally I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

Docetaxel B-Claim
has I-Claim
shown I-Claim
activity I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim

SLN B-Claim
biopsy I-Claim
is I-Claim
an I-Claim
effective I-Claim
and I-Claim
well-tolerated I-Claim
procedure I-Claim
. I-Claim

The B-Claim
use I-Claim
of I-Claim
home-based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high-quality I-Claim
data I-Claim
. I-Claim

VC B-Claim
, I-Claim
GC I-Claim
, I-Claim
and I-Claim
TC I-Claim
are I-Claim
not I-Claim
superior I-Claim
to I-Claim
PC I-Claim
in I-Claim
terms I-Claim
of I-Claim
overall I-Claim
survival I-Claim
( I-Claim
OS I-Claim
) I-Claim
. I-Claim

LLLT B-Claim
was I-Claim
effective I-Claim
in I-Claim
improving I-Claim
the I-Claim
patient I-Claim
's I-Claim
subjective I-Claim
experience I-Claim
of I-Claim
OM I-Claim
and I-Claim
QOL I-Claim
in I-Claim
HNC I-Claim
patients I-Claim
receiving I-Claim
CRT I-Claim
. I-Claim

Tamoxifen B-Claim
( I-Claim
TMX I-Claim
) I-Claim
is I-Claim
believed I-Claim
to I-Claim
inhibit I-Claim
HCC I-Claim
positive I-Claim
for I-Claim
estrogen I-Claim
receptor I-Claim
( I-Claim
ER I-Claim
) I-Claim
, I-Claim
but I-Claim
most I-Claim
HCCs I-Claim
are I-Claim
ER I-Claim
negative I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
VNR I-Claim
on I-Claim
day I-Claim
1-8 I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
may I-Claim
be I-Claim
considered I-Claim
as I-Claim
a I-Claim
reference I-Claim
regimen I-Claim
for I-Claim
the I-Claim
treatment I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
disease I-Claim
and I-Claim
those I-Claim
who I-Claim
deserve I-Claim
a I-Claim
postoperative I-Claim
therapy I-Claim
, I-Claim
and I-Claim
for I-Claim
future I-Claim
studies I-Claim
. I-Claim

In B-Claim
conclusion I-Claim
, I-Claim
treatment I-Claim
with I-Claim
carboplatin I-Claim
and I-Claim
etoposide I-Claim
can I-Claim
improve I-Claim
both I-Claim
the I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
the I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

AT B-Claim
significantly I-Claim
improves I-Claim
TTP I-Claim
and I-Claim
ORR I-Claim
compared I-Claim
with I-Claim
AC I-Claim
in I-Claim
patients I-Claim
with I-Claim
MBC I-Claim
, I-Claim
but B-Claim
there I-Claim
is I-Claim
no I-Claim
difference I-Claim
in I-Claim
OS I-Claim
. I-Claim

Genotypes B-Claim
of I-Claim
glutathione-related I-Claim
enzymes I-Claim
, I-Claim
especially I-Claim
GCLC I-Claim
, I-Claim
may I-Claim
be I-Claim
used I-Claim
as I-Claim
host I-Claim
factors I-Claim
in I-Claim
predicting I-Claim
patients I-Claim
' I-Claim
survival I-Claim
after I-Claim
platinum-based I-Claim
chemotherapy I-Claim
. I-Claim

These B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every-2-weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim

Findings B-Claim
suggest I-Claim
that I-Claim
self-efficacy I-Claim
may I-Claim
influence I-Claim
long-term I-Claim
maintenance I-Claim
of I-Claim
healthy I-Claim
lifestyle I-Claim
practices I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim

The B-Claim
study I-Claim
fails I-Claim
to I-Claim
demonstrate I-Claim
efficacy I-Claim
of I-Claim
dl-alpha I-Claim
tocopheryl I-Claim
acetate I-Claim
plus I-Claim
pentoxifylline I-Claim
in I-Claim
patients I-Claim
with I-Claim
arm I-Claim
lymphoedema I-Claim
following I-Claim
axillary I-Claim
surgery I-Claim
and I-Claim
lymphatic I-Claim
radiotherapy I-Claim
, I-Claim
nor I-Claim
does I-Claim
it I-Claim
suggest I-Claim
any I-Claim
benefits I-Claim
of I-Claim
these I-Claim
drugs I-Claim
in I-Claim
radiation-induced I-Claim
induration I-Claim
( I-Claim
fibrosis I-Claim
) I-Claim
in I-Claim
the I-Claim
breast I-Claim
, I-Claim
chest I-Claim
wall I-Claim
, I-Claim
pectoral I-Claim
fold I-Claim
, I-Claim
axilla I-Claim
or I-Claim
supraclavicular I-Claim
fossa I-Claim
. I-Claim

Clinical B-Claim
interventions I-Claim
to I-Claim
address I-Claim
common I-Claim
symptoms I-Claim
associated I-Claim
with I-Claim
treatment I-Claim
should I-Claim
be I-Claim
considered I-Claim
to I-Claim
improve I-Claim
physical I-Claim
and I-Claim
emotional I-Claim
functioning I-Claim
at I-Claim
the I-Claim
end I-Claim
of I-Claim
primary I-Claim
treatment I-Claim
for I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

The B-Claim
addition I-Claim
of I-Claim
ASA404 I-Claim
to I-Claim
carboplatin I-Claim
and I-Claim
paclitaxel I-Claim
, I-Claim
although I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
, I-Claim
failed I-Claim
to I-Claim
improve I-Claim
frontline I-Claim
efficacy I-Claim
in I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim

Maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
Asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
without I-Claim
progression I-Claim
after I-Claim
first-line I-Claim
chemotherapy I-Claim
. I-Claim

Analyses B-Claim
by I-Claim
bortezomib I-Claim
dose I-Claim
intensity I-Claim
indicated I-Claim
better I-Claim
HRQoL I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
lower I-Claim
dose I-Claim
intensity I-Claim
. I-Claim

In B-Claim
endocrine I-Claim
therapy I-Claim
trials I-Claim
in I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
patients I-Claim
with I-Claim
response I-Claim
( I-Claim
complete I-Claim
response/partial I-Claim
response I-Claim
[ I-Claim
CR/PR I-Claim
] I-Claim
) I-Claim
and I-Claim
patients I-Claim
with I-Claim
stable I-Claim
disease I-Claim
for I-Claim
at I-Claim
least I-Claim
6 I-Claim
months I-Claim
( I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
have I-Claim
shown I-Claim
similar I-Claim
survival I-Claim
and I-Claim
therefore I-Claim
are I-Claim
often I-Claim
defined I-Claim
as I-Claim
a I-Claim
population I-Claim
with I-Claim
clinical I-Claim
benefit I-Claim
( I-Claim
patients I-Claim
with I-Claim
CR/PR I-Claim
or I-Claim
SD I-Claim
( I-Claim
6m I-Claim
) I-Claim
) I-Claim
. I-Claim

Hormone B-Claim
replacement I-Claim
therapy I-Claim
increases I-Claim
cardiovascular I-Claim
and I-Claim
thromboembolic I-Claim
risk I-Claim
when I-Claim
started I-Claim
many I-Claim
years I-Claim
after I-Claim
the I-Claim
menopause I-Claim
. I-Claim

Global B-Claim
health I-Claim
status/QOL I-Claim
substantially I-Claim
improved I-Claim
with I-Claim
ECF I-Claim
and I-Claim
remained I-Claim
similar I-Claim
to I-Claim
baseline I-Claim
with I-Claim
both I-Claim
docetaxel I-Claim
regimens I-Claim
. I-Claim

Switching B-Claim
to I-Claim
anastrozole I-Claim
strongly I-Claim
decreased I-Claim
the I-Claim
endometrial I-Claim
thickness I-Claim
and I-Claim
uterine I-Claim
volume I-Claim
but I-Claim
increased I-Claim
sexual I-Claim
disturbances I-Claim
. I-Claim

Given B-Claim
the I-Claim
results I-Claim
of I-Claim
the I-Claim
TEAM I-Claim
trial I-Claim
, I-Claim
upfront I-Claim
use I-Claim
of I-Claim
tamoxifen I-Claim
followed I-Claim
by I-Claim
an I-Claim
aromatase I-Claim
inhibitor I-Claim
( I-Claim
AI I-Claim
) I-Claim
may I-Claim
be I-Claim
an I-Claim
important I-Claim
option I-Claim
for I-Claim
adjuvant I-Claim
endocrine I-Claim
therapy I-Claim
in I-Claim
Japanese I-Claim
postmenopausal I-Claim
women I-Claim
. I-Claim

Aerobic B-Claim
exercise I-Claim
and I-Claim
psychosocial I-Claim
interventions I-Claim
have I-Claim
been I-Claim
shown I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
this I-Claim
symptom I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
. I-Claim

HDC B-Claim
has I-Claim
a I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QOL I-Claim
even I-Claim
after I-Claim
treatment I-Claim
phase I-Claim
. I-Claim

In B-Claim
women I-Claim
with I-Claim
symptomatic I-Claim
fibroids I-Claim
, I-Claim
the I-Claim
faster I-Claim
recovery I-Claim
after I-Claim
embolization I-Claim
must I-Claim
be I-Claim
weighed I-Claim
against I-Claim
the I-Claim
need I-Claim
for I-Claim
further I-Claim
treatment I-Claim
in I-Claim
a I-Claim
minority I-Claim
of I-Claim
patients I-Claim
. I-Claim

The B-Claim
3-hour I-Claim
infusion I-Claim
of I-Claim
Taxol I-Claim
is I-Claim
safe I-Claim
when I-Claim
given I-Claim
with I-Claim
premedication I-Claim
and I-Claim
is I-Claim
associated I-Claim
with I-Claim
less I-Claim
neutropenia I-Claim
. I-Claim

Replacement B-Claim
of I-Claim
most I-Claim
hospital I-Claim
follow-up I-Claim
visits I-Claim
in I-Claim
the I-Claim
first I-Claim
year I-Claim
after I-Claim
breast I-Claim
cancer I-Claim
treatment I-Claim
by I-Claim
nurse-led I-Claim
telephone I-Claim
follow-up I-Claim
does I-Claim
not I-Claim
impede I-Claim
patient I-Claim
outcomes I-Claim
. I-Claim

It B-Claim
should I-Claim
probably I-Claim
not I-Claim
be I-Claim
tested I-Claim
further I-Claim
, I-Claim
but B-Claim
its I-Claim
antimetabolite I-Claim
schedules I-Claim
and I-Claim
frequent I-Claim
drug I-Claim
administration I-Claim
( I-Claim
ie I-Claim
, I-Claim
dose I-Claim
density I-Claim
) I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
development I-Claim
of I-Claim
new I-Claim
regimens I-Claim
. I-Claim

The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim

In B-Claim
cachectic I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
, I-Claim
oral I-Claim
melatonin I-Claim
20 I-Claim
mg I-Claim
at I-Claim
night I-Claim
did I-Claim
not I-Claim
improve I-Claim
appetite I-Claim
, I-Claim
weight I-Claim
, I-Claim
or I-Claim
quality I-Claim
of I-Claim
life I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
. I-Claim

On B-Claim
the I-Claim
basis I-Claim
of I-Claim
HRQOL I-Claim
results I-Claim
, I-Claim
the I-Claim
authors I-Claim
determined I-Claim
that I-Claim
UAE I-Claim
is I-Claim
a I-Claim
good I-Claim
alternative I-Claim
to I-Claim
hysterectomy I-Claim
. I-Claim

MA.17 B-Claim
showed I-Claim
that I-Claim
letrozole I-Claim
is I-Claim
extremely I-Claim
well-tolerated I-Claim
relative I-Claim
to I-Claim
placebo I-Claim
. I-Claim

Although B-Claim
it I-Claim
is I-Claim
premature I-Claim
to I-Claim
make I-Claim
any I-Claim
determination I-Claim
as I-Claim
to I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
the I-Claim
interventions I-Claim
tested I-Claim
in I-Claim
this I-Claim
feasibility I-Claim
study I-Claim
, I-Claim
these B-Claim
results I-Claim
indicate I-Claim
that I-Claim
pursuing I-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
model I-Claim
, I-Claim
as I-Claim
well I-Claim
as I-Claim
standard I-Claim
IIIs I-Claim
, I-Claim
may I-Claim
be I-Claim
fruitful I-Claim
areas I-Claim
of I-Claim
future I-Claim
research I-Claim
. I-Claim

Subjective B-Claim
benefit I-Claim
after I-Claim
intravenous I-Claim
pamidronate I-Claim
is I-Claim
confirmed I-Claim
in I-Claim
this I-Claim
placebo-controlled I-Claim
study I-Claim
. I-Claim

Thus B-Claim
, I-Claim
docetaxel-carboplatin I-Claim
represents I-Claim
an I-Claim
alternative I-Claim
first-line I-Claim
chemotherapy I-Claim
regimen I-Claim
for I-Claim
patients I-Claim
with I-Claim
newly I-Claim
diagnosed I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim

Patients B-Claim
who I-Claim
underwent I-Claim
gastric I-Claim
tube I-Claim
reconstruction I-Claim
develop I-Claim
less I-Claim
postoperative I-Claim
digestive I-Claim
tract I-Claim
complications I-Claim
, I-Claim
and I-Claim
have I-Claim
a I-Claim
quicker I-Claim
recovery I-Claim
and I-Claim
a I-Claim
better I-Claim
QoL I-Claim
during I-Claim
the I-Claim
follow-up I-Claim
period I-Claim
. I-Claim

rhTSH B-Claim
preserves I-Claim
QoL I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
RRA I-Claim
with I-Claim
similar I-Claim
rates I-Claim
of I-Claim
ablation I-Claim
success I-Claim
compared I-Claim
to I-Claim
hypothyrodism I-Claim
. I-Claim

Both B-Claim
the I-Claim
III I-Claim
+ I-Claim
ISG I-Claim
and I-Claim
III-only I-Claim
demonstrated I-Claim
pre-post I-Claim
reductions I-Claim
in I-Claim
depressive I-Claim
symptoms I-Claim
and I-Claim
high I-Claim
rates I-Claim
of I-Claim
utilization I-Claim
compared I-Claim
with I-Claim
other I-Claim
web-based I-Claim
treatments I-Claim
for I-Claim
depression I-Claim
. I-Claim

Our B-Claim
preliminary I-Claim
data I-Claim
suggest I-Claim
that I-Claim
rhDNase I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
study I-Claim
primary I-Claim
endpoints I-Claim
of I-Claim
QOL I-Claim
measures I-Claim
compared I-Claim
with I-Claim
the I-Claim
placebo I-Claim
group I-Claim
. I-Claim

In B-Claim
advanced I-Claim
not I-Claim
selected I-Claim
NSCLC I-Claim
chemotherapy I-Claim
achieved I-Claim
an I-Claim
advantage I-Claim
of I-Claim
approximately I-Claim
1-2 I-Claim
months I-Claim
on I-Claim
median I-Claim
survival I-Claim
versus I-Claim
best I-Claim
supportive I-Claim
care I-Claim
. I-Claim

A B-Claim
combination I-Claim
regimen I-Claim
of I-Claim
MA I-Claim
and I-Claim
thalidomide I-Claim
is I-Claim
more I-Claim
effective I-Claim
than I-Claim
MA I-Claim
alone I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
CACS I-Claim
. I-Claim

The B-Claim
new I-Claim
bone I-Claim
resorption I-Claim
markers I-Claim
of I-Claim
collagen I-Claim
breakdown I-Claim
were I-Claim
able I-Claim
to I-Claim
predict I-Claim
clinical I-Claim
response I-Claim
to I-Claim
pamidronate I-Claim
. I-Claim

Intraperitoneal B-Claim
administration I-Claim
limits I-Claim
cardiotoxicity I-Claim
of I-Claim
verapamil I-Claim
. I-Claim

The B-Claim
high I-Claim
effectiveness I-Claim
observed I-Claim
could I-Claim
be I-Claim
attributed I-Claim
in I-Claim
part I-Claim
to I-Claim
early I-Claim
treatment I-Claim
with I-Claim
epoetin I-Claim
alfa I-Claim
. I-Claim

With B-Claim
the I-Claim
exception I-Claim
of I-Claim
tumor I-Claim
hemorrhage-type I-Claim
events I-Claim
with I-Claim
gefitinib I-Claim
, I-Claim
the I-Claim
adverse I-Claim
event I-Claim
profiles I-Claim
were I-Claim
generally I-Claim
consistent I-Claim
with I-Claim
those I-Claim
previously I-Claim
observed I-Claim
. I-Claim

Women B-Claim
with I-Claim
breast I-Claim
cancer I-Claim
may I-Claim
have I-Claim
an I-Claim
even I-Claim
higher I-Claim
risk I-Claim
of I-Claim
depression I-Claim
particularly I-Claim
in I-Claim
a I-Claim
postmenopausal I-Claim
or I-Claim
estrogen I-Claim
deficiency I-Claim
state I-Claim
. I-Claim

This B-Claim
confirms I-Claim
that I-Claim
the I-Claim
two-drug I-Claim
combination I-Claim
NP I-Claim
is I-Claim
a I-Claim
reference I-Claim
treatment I-Claim
for I-Claim
metastatic I-Claim
NSCLC I-Claim
. I-Claim

The B-Claim
analgesic I-Claim
effects I-Claim
of I-Claim
amitriptyline I-Claim
were I-Claim
slight I-Claim
and I-Claim
associated I-Claim
with I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

The B-Claim
combination I-Claim
of I-Claim
day I-Claim
1-8 I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
3 I-Claim
weeks I-Claim
is I-Claim
less I-Claim
toxic I-Claim
and I-Claim
better I-Claim
tolerated I-Claim
than I-Claim
the I-Claim
regimen I-Claim
of I-Claim
weekly I-Claim
VNR I-Claim
plus I-Claim
CDDP I-Claim
every I-Claim
4 I-Claim
weeks I-Claim
. I-Claim

Previous B-Claim
trials I-Claim
have I-Claim
suggested I-Claim
a I-Claim
quality-of-life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
improvement I-Claim
for I-Claim
anemic I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
erythropoietin I-Claim
, I-Claim
but I-Claim
few I-Claim
used I-Claim
QOL I-Claim
as I-Claim
the I-Claim
primary I-Claim
outcome I-Claim
. I-Claim

HDCT B-Claim
was I-Claim
associated I-Claim
with I-Claim
more I-Claim
acute I-Claim
adverse I-Claim
effects I-Claim
. I-Claim

Darbepoetin B-Claim
alfa I-Claim
, I-Claim
when I-Claim
administered I-Claim
synchronously I-Claim
with I-Claim
chemotherapy I-Claim
, I-Claim
on I-Claim
an I-Claim
EDS I-Claim
appears I-Claim
to I-Claim
be I-Claim
similarly I-Claim
efficacious I-Claim
to I-Claim
darbepoetin I-Claim
alfa I-Claim
weekly I-Claim
dosing I-Claim
with I-Claim
no I-Claim
unexpected I-Claim
adverse I-Claim
events I-Claim
. I-Claim

Erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
Asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
SATURN I-Claim
population I-Claim
. I-Claim

AM B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim

More B-Claim
patients I-Claim
treated I-Claim
on I-Claim
4 I-Claim
consecutive I-Claim
days I-Claim
reported I-Claim
a I-Claim
clinically I-Claim
meaningful I-Claim
increase I-Claim
in I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
interpretation I-Claim
of I-Claim
these I-Claim
results I-Claim
is I-Claim
challenging I-Claim
due I-Claim
to I-Claim
baseline I-Claim
imbalance I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
. I-Claim

Postoperative B-Claim
adjuvant I-Claim
chemoradiation I-Claim
treatment I-Claim
after I-Claim
curative I-Claim
resection I-Claim
for I-Claim
rectal I-Claim
cancer I-Claim
was I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
recurrence I-Claim
and I-Claim
improve I-Claim
a I-Claim
survival I-Claim
rate I-Claim
. I-Claim

Although B-Claim
the I-Claim
ability I-Claim
of I-Claim
dignity I-Claim
therapy I-Claim
to I-Claim
mitigate I-Claim
outright I-Claim
distress I-Claim
, I-Claim
such I-Claim
as I-Claim
depression I-Claim
, I-Claim
desire I-Claim
for I-Claim
death I-Claim
or I-Claim
suicidality I-Claim
, I-Claim
has I-Claim
yet I-Claim
to I-Claim
be I-Claim
proven I-Claim
, I-Claim
its B-Claim
benefits I-Claim
in I-Claim
terms I-Claim
of I-Claim
self-reported I-Claim
end-of-life I-Claim
experiences I-Claim
support I-Claim
its I-Claim
clinical I-Claim
application I-Claim
for I-Claim
patients I-Claim
nearing I-Claim
death I-Claim
. I-Claim

However B-Claim
, I-Claim
it I-Claim
may I-Claim
be I-Claim
associated I-Claim
with I-Claim
more I-Claim
inconvenience I-Claim
in I-Claim
wound I-Claim
care I-Claim
and I-Claim
longer I-Claim
healing I-Claim
time I-Claim
than I-Claim
rhomboid I-Claim
excision I-Claim
and I-Claim
Lindberg I-Claim
flap I-Claim
. I-Claim

CBT B-Claim
and I-Claim
PE I-Claim
can I-Claim
have I-Claim
salutary I-Claim
effects I-Claim
on I-Claim
endocrine I-Claim
symptoms I-Claim
and I-Claim
, I-Claim
to I-Claim
a I-Claim
lesser I-Claim
degree I-Claim
, I-Claim
on I-Claim
sexuality I-Claim
and I-Claim
physical I-Claim
functioning I-Claim
of I-Claim
patients I-Claim
with I-Claim
breast I-Claim
cancer I-Claim
experiencing I-Claim
treatment-induced I-Claim
menopause I-Claim
. I-Claim

This B-Claim
translational I-Claim
intervention I-Claim
trial I-Claim
, I-Claim
delivered I-Claim
either I-Claim
FtF I-Claim
or I-Claim
Tel I-Claim
, I-Claim
supports I-Claim
exercise I-Claim
as I-Claim
a I-Claim
form I-Claim
of I-Claim
adjuvant I-Claim
breast I-Claim
cancer I-Claim
therapy I-Claim
that I-Claim
can I-Claim
prevent I-Claim
declines I-Claim
in I-Claim
fitness I-Claim
and I-Claim
function I-Claim
during I-Claim
treatment I-Claim
and I-Claim
optimise I-Claim
recovery I-Claim
post-treatment I-Claim
. I-Claim

IMCP B-Claim
has I-Claim
clear I-Claim
short-term I-Claim
benefits I-Claim
for I-Claim
spiritual I-Claim
suffering I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
. I-Claim

Increased B-Claim
expression I-Claim
of I-Claim
metalloproteinases I-Claim
is I-Claim
associated I-Claim
with I-Claim
poor I-Claim
prognosis I-Claim
in I-Claim
small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
SCLC I-Claim
) I-Claim
. I-Claim

Whether B-Claim
such I-Claim
a I-Claim
lozenge I-Claim
would I-Claim
be I-Claim
beneficial I-Claim
in I-Claim
treatment I-Claim
situations I-Claim
where I-Claim
rate I-Claim
of I-Claim
severe I-Claim
mucositis I-Claim
is I-Claim
higher I-Claim
( I-Claim
ie I-Claim
, I-Claim
in I-Claim
patients I-Claim
treated I-Claim
with I-Claim
unconventional I-Claim
fractionation I-Claim
or I-Claim
with I-Claim
concomitant I-Claim
chemotherapy I-Claim
) I-Claim
is I-Claim
unknown I-Claim
. I-Claim

Exercise B-Claim
training I-Claim
during I-Claim
breast I-Claim
cancer I-Claim
chemotherapy I-Claim
may I-Claim
result I-Claim
in I-Claim
some I-Claim
longer-term I-Claim
and I-Claim
late I-Claim
effects I-Claim
for I-Claim
selected I-Claim
patient-rated I-Claim
outcomes I-Claim
. I-Claim

Although B-Claim
addition I-Claim
of I-Claim
radiotherapy I-Claim
to I-Claim
endocrine I-Claim
treatment I-Claim
significantly I-Claim
increased I-Claim
some I-Claim
treatment-related I-Claim
symptoms I-Claim
, I-Claim
none I-Claim
were I-Claim
serious I-Claim
. I-Claim

A B-Claim
more I-Claim
effective I-Claim
, I-Claim
better I-Claim
tolerated I-Claim
version I-Claim
of I-Claim
this I-Claim
FUP I-Claim
combination I-Claim
is I-Claim
needed I-Claim
. I-Claim

There B-Claim
were I-Claim
significant I-Claim
differences I-Claim
between I-Claim
treatment I-Claim
groups I-Claim
favouring I-Claim
the I-Claim
SNB I-Claim
group I-Claim
throughout I-Claim
the I-Claim
18 I-Claim
months I-Claim
assessment I-Claim
. I-Claim

Treatment B-Claim
with I-Claim
PB+G I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim

In B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non-small-cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
ATP I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim

Its B-Claim
leakage I-Claim
rate I-Claim
was I-Claim
lower I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
was I-Claim
better I-Claim
. I-Claim

Improvements B-Claim
were I-Claim
seen I-Claim
for I-Claim
symptom I-Claim
scores I-Claim
over I-Claim
the I-Claim
study I-Claim
period I-Claim
. I-Claim

Exercise B-Claim
training I-Claim
to I-Claim
improve I-Claim
cardiovascular I-Claim
fitness I-Claim
should I-Claim
be I-Claim
considered I-Claim
in I-Claim
the I-Claim
management I-Claim
of I-Claim
lymphoma I-Claim
patients I-Claim
. I-Claim

Future B-Claim
work I-Claim
is I-Claim
needed I-Claim
to I-Claim
improve I-Claim
the I-Claim
design I-Claim
and I-Claim
the I-Claim
planning I-Claim
of I-Claim
these I-Claim
interventions I-Claim
to I-Claim
improve I-Claim
program I-Claim
adherence I-Claim
. I-Claim

Combined B-Claim
with I-Claim
QOL I-Claim
results I-Claim
, I-Claim
the I-Claim
significant I-Claim
increase I-Claim
in I-Claim
response I-Claim
and I-Claim
PFS I-Claim
in I-Claim
the I-Claim
CP I-Claim
arm I-Claim
and I-Claim
the I-Claim
higher I-Claim
drop-out I-Claim
rate I-Claim
in I-Claim
the I-Claim
C I-Claim
arm I-Claim
suggest I-Claim
a I-Claim
better I-Claim
outcome I-Claim
for I-Claim
the I-Claim
combination I-Claim
regimen I-Claim
despite I-Claim
its I-Claim
increased I-Claim
myelosuppression I-Claim
. I-Claim

The B-Premise
ablation I-Premise
rate I-Premise
was I-Premise
equivalent I-Premise
between I-Premise
the I-Premise
( I-Premise
131 I-Premise
) I-Premise
I I-Premise
doses I-Premise
and I-Premise
between I-Premise
the I-Premise
thyrotropin-stimulation I-Premise
methods I-Premise
. I-Premise

Hospice B-Premise
care I-Premise
was I-Premise
so I-Premise
good I-Premise
during I-Premise
the I-Premise
study I-Premise
that I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
improved I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
standard I-Premise
care I-Premise
and I-Premise
left I-Premise
little I-Premise
room I-Premise
for I-Premise
improvement I-Premise
in I-Premise
other I-Premise
variables I-Premise
. I-Premise

Patients B-Premise
with I-Premise
PSA I-Premise
nadir I-Premise
≤ I-Premise
0.2 I-Premise
ng/ml I-Premise
, I-Premise
though I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
2-year I-Premise
risk I-Premise
of I-Premise
progression I-Premise
compared I-Premise
to I-Premise
CAD I-Premise
( I-Premise
53 I-Premise
% I-Premise
vs. I-Premise
31 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Evidence B-Premise
of I-Premise
a I-Premise
homeopathic I-Premise
" I-Premise
drug I-Premise
proving I-Premise
" I-Premise
in I-Premise
the I-Premise
subjects I-Premise
receiving I-Premise
the I-Premise
homeopathic I-Premise
combination I-Premise
medicine I-Premise
who I-Premise
were I-Premise
not I-Premise
taking I-Premise
tamoxifen I-Premise
also I-Premise
was I-Premise
found I-Premise
. I-Premise

The B-Premise
median I-Premise
duration I-Premise
of I-Premise
response I-Premise
was I-Premise
8.8 I-Premise
and I-Premise
8.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
Study I-Premise
A I-Premise
and I-Premise
Study I-Premise
B I-Premise
. I-Premise

The B-Premise
CCSP I-Premise
improved I-Premise
QOL I-Premise
for I-Premise
patients I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
. I-Premise

Rates B-Premise
of I-Premise
serious I-Premise
adverse I-Premise
events I-Premise
were I-Premise
25.6 I-Premise
and I-Premise
23.4 I-Premise
per I-Premise
100 I-Premise
patient-years I-Premise
in I-Premise
the I-Premise
double-blind I-Premise
versus I-Premise
cumulative I-Premise
period I-Premise
. I-Premise

The B-Premise
response I-Premise
rate I-Premise
was I-Premise
low I-Premise
in I-Premise
both I-Premise
arms I-Premise
, I-Premise
but I-Premise
superior I-Premise
in I-Premise
the I-Premise
FUP I-Premise
arm I-Premise
: I-Premise
12 I-Premise
% I-Premise
versus I-Premise
0 I-Premise
% I-Premise
( I-Premise
intention-to-treat I-Premise
analysis I-Premise
, I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Treatment-related B-Premise
mortality I-Premise
occurred I-Premise
in I-Premise
five I-Premise
patients I-Premise
( I-Premise
5.3 I-Premise
% I-Premise
) I-Premise
receiving I-Premise
irinotecan I-Premise
weekly I-Premise
and I-Premise
three I-Premise
patients I-Premise
( I-Premise
1.6 I-Premise
% I-Premise
) I-Premise
given I-Premise
therapy I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.12 I-Premise
) I-Premise
. I-Premise

Eighty B-Premise
percent I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
second-line I-Premise
chemotherapy I-Premise
in I-Premise
control I-Premise
arm I-Premise
were I-Premise
treated I-Premise
with I-Premise
continuous I-Premise
infusion I-Premise
5-FU I-Premise
. I-Premise

From B-Premise
the I-Premise
1-year I-Premise
survival I-Premise
analysis I-Premise
, I-Premise
the I-Premise
hazard I-Premise
ratio I-Premise
for I-Premise
probability I-Premise
of I-Premise
death I-Premise
was I-Premise
1.29 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.96 I-Premise
to I-Premise
1.72 I-Premise
) I-Premise
. I-Premise

No B-Premise
evidence I-Premise
of I-Premise
a I-Premise
difference I-Premise
was I-Premise
observed I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
activity I-Premise
level I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
and I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
as I-Premise
recorded I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

A B-Premise
trend I-Premise
towards I-Premise
increased I-Premise
myelosuppression I-Premise
and I-Premise
infectious I-Premise
complications I-Premise
with I-Premise
TCF I-Premise
versus I-Premise
TC I-Premise
or I-Premise
ECF I-Premise
was I-Premise
observed I-Premise
. I-Premise

The B-Premise
final I-Premise
multivariate I-Premise
model I-Premise
predicted I-Premise
poor I-Premise
survival I-Premise
with I-Premise
multiple I-Premise
sites I-Premise
of I-Premise
visceral I-Premise
disease I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
, I-Premise
DFI I-Premise
< I-Premise
/=2 I-Premise
years I-Premise
( I-Premise
P=0.026 I-Premise
) I-Premise
and I-Premise
pain I-Premise
( I-Premise
P=0.003 I-Premise
) I-Premise
. I-Premise

Although B-Premise
the I-Premise
change I-Premise
in I-Premise
fiber I-Premise
intake I-Premise
between I-Premise
the I-Premise
groups I-Premise
was I-Premise
not I-Premise
significant I-Premise
, I-Premise
there B-Premise
was I-Premise
a I-Premise
trend I-Premise
in I-Premise
the I-Premise
anticipated I-Premise
direction I-Premise
( I-Premise
P=0.083 I-Premise
) I-Premise
. I-Premise

The B-Premise
nutrition I-Premise
intervention I-Premise
group I-Premise
had I-Premise
a I-Premise
higher I-Premise
mean I-Premise
protein I-Premise
intake I-Premise
( I-Premise
1.1 I-Premise
to I-Premise
1.3 I-Premise
g/kg/day I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
standard I-Premise
practice I-Premise
group I-Premise
( I-Premise
1.0 I-Premise
to I-Premise
1.1 I-Premise
g/kg/day I-Premise
) I-Premise
( I-Premise
P=0.001 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
carrying I-Premise
a I-Premise
GCLC I-Premise
77 I-Premise
genotype I-Premise
had I-Premise
a I-Premise
worse I-Premise
overall I-Premise
survival I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
( I-Premise
HR I-Premise
) I-Premise
= I-Premise
1.5 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
significant I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
interaction I-Premise
effects I-Premise
on I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
with I-Premise
differences I-Premise
being I-Premise
observed I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
and I-Premise
the I-Premise
UC I-Premise
group I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
erlotinib I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
median I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
for I-Premise
all I-Premise
three I-Premise
symptoms I-Premise
( I-Premise
4.9 I-Premise
v I-Premise
3.7 I-Premise
months I-Premise
for I-Premise
cough I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
";" I-Premise
4.7 I-Premise
v I-Premise
2.9 I-Premise
months I-Premise
for I-Premise
dyspnea I-Premise
[ I-Premise
P I-Premise
= I-Premise
.04 I-Premise
] I-Premise
, I-Premise
and I-Premise
2.8 I-Premise
v I-Premise
1.9 I-Premise
months I-Premise
for I-Premise
pain I-Premise
[ I-Premise
P I-Premise
= I-Premise
.03 I-Premise
] I-Premise
) I-Premise
. I-Premise

At B-Premise
enrollment I-Premise
, I-Premise
symptoms I-Premise
, I-Premise
including I-Premise
muscle I-Premise
stiffness I-Premise
, I-Premise
breast I-Premise
sensitivity I-Premise
, I-Premise
aches I-Premise
and I-Premise
pains I-Premise
, I-Premise
tendency I-Premise
to I-Premise
take I-Premise
naps I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
concentrating I-Premise
, I-Premise
were I-Premise
common I-Premise
among I-Premise
patients I-Premise
in I-Premise
all I-Premise
groups I-Premise
and I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
poor I-Premise
physical I-Premise
functioning I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
. I-Premise

When B-Premise
combined I-Premise
hormone I-Premise
therapy I-Premise
( I-Premise
n=2196 I-Premise
) I-Premise
was I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
n=2189 I-Premise
) I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
significant I-Premise
increase I-Premise
in I-Premise
the I-Premise
number I-Premise
of I-Premise
major I-Premise
cardiovascular I-Premise
events I-Premise
( I-Premise
7 I-Premise
v I-Premise
0 I-Premise
, I-Premise
P=0.016 I-Premise
) I-Premise
and I-Premise
venous I-Premise
thromboembolisms I-Premise
( I-Premise
22 I-Premise
v I-Premise
3 I-Premise
, I-Premise
hazard I-Premise
ratio I-Premise
7.36 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
2.20 I-Premise
to I-Premise
24.60 I-Premise
) I-Premise
) I-Premise
. I-Premise

The B-Premise
MMP I-Premise
appears I-Premise
to I-Premise
benefit I-Premise
older I-Premise
BCSs I-Premise
by I-Premise
reducing I-Premise
fear I-Premise
of I-Premise
recurrence I-Premise
and I-Premise
improving I-Premise
mindfulness I-Premise
attitude I-Premise
. I-Premise

Comparing B-Premise
survival I-Premise
for I-Premise
the I-Premise
two I-Premise
dose I-Premise
levels I-Premise
of I-Premise
paclitaxel I-Premise
revealed I-Premise
no I-Premise
significant I-Premise
difference I-Premise
. I-Premise

HRQOL B-Premise
and I-Premise
symptom I-Premise
relief I-Premise
were I-Premise
equivalent I-Premise
in I-Premise
the I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
physical I-Premise
function I-Premise
( I-Premise
P=0.044 I-Premise
) I-Premise
and I-Premise
constipation I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
showed I-Premise
an I-Premise
improvement I-Premise
during I-Premise
induction I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
MP I-Premise
arm I-Premise
. I-Premise

QoL B-Premise
was I-Premise
better I-Premise
preserved I-Premise
in I-Premise
rhTSH I-Premise
Group I-Premise
than I-Premise
in I-Premise
T4-WD I-Premise
and I-Premise
T3-WD I-Premise
Groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

In B-Premise
the I-Premise
-5 I-Premise
versus I-Premise
3-day I-Premise
comparison I-Premise
, I-Premise
the I-Premise
projected I-Premise
2-year I-Premise
PFS I-Premise
is I-Premise
88.8 I-Premise
% I-Premise
and I-Premise
89.7 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
difference I-Premise
, I-Premise
-0.9 I-Premise
% I-Premise
, I-Premise
( I-Premise
80 I-Premise
% I-Premise
CL I-Premise
, I-Premise
-4.1 I-Premise
% I-Premise
, I-Premise
+2.2 I-Premise
% I-Premise
) I-Premise
. I-Premise

Of B-Premise
group I-Premise
1 I-Premise
patients I-Premise
67 I-Premise
% I-Premise
had I-Premise
gynecomastia I-Premise
compared I-Premise
with I-Premise
8 I-Premise
% I-Premise
in I-Premise
group I-Premise
2 I-Premise
and I-Premise
34 I-Premise
% I-Premise
in I-Premise
group I-Premise
3 I-Premise
. I-Premise

Food B-Premise
intake I-Premise
improved I-Premise
more I-Premise
rapidly I-Premise
after I-Premise
stent I-Premise
placement I-Premise
than I-Premise
after I-Premise
GJJ I-Premise
( I-Premise
GOO I-Premise
Scoring I-Premise
System I-Premise
score I-Premise
> I-Premise
or I-Premise
= I-Premise
2 I-Premise
: I-Premise
median I-Premise
5 I-Premise
vs I-Premise
8 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
< I-Premise
.01 I-Premise
) I-Premise
but B-Premise
long-term I-Premise
relief I-Premise
was I-Premise
better I-Premise
after I-Premise
GJJ I-Premise
, I-Premise
with I-Premise
more I-Premise
patients I-Premise
living I-Premise
more I-Premise
days I-Premise
with I-Premise
a I-Premise
GOO I-Premise
Scoring I-Premise
System I-Premise
score I-Premise
of I-Premise
2 I-Premise
or I-Premise
more I-Premise
than I-Premise
after I-Premise
stent I-Premise
placement I-Premise
( I-Premise
72 I-Premise
vs I-Premise
50 I-Premise
days I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
P I-Premise
= I-Premise
.05 I-Premise
) I-Premise
. I-Premise

A B-Premise
significantly I-Premise
lower I-Premise
serum I-Premise
interleukin-6 I-Premise
level I-Premise
was I-Premise
found I-Premise
in I-Premise
comparing I-Premise
glutamine-enriched I-Premise
with I-Premise
standard I-Premise
TPN I-Premise
( I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
but B-Premise
not I-Premise
in I-Premise
interleukin-10 I-Premise
( I-Premise
P I-Premise
= I-Premise
0.374 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
levels I-Premise
( I-Premise
P I-Premise
= I-Premise
0.653 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
QOL I-Premise
drop-out I-Premise
for I-Premise
any I-Premise
reason I-Premise
was I-Premise
higher I-Premise
for I-Premise
C I-Premise
( I-Premise
53 I-Premise
% I-Premise
) I-Premise
compared I-Premise
to I-Premise
CP I-Premise
( I-Premise
38 I-Premise
% I-Premise
) I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
patients I-Premise
receiving I-Premise
vinorelbine I-Premise
";" I-Premise
median B-Premise
survival I-Premise
increased I-Premise
from I-Premise
21 I-Premise
to I-Premise
28 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
vinorelbine-treated I-Premise
group I-Premise
. I-Premise

Results B-Premise
showed I-Premise
improved I-Premise
patient I-Premise
depression I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
as I-Premise
a I-Premise
result I-Premise
of I-Premise
the I-Premise
intervention I-Premise
and I-Premise
improvement I-Premise
in I-Premise
both I-Premise
groups I-Premise
in I-Premise
patients I-Premise
' I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
of I-Premise
all I-Premise
406 I-Premise
eligible I-Premise
patients I-Premise
was I-Premise
346 I-Premise
days I-Premise
with I-Premise
15 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
alive I-Premise
at I-Premise
two I-Premise
years I-Premise
. I-Premise

QOL B-Premise
was I-Premise
preserved I-Premise
longer I-Premise
for I-Premise
patients I-Premise
on I-Premise
DCF I-Premise
than I-Premise
those I-Premise
on I-Premise
CF I-Premise
for I-Premise
all I-Premise
time I-Premise
to I-Premise
deterioration I-Premise
analyses I-Premise
, I-Premise
demonstrating I-Premise
the I-Premise
statistical I-Premise
superiority I-Premise
of I-Premise
DCF I-Premise
compared I-Premise
with I-Premise
CF I-Premise
. I-Premise

No B-Premise
group-related I-Premise
negative I-Premise
effects I-Premise
were I-Premise
observed I-Premise
and I-Premise
the I-Premise
global I-Premise
satisfaction I-Premise
levels I-Premise
were I-Premise
very I-Premise
high I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
for I-Premise
patients I-Premise
with I-Premise
ER-positive I-Premise
tumors I-Premise
, I-Premise
addition I-Premise
of I-Premise
CMF I-Premise
provided I-Premise
no I-Premise
benefit I-Premise
in I-Premise
terms I-Premise
of I-Premise
DFS I-Premise
( I-Premise
5-year I-Premise
DFS I-Premise
= I-Premise
84 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
85 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
-1 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-6 I-Premise
% I-Premise
to I-Premise
4 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.99 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.75 I-Premise
to I-Premise
1.30 I-Premise
";" I-Premise
P I-Premise
=.92 I-Premise
) I-Premise
or I-Premise
OS I-Premise
( I-Premise
5-year I-Premise
OS I-Premise
= I-Premise
95 I-Premise
% I-Premise
for I-Premise
CMF I-Premise
-- I-Premise
> I-Premise
tamoxifen I-Premise
versus I-Premise
93 I-Premise
% I-Premise
for I-Premise
tamoxifen I-Premise
alone I-Premise
";" I-Premise
difference I-Premise
= I-Premise
2 I-Premise
% I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1 I-Premise
% I-Premise
to I-Premise
5 I-Premise
% I-Premise
";" I-Premise
RR I-Premise
= I-Premise
0.95 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.64 I-Premise
to I-Premise
1.40 I-Premise
";" I-Premise
P I-Premise
=.80 I-Premise
) I-Premise
. I-Premise

Two B-Premise
patients I-Premise
( I-Premise
1.3 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
gefitinib I-Premise
arm I-Premise
developed I-Premise
interstitial I-Premise
lung I-Premise
disease I-Premise
and I-Premise
died I-Premise
. I-Premise

Consolidation B-Premise
chemotherapy I-Premise
was I-Premise
completed I-Premise
in I-Premise
75 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
. I-Premise

Among B-Premise
patients I-Premise
with I-Premise
limited-stage I-Premise
disease I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
evidence I-Premise
of I-Premise
a I-Premise
survival I-Premise
difference I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
0.91 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.73 I-Premise
to I-Premise
1.15 I-Premise
) I-Premise
, I-Premise
but B-Premise
among I-Premise
patients I-Premise
with I-Premise
extensive I-Premise
disease I-Premise
, I-Premise
survival I-Premise
was I-Premise
worse I-Premise
in I-Premise
the I-Premise
thalidomide I-Premise
group I-Premise
( I-Premise
HR I-Premise
for I-Premise
death I-Premise
= I-Premise
1.36 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
1.10 I-Premise
to I-Premise
1.68 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
with I-Premise
a I-Premise
PS I-Premise
of I-Premise
0-1 I-Premise
and I-Premise
a I-Premise
resected I-Premise
tumor I-Premise
had I-Premise
the I-Premise
significantly I-Premise
longest I-Premise
survival I-Premise
both I-Premise
in I-Premise
EEP-L I-Premise
treated I-Premise
patients I-Premise
and I-Premise
in I-Premise
all I-Premise
evaluable I-Premise
patients I-Premise
in I-Premise
the I-Premise
two I-Premise
studies I-Premise
. I-Premise

The B-Premise
scapula-oriented I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improvements I-Premise
in I-Premise
pain I-Premise
, I-Premise
physical I-Premise
function I-Premise
, I-Premise
social I-Premise
function I-Premise
, I-Premise
and I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
compared I-Premise
with I-Premise
baseline I-Premise
, I-Premise
whereas I-Premise
the I-Premise
general I-Premise
exercise I-Premise
group I-Premise
showed I-Premise
improved I-Premise
fatigue I-Premise
and I-Premise
range I-Premise
of I-Premise
motion I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
or I-Premise
4 I-Premise
granulocytopenia I-Premise
was I-Premise
equivalent I-Premise
in I-Premise
both I-Premise
arms I-Premise
but I-Premise
more I-Premise
grade I-Premise
3/4 I-Premise
neurotoxicity I-Premise
, I-Premise
mild I-Premise
venous I-Premise
toxicity I-Premise
, I-Premise
and I-Premise
FN I-Premise
were I-Premise
seen I-Premise
on I-Premise
arm I-Premise
1 I-Premise
. I-Premise

Grade B-Premise
3/4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
29 I-Premise
% I-Premise
of I-Premise
patients I-Premise
treated I-Premise
weekly I-Premise
and I-Premise
34 I-Premise
% I-Premise
of I-Premise
those I-Premise
treated I-Premise
once I-Premise
every I-Premise
3 I-Premise
weeks I-Premise
( I-Premise
P I-Premise
=.35 I-Premise
) I-Premise
. I-Premise

The B-Premise
mean I-Premise
liver I-Premise
volume I-Premise
decreased I-Premise
2.9 I-Premise
% I-Premise
, I-Premise
from I-Premise
4606 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
: I-Premise
547-8665 I-Premise
) I-Premise
to I-Premise
4471 I-Premise
mL I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
542-8401 I-Premise
mL I-Premise
) I-Premise
, I-Premise
in I-Premise
patients I-Premise
given I-Premise
lanreotide I-Premise
. I-Premise

Overall B-Premise
, I-Premise
patients I-Premise
treated I-Premise
with I-Premise
either I-Premise
docetaxel-containing I-Premise
regimen I-Premise
had I-Premise
better I-Premise
QoL I-Premise
than I-Premise
VC-treated I-Premise
patients I-Premise
( I-Premise
LCSS I-Premise
global I-Premise
item I-Premise
" I-Premise
QoL I-Premise
today I-Premise
" I-Premise
: I-Premise
P=0.064 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P=0.016 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
";" I-Premise
EQ-5D I-Premise
global I-Premise
item I-Premise
" I-Premise
health I-Premise
state I-Premise
today I-Premise
" I-Premise
: I-Premise
P=0.016 I-Premise
for I-Premise
DC I-Premise
and I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
for I-Premise
DCb I-Premise
versus I-Premise
VC I-Premise
) I-Premise
. I-Premise

Tamoxifen B-Premise
reduced I-Premise
the I-Premise
risk I-Premise
of I-Premise
invasive I-Premise
breast I-Premise
cancer I-Premise
by I-Premise
49 I-Premise
% I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
< I-Premise
.00001 I-Premise
) I-Premise
, I-Premise
with I-Premise
cumulative I-Premise
incidence I-Premise
through I-Premise
69 I-Premise
months I-Premise
of I-Premise
follow-up I-Premise
of I-Premise
43.4 I-Premise
versus I-Premise
22.0 I-Premise
per I-Premise
1000 I-Premise
women I-Premise
in I-Premise
the I-Premise
placebo I-Premise
and I-Premise
tamoxifen I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Median B-Premise
survival I-Premise
from I-Premise
randomisation I-Premise
was I-Premise
25·7 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
23·0-27·9 I-Premise
) I-Premise
for I-Premise
patients I-Premise
on I-Premise
early I-Premise
treatment I-Premise
and I-Premise
27·1 I-Premise
months I-Premise
( I-Premise
22·8-30·9 I-Premise
) I-Premise
for I-Premise
those I-Premise
on I-Premise
delayed I-Premise
treatment I-Premise
. I-Premise

Mean B-Premise
hemoglobin I-Premise
levels I-Premise
were I-Premise
higher I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
placebo I-Premise
group I-Premise
after I-Premise
4 I-Premise
cycles I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
treatment-related I-Premise
adverse I-Premise
events I-Premise
were I-Premise
rash I-Premise
, I-Premise
diarrhea I-Premise
and I-Premise
pruritus I-Premise
. I-Premise

Kaplan-Meier B-Premise
survival I-Premise
curves I-Premise
demonstrated I-Premise
better I-Premise
survival I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
than I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

The B-Premise
incidence I-Premise
of I-Premise
RBC I-Premise
transfusion I-Premise
for I-Premise
placebo I-Premise
and I-Premise
epoetin I-Premise
treatment I-Premise
arms I-Premise
was I-Premise
39.6 I-Premise
% I-Premise
and I-Premise
25.3 I-Premise
% I-Premise
( I-Premise
P I-Premise
= I-Premise
.005 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
between I-Premise
gender I-Premise
and I-Premise
KPS I-Premise
using I-Premise
FLIC I-Premise
( I-Premise
P I-Premise
= I-Premise
0.009 I-Premise
) I-Premise
, I-Premise
which I-Premise
also I-Premise
showed I-Premise
a I-Premise
trend I-Premise
toward I-Premise
significance I-Premise
with I-Premise
FACT I-Premise
( I-Premise
P I-Premise
= I-Premise
0.09 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
difference I-Premise
in I-Premise
median I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
5.5 I-Premise
months I-Premise
v I-Premise
3.1 I-Premise
months I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
and I-Premise
overall I-Premise
survival I-Premise
times I-Premise
were I-Premise
3.2 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.8 I-Premise
to I-Premise
4.6 I-Premise
months I-Premise
) I-Premise
and I-Premise
6.8 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.6 I-Premise
to I-Premise
11.1 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
4.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3.5 I-Premise
to I-Premise
6.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
9.5 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
6.9 I-Premise
to I-Premise
12.2 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-cisplatin I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
and I-Premise
6.9 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
5.5 I-Premise
to I-Premise
8.3 I-Premise
months I-Premise
) I-Premise
and I-Premise
11.3 I-Premise
months I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
9.3 I-Premise
to I-Premise
13.3 I-Premise
months I-Premise
) I-Premise
with I-Premise
LV5FU2-irinotecan I-Premise
, I-Premise
respectively I-Premise
. I-Premise

However B-Premise
, I-Premise
at I-Premise
6 I-Premise
months I-Premise
, I-Premise
total I-Premise
quality-of-life I-Premise
scores I-Premise
were I-Premise
higher I-Premise
for I-Premise
intervention I-Premise
group I-Premise
patients I-Premise
than I-Premise
controls I-Premise
( I-Premise
106.0 I-Premise
vs I-Premise
98.6 I-Premise
) I-Premise
. I-Premise

Dermatology B-Premise
Life I-Premise
Quality I-Premise
Index I-Premise
( I-Premise
DLQI I-Premise
) I-Premise
scores I-Premise
were I-Premise
assessed I-Premise
for I-Premise
each I-Premise
treatment I-Premise
modality I-Premise
at I-Premise
week I-Premise
4 I-Premise
and I-Premise
were I-Premise
1.95 I-Premise
and I-Premise
1.38 I-Premise
, I-Premise
respectively I-Premise
( I-Premise
p I-Premise
= I-Premise
.20 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
in I-Premise
any I-Premise
of I-Premise
the I-Premise
subjects I-Premise
revealed I-Premise
by I-Premise
the I-Premise
questionnaire I-Premise
regarding I-Premise
subjective I-Premise
or I-Premise
objective I-Premise
symptoms I-Premise
, I-Premise
or I-Premise
by I-Premise
the I-Premise
SF-8 I-Premise
between I-Premise
the I-Premise
daytime I-Premise
group I-Premise
and I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
after I-Premise
3 I-Premise
months I-Premise
of I-Premise
treatment I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
serious I-Premise
events I-Premise
with I-Premise
the I-Premise
1 I-Premise
+ I-Premise
2.5 I-Premise
dosage I-Premise
or I-Premise
after I-Premise
ccHRT I-Premise
discontinuation I-Premise
. I-Premise

The B-Premise
Independent I-Premise
Review I-Premise
Committee-assessed I-Premise
PFS I-Premise
hazard I-Premise
ratio I-Premise
was I-Premise
0.72 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.54 I-Premise
to I-Premise
0.94 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0162 I-Premise
";" I-Premise
median I-Premise
PFS I-Premise
, I-Premise
13.9 I-Premise
v I-Premise
16.8 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
PFS I-Premise
events I-Premise
in I-Premise
53 I-Premise
% I-Premise
) I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
of I-Premise
more I-Premise
than I-Premise
3 I-Premise
years I-Premise
, I-Premise
survival I-Premise
did I-Premise
not I-Premise
differ I-Premise
among I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
( I-Premise
median I-Premise
FU I-Premise
+ I-Premise
LV I-Premise
, I-Premise
11.1 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.2 I-Premise
to I-Premise
15.0 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
, I-Premise
13.0 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
10.4 I-Premise
to I-Premise
15.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
FU24h I-Premise
+ I-Premise
LV I-Premise
, I-Premise
13.7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
12.0 I-Premise
to I-Premise
16.4 I-Premise
months I-Premise
] I-Premise
";" I-Premise
P I-Premise
=.724 I-Premise
) I-Premise
. I-Premise

Cetuximab B-Premise
preserved I-Premise
GHS I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-0.2 I-Premise
v I-Premise
-18.1 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Toxicity B-Premise
profiles I-Premise
were I-Premise
similar I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
of I-Premise
the I-Premise
study I-Premise
. I-Premise

Similar B-Premise
results I-Premise
were I-Premise
observed I-Premise
using I-Premise
the I-Premise
LENT-SOMA I-Premise
scale I-Premise
. I-Premise

On B-Premise
the I-Premise
response I-Premise
analysis I-Premise
, I-Premise
a I-Premise
significant I-Premise
difference I-Premise
was I-Premise
seen I-Premise
between I-Premise
groups I-Premise
for I-Premise
the I-Premise
bodily I-Premise
pain I-Premise
domain I-Premise
( I-Premise
percentage I-Premise
of I-Premise
patients I-Premise
reporting I-Premise
a I-Premise
worsening I-Premise
of I-Premise
QOL I-Premise
, I-Premise
47 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
51 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.009 I-Premise
) I-Premise
and I-Premise
the I-Premise
vasomotor I-Premise
domain I-Premise
( I-Premise
22 I-Premise
% I-Premise
placebo I-Premise
v I-Premise
29 I-Premise
% I-Premise
letrozole I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Furthermore B-Premise
, I-Premise
statistically I-Premise
significant I-Premise
improvements I-Premise
in I-Premise
exercise I-Premise
capacity I-Premise
and I-Premise
muscle I-Premise
force I-Premise
of I-Premise
upper I-Premise
and I-Premise
lower I-Premise
extremities I-Premise
were I-Premise
displayed I-Premise
after I-Premise
rehabilitation I-Premise
. I-Premise

Response B-Premise
rates I-Premise
were I-Premise
55 I-Premise
% I-Premise
with I-Premise
gefitinib I-Premise
and I-Premise
46 I-Premise
% I-Premise
with I-Premise
GP I-Premise
( I-Premise
P I-Premise
= I-Premise
.101 I-Premise
) I-Premise
. I-Premise

Objective B-Premise
response I-Premise
rate I-Premise
was I-Premise
similar I-Premise
for I-Premise
fulvestrant I-Premise
500 I-Premise
mg I-Premise
and I-Premise
250 I-Premise
mg I-Premise
( I-Premise
9.1 I-Premise
% I-Premise
v I-Premise
10.2 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
groups I-Premise
regarding I-Premise
quality I-Premise
of I-Premise
life I-Premise
, I-Premise
complications I-Premise
, I-Premise
drainage I-Premise
time I-Premise
, I-Premise
hospital I-Premise
stay I-Premise
, I-Premise
and I-Premise
survival I-Premise
. I-Premise

The B-Premise
treatments I-Premise
gave I-Premise
rise I-Premise
to I-Premise
different I-Premise
rates I-Premise
of I-Premise
grade I-Premise
3-4 I-Premise
neutropenia I-Premise
( I-Premise
3 I-Premise
, I-Premise
4 I-Premise
, I-Premise
11 I-Premise
and I-Premise
14 I-Premise
% I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
LV5FU2 I-Premise
, I-Premise
ldLV5FU2 I-Premise
, I-Premise
HD-FU I-Premise
and I-Premise
Tomudex I-Premise
arms I-Premise
, I-Premise
respectively I-Premise
, I-Premise
p I-Premise
= I-Premise
0.028 I-Premise
) I-Premise
, I-Premise
leucopenia I-Premise
and I-Premise
vomiting I-Premise
. I-Premise

In B-Premise
patients I-Premise
who I-Premise
had I-Premise
tumors I-Premise
with I-Premise
wild-type I-Premise
KRAS I-Premise
status I-Premise
, I-Premise
cetuximab I-Premise
resulted I-Premise
in I-Premise
less I-Premise
PF I-Premise
deterioration I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
( I-Premise
-0.7 I-Premise
v I-Premise
-7.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.11 I-Premise
) I-Premise
and I-Premise
16 I-Premise
weeks I-Premise
( I-Premise
-3.4 I-Premise
v I-Premise
-13.8 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
compared I-Premise
with I-Premise
BSC I-Premise
. I-Premise

CP B-Premise
resulted I-Premise
in I-Premise
more I-Premise
anastomotic I-Premise
leaks I-Premise
. I-Premise

At B-Premise
12 I-Premise
months I-Premise
post-randomisation I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
between I-Premise
treatment I-Premise
and I-Premise
control I-Premise
groups I-Premise
in I-Premise
terms I-Premise
of I-Premise
arm I-Premise
volume I-Premise
. I-Premise

Trained B-Premise
versus I-Premise
control I-Premise
patients I-Premise
reported I-Premise
reduced I-Premise
barriers I-Premise
to I-Premise
pain I-Premise
relief I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
, I-Premise
lower I-Premise
usual I-Premise
pain I-Premise
( I-Premise
P=.03 I-Premise
) I-Premise
, I-Premise
and I-Premise
greater I-Premise
opioid I-Premise
use I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
treatment I-Premise
groups I-Premise
reported I-Premise
improved I-Premise
QoL I-Premise
, I-Premise
fitness I-Premise
and I-Premise
fatigue I-Premise
over I-Premise
time I-Premise
and I-Premise
changes I-Premise
observed I-Premise
between I-Premise
baseline I-Premise
and I-Premise
post-intervention I-Premise
were I-Premise
clinically I-Premise
relevant I-Premise
. I-Premise

The B-Premise
most I-Premise
common I-Premise
site I-Premise
of I-Premise
systemic I-Premise
recurrence I-Premise
was I-Premise
the I-Premise
liver I-Premise
. I-Premise

In B-Premise
a I-Premise
quality-of-life I-Premise
analysis I-Premise
, I-Premise
all I-Premise
significant I-Premise
differences I-Premise
, I-Premise
except I-Premise
on I-Premise
diarrhoea I-Premise
score I-Premise
, I-Premise
were I-Premise
in I-Premise
favour I-Premise
of I-Premise
the I-Premise
irinotecan I-Premise
group I-Premise
. I-Premise

At B-Premise
3 I-Premise
months I-Premise
, I-Premise
G1 I-Premise
maintained I-Premise
nutritional I-Premise
intake I-Premise
and I-Premise
G2/G3 I-Premise
returned I-Premise
to I-Premise
baseline I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
the I-Premise
anorectal I-Premise
manometry I-Premise
and I-Premise
endoanal I-Premise
ultrasound I-Premise
findings I-Premise
. I-Premise

Transient B-Premise
grade I-Premise
4 I-Premise
neutropenia I-Premise
occurred I-Premise
in I-Premise
18 I-Premise
and I-Premise
2 I-Premise
patients I-Premise
, I-Premise
and I-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
thrombosis I-Premise
in I-Premise
7 I-Premise
patients I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
Arm I-Premise
A I-Premise
and I-Premise
Arm I-Premise
B I-Premise
respectively I-Premise
. I-Premise

The B-Premise
QLQ-C30 I-Premise
subscales I-Premise
pain I-Premise
( I-Premise
P=0.12 I-Premise
) I-Premise
, I-Premise
insomnia I-Premise
( I-Premise
P=0.068 I-Premise
) I-Premise
, I-Premise
appetite I-Premise
loss I-Premise
( I-Premise
P=0.074 I-Premise
) I-Premise
and I-Premise
the I-Premise
QLQ-MY24 I-Premise
item I-Premise
sick I-Premise
( I-Premise
P=0.086 I-Premise
) I-Premise
scored I-Premise
marginally I-Premise
better I-Premise
during I-Premise
thalidomide I-Premise
maintenance I-Premise
. I-Premise

Exemestane B-Premise
patients I-Premise
reported I-Premise
more I-Premise
bone/muscle I-Premise
aches I-Premise
( I-Premise
P I-Premise
< I-Premise
.0001 I-Premise
) I-Premise
, I-Premise
vaginal I-Premise
dryness I-Premise
( I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
, I-Premise
and I-Premise
difficulty I-Premise
sleeping I-Premise
( I-Premise
P I-Premise
= I-Premise
.03 I-Premise
) I-Premise
. I-Premise

No B-Premise
unexpected I-Premise
adverse I-Premise
events I-Premise
were I-Premise
observed I-Premise
, I-Premise
except B-Premise
for I-Premise
tumor I-Premise
hemorrhage-type I-Premise
events I-Premise
with I-Premise
gefitinib I-Premise
( I-Premise
8.9 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
250 I-Premise
mg/day I-Premise
";" I-Premise
11.4 I-Premise
% I-Premise
, I-Premise
gefitinib I-Premise
500 I-Premise
mg/day I-Premise
";" I-Premise
1.9 I-Premise
% I-Premise
, I-Premise
methotrexate I-Premise
) I-Premise
. I-Premise

The B-Premise
HR I-Premise
for I-Premise
overall I-Premise
survival I-Premise
was I-Premise
0.96 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.75-1.23 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.7349 I-Premise
) I-Premise
. I-Premise

Four B-Premise
toxic I-Premise
deaths I-Premise
occurred I-Premise
in I-Premise
the I-Premise
NP I-Premise
arm I-Premise
and I-Premise
eight I-Premise
in I-Premise
the I-Premise
NIP I-Premise
arm I-Premise
. I-Premise

The B-Premise
SCNS I-Premise
physical I-Premise
and I-Premise
patient I-Premise
care I-Premise
subscales I-Premise
( I-Premise
-14.2 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-26.2 I-Premise
to I-Premise
-2.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
and I-Premise
-7.4 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-13.7 I-Premise
to I-Premise
-1.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
and I-Premise
self-reported I-Premise
health I-Premise
state I-Premise
( I-Premise
12.8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3.2 I-Premise
to I-Premise
22.4 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
also I-Premise
differed I-Premise
significantly I-Premise
. I-Premise

By B-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
treatment I-Premise
period I-Premise
, I-Premise
hot I-Premise
flash I-Premise
scores I-Premise
( I-Premise
frequency I-Premise
x I-Premise
average I-Premise
severity I-Premise
) I-Premise
decreased I-Premise
68 I-Premise
% I-Premise
from I-Premise
baseline I-Premise
to I-Premise
end I-Premise
point I-Premise
in I-Premise
the I-Premise
hypnosis I-Premise
arm I-Premise
( I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
night I-Premise
awakenings I-Premise
( I-Premise
Actigraph I-Premise
) I-Premise
pattern I-Premise
was I-Premise
significantly I-Premise
different I-Premise
by I-Premise
group I-Premise
over I-Premise
time I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
, I-Premise
with I-Premise
no I-Premise
differences I-Premise
between I-Premise
groups I-Premise
at I-Premise
90 I-Premise
days I-Premise
or I-Premise
at I-Premise
1 I-Premise
year I-Premise
. I-Premise

GHRQL B-Premise
was I-Premise
initially I-Premise
worse I-Premise
for I-Premise
the I-Premise
RP+RT I-Premise
arm I-Premise
but I-Premise
improved I-Premise
over I-Premise
time I-Premise
and I-Premise
was I-Premise
better I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
period I-Premise
than I-Premise
the I-Premise
GHRQL I-Premise
reported I-Premise
for I-Premise
RP I-Premise
alone I-Premise
( I-Premise
treatment I-Premise
arm I-Premise
x I-Premise
time I-Premise
interaction I-Premise
, I-Premise
P I-Premise
= I-Premise
.0004 I-Premise
) I-Premise
. I-Premise

No B-Premise
differences I-Premise
were I-Premise
observed I-Premise
in I-Premise
global I-Premise
quality I-Premise
of I-Premise
life I-Premise
subdomain I-Premise
( I-Premise
P=0.40 I-Premise
) I-Premise
between I-Premise
the I-Premise
two I-Premise
regimen I-Premise
. I-Premise

Patient B-Premise
diaries I-Premise
demonstrated I-Premise
lower I-Premise
swallowing I-Premise
dysfunction I-Premise
AUC I-Premise
with I-Premise
amifostine I-Premise
( I-Premise
z I-Premise
test I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
, I-Premise
patients I-Premise
receiving I-Premise
goserelin I-Premise
alone I-Premise
showed I-Premise
a I-Premise
marked I-Premise
improvement I-Premise
or I-Premise
less I-Premise
deterioration I-Premise
in I-Premise
QOL I-Premise
measures I-Premise
over I-Premise
the I-Premise
first I-Premise
6 I-Premise
months I-Premise
than I-Premise
those I-Premise
patients I-Premise
treated I-Premise
with I-Premise
CMF I-Premise
. I-Premise

A B-Premise
7 I-Premise
% I-Premise
response I-Premise
rate I-Premise
was I-Premise
observed I-Premise
with I-Premise
topotecan I-Premise
( I-Premise
complete I-Premise
response I-Premise
, I-Premise
2 I-Premise
% I-Premise
";" I-Premise
partial I-Premise
response I-Premise
, I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

Participants B-Premise
completing I-Premise
the I-Premise
intervention I-Premise
demonstrated I-Premise
improvement I-Premise
in I-Premise
male I-Premise
overall I-Premise
distress I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
male I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
, I-Premise
and I-Premise
female I-Premise
global I-Premise
sexual I-Premise
function I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
at I-Premise
3-month I-Premise
follow-up I-Premise
, I-Premise
but B-Premise
regression I-Premise
toward I-Premise
baseline I-Premise
was I-Premise
noted I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
. I-Premise

QOL B-Premise
was I-Premise
not I-Premise
significantly I-Premise
different I-Premise
between I-Premise
the I-Premise
two I-Premise
arms I-Premise
, I-Premise
except I-Premise
for I-Premise
pain I-Premise
, I-Premise
which I-Premise
showed I-Premise
more I-Premise
clinically I-Premise
meaningful I-Premise
improvement I-Premise
and I-Premise
less I-Premise
deterioration I-Premise
at I-Premise
6 I-Premise
weeks I-Premise
follow-up I-Premise
( I-Premise
v I-Premise
pretreatment I-Premise
) I-Premise
in I-Premise
the I-Premise
AM I-Premise
arm I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

One B-Premise
patient I-Premise
died I-Premise
of I-Premise
febrile I-Premise
neutropenia I-Premise
during I-Premise
treatment I-Premise
. I-Premise

Concomitant B-Premise
or I-Premise
prior I-Premise
use I-Premise
of I-Premise
protease I-Premise
inhibitors I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
affect I-Premise
the I-Premise
patient I-Premise
's I-Premise
response I-Premise
to I-Premise
treatment I-Premise
( I-Premise
P I-Premise
= I-Premise
0.183 I-Premise
) I-Premise
. I-Premise

DC/CIK B-Premise
treatment I-Premise
prolongs I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
3.20 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.94-3.50 I-Premise
] I-Premise
vs I-Premise
2.56 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
2.39-2.73 I-Premise
] I-Premise
";" I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
in I-Premise
failure-free I-Premise
survival I-Premise
, I-Premise
time I-Premise
to I-Premise
locoregional I-Premise
failure I-Premise
, I-Premise
or I-Premise
quality I-Premise
of I-Premise
life I-Premise
as I-Premise
measured I-Premise
by I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Head I-Premise
and I-Premise
Neck I-Premise
. I-Premise

The B-Premise
5-year I-Premise
biochemical I-Premise
+/- I-Premise
clinical I-Premise
relapse-free I-Premise
and I-Premise
overall I-Premise
survival I-Premise
was I-Premise
55.9 I-Premise
% I-Premise
and I-Premise
85.3 I-Premise
% I-Premise
respectively I-Premise
for I-Premise
all I-Premise
patients I-Premise
, I-Premise
and I-Premise
did I-Premise
not I-Premise
differ I-Premise
between I-Premise
the I-Premise
two I-Premise
schedules I-Premise
. I-Premise

Patients B-Premise
allocated I-Premise
to I-Premise
misoprostol I-Premise
did I-Premise
report I-Premise
slightly I-Premise
increased I-Premise
soreness I-Premise
( I-Premise
7.6 I-Premise
vs I-Premise
6.9 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
and I-Premise
a I-Premise
greater I-Premise
use I-Premise
of I-Premise
analgesics I-Premise
. I-Premise

Median B-Premise
relative I-Premise
dose I-Premise
intensity I-Premise
over I-Premise
eight I-Premise
cycles I-Premise
( I-Premise
DI8 I-Premise
) I-Premise
was I-Premise
78 I-Premise
% I-Premise
for I-Premise
CPT-11 I-Premise
and I-Premise
82 I-Premise
% I-Premise
for I-Premise
5-FU I-Premise
. I-Premise

PIDs B-Premise
were I-Premise
0·9 I-Premise
and I-Premise
0·3 I-Premise
in I-Premise
the I-Premise
oxycodone/paracetamol I-Premise
and I-Premise
placebo I-Premise
groups I-Premise
respectively I-Premise
, I-Premise
on I-Premise
day I-Premise
1 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
, I-Premise
and I-Premise
1·5 I-Premise
and I-Premise
0·3 I-Premise
respectively I-Premise
on I-Premise
day I-Premise
3 I-Premise
( I-Premise
P I-Premise
< I-Premise
0·001 I-Premise
) I-Premise
. I-Premise

Median B-Premise
survival I-Premise
was I-Premise
14.6 I-Premise
months I-Premise
( I-Premise
temozolomide I-Premise
+ I-Premise
radiotherapy I-Premise
) I-Premise
versus I-Premise
12.1 I-Premise
months I-Premise
( I-Premise
radiotherapy I-Premise
alone I-Premise
) I-Premise
. I-Premise

Thirty-two B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
19 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
experienced I-Premise
Grade I-Premise
3 I-Premise
or I-Premise
higher I-Premise
adverse I-Premise
events I-Premise
( I-Premise
graded I-Premise
using I-Premise
the I-Premise
National I-Premise
Cancer I-Premise
Institute I-Premise
Common I-Premise
Toxicity I-Premise
Criteria I-Premise
[ I-Premise
version I-Premise
2.0 I-Premise
] I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.025 I-Premise
) I-Premise
. I-Premise

Analgesic B-Premise
cost I-Premise
and I-Premise
hospital I-Premise
stay I-Premise
were I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
treated I-Premise
groups I-Premise
than I-Premise
in I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Mean B-Premise
weight I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
were I-Premise
-1.0 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
-1.5 I-Premise
to I-Premise
-0.5 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
0.2 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-0.2 I-Premise
to I-Premise
+0.6 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
=.002 I-Premise
) I-Premise
. I-Premise

After B-Premise
2 I-Premise
and I-Premise
3 I-Premise
years I-Premise
, I-Premise
this I-Premise
had I-Premise
decreased I-Premise
to I-Premise
49 I-Premise
% I-Premise
and I-Premise
41 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Time B-Premise
to I-Premise
pain I-Premise
and I-Premise
time I-Premise
to I-Premise
analgesic I-Premise
use I-Premise
were I-Premise
significantly I-Premise
delayed I-Premise
in I-Premise
patients I-Premise
receiving I-Premise
erlotinib I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR=0.61 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.42-0.88 I-Premise
] I-Premise
";" I-Premise
p=0.0080 I-Premise
and I-Premise
HR=0.66 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.46-0.94 I-Premise
] I-Premise
";" I-Premise
p=0.0199 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

Complete B-Premise
remission I-Premise
was I-Premise
achieved I-Premise
in I-Premise
91 I-Premise
% I-Premise
( I-Premise
170/186 I-Premise
) I-Premise
of I-Premise
all I-Premise
patients I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
other I-Premise
treatment-related I-Premise
side I-Premise
effects I-Premise
between I-Premise
groups I-Premise
. I-Premise

Severe B-Premise
nonhematologic I-Premise
toxicity I-Premise
was I-Premise
infrequent I-Premise
in I-Premise
both I-Premise
groups I-Premise
, I-Premise
including I-Premise
grade I-Premise
3/4 I-Premise
cardiac I-Premise
events I-Premise
( I-Premise
AT I-Premise
, I-Premise
3 I-Premise
% I-Premise
";" I-Premise
AC I-Premise
, I-Premise
4 I-Premise
% I-Premise
) I-Premise
. I-Premise

Sentinel B-Premise
nodes I-Premise
were I-Premise
found I-Premise
in I-Premise
95 I-Premise
% I-Premise
of I-Premise
the I-Premise
SNBM I-Premise
group I-Premise
( I-Premise
29 I-Premise
% I-Premise
positive I-Premise
) I-Premise
and I-Premise
93 I-Premise
% I-Premise
of I-Premise
the I-Premise
RAC I-Premise
group I-Premise
( I-Premise
25 I-Premise
% I-Premise
positive I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
1.01 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.77 I-Premise
to I-Premise
1.32 I-Premise
) I-Premise
. I-Premise

The B-Premise
duration I-Premise
of I-Premise
survival I-Premise
and I-Premise
disease-free I-Premise
survival I-Premise
at I-Premise
2 I-Premise
years I-Premise
after I-Premise
randomization I-Premise
were I-Premise
estimated I-Premise
at I-Premise
22 I-Premise
% I-Premise
and I-Premise
19 I-Premise
% I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
22 I-Premise
% I-Premise
and I-Premise
14 I-Premise
% I-Premise
for I-Premise
the I-Premise
GM-CSF I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
NS I-Premise
) I-Premise
. I-Premise

Cox B-Premise
multivariate I-Premise
analysis I-Premise
showed I-Premise
paclitaxel I-Premise
plus I-Premise
supportive I-Premise
care I-Premise
to I-Premise
be I-Premise
statistically I-Premise
significantly I-Premise
associated I-Premise
with I-Premise
improved I-Premise
survival I-Premise
( I-Premise
two-sided I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
. I-Premise

The B-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
was I-Premise
achieved I-Premise
in I-Premise
28 I-Premise
% I-Premise
of I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
and I-Premise
26 I-Premise
% I-Premise
of I-Premise
patients I-Premise
from I-Premise
the I-Premise
delayed I-Premise
treatment I-Premise
group I-Premise
( I-Premise
27/97 I-Premise
and I-Premise
27/103 I-Premise
, I-Premise
respectively I-Premise
";" I-Premise
absolute I-Premise
difference I-Premise
1.6 I-Premise
% I-Premise
, I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-10.7 I-Premise
% I-Premise
to I-Premise
13.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

Patients B-Premise
receiving I-Premise
FLOT I-Premise
exhibited I-Premise
higher I-Premise
response I-Premise
rates I-Premise
and I-Premise
had I-Premise
improved I-Premise
disease-free I-Premise
and I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
. I-Premise

Women B-Premise
with I-Premise
advanced I-Premise
breast I-Premise
cancer I-Premise
randomized I-Premise
to I-Premise
the I-Premise
seated I-Premise
exercise I-Premise
intervention I-Premise
had I-Premise
a I-Premise
slower I-Premise
decline I-Premise
in I-Premise
total I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
and I-Premise
less I-Premise
increase I-Premise
in I-Premise
fatigue I-Premise
scores I-Premise
starting I-Premise
with I-Premise
the I-Premise
third I-Premise
cycle I-Premise
of I-Premise
chemotherapy I-Premise
. I-Premise

Over B-Premise
the I-Premise
first I-Premise
15 I-Premise
months I-Premise
, I-Premise
radiotherapy I-Premise
for I-Premise
this I-Premise
population I-Premise
is I-Premise
not I-Premise
a I-Premise
cost-effective I-Premise
treatment I-Premise
. I-Premise

No B-Premise
adverse I-Premise
events I-Premise
or I-Premise
skeletal I-Premise
complications I-Premise
occurred I-Premise
during I-Premise
the I-Premise
supervised I-Premise
exercise I-Premise
sessions I-Premise
. I-Premise

At B-Premise
first I-Premise
follow-up I-Premise
, I-Premise
groups I-Premise
differed I-Premise
only I-Premise
in I-Premise
social I-Premise
functioning I-Premise
, I-Premise
favouring I-Premise
the I-Premise
radiotherapy-only I-Premise
group I-Premise
( I-Premise
mean I-Premise
score I-Premise
79.0 I-Premise
[ I-Premise
SD I-Premise
3.2 I-Premise
] I-Premise
for I-Premise
patients I-Premise
assigned I-Premise
radiotherapy I-Premise
vs I-Premise
67.4 I-Premise
[ I-Premise
2.7 I-Premise
] I-Premise
for I-Premise
those I-Premise
assigned I-Premise
radiotherapy I-Premise
and I-Premise
temozolomide I-Premise
";" I-Premise
difference I-Premise
between I-Premise
groups I-Premise
11.6 I-Premise
points I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
3.5-19.7 I-Premise
] I-Premise
, I-Premise
p=0.0052 I-Premise
) I-Premise
. I-Premise

The B-Premise
total I-Premise
efficiencies I-Premise
of I-Premise
non-squamous I-Premise
cell I-Premise
carcinoma I-Premise
were I-Premise
27.62 I-Premise
% I-Premise
and I-Premise
16.00 I-Premise
% I-Premise
. I-Premise

Major B-Premise
toxicity I-Premise
was I-Premise
similar I-Premise
across I-Premise
all I-Premise
three I-Premise
groups I-Premise
. I-Premise

In B-Premise
both I-Premise
the I-Premise
patients I-Premise
' I-Premise
subjective I-Premise
assessment I-Premise
of I-Premise
their I-Premise
QL I-Premise
and I-Premise
the I-Premise
physicians I-Premise
' I-Premise
perception I-Premise
of I-Premise
the I-Premise
patients I-Premise
' I-Premise
QL I-Premise
, I-Premise
the I-Premise
largest I-Premise
adverse I-Premise
QL I-Premise
effects I-Premise
of I-Premise
Ax I-Premise
were I-Premise
observed I-Premise
from I-Premise
baseline I-Premise
to I-Premise
the I-Premise
first I-Premise
postoperative I-Premise
assessment I-Premise
, I-Premise
but B-Premise
the I-Premise
differences I-Premise
tended I-Premise
to I-Premise
disappear I-Premise
in I-Premise
6 I-Premise
to I-Premise
12 I-Premise
months I-Premise
. I-Premise

Operative B-Premise
time I-Premise
was I-Premise
53 I-Premise
minutes I-Premise
longer I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
. I-Premise

Overall B-Premise
patient-recorded I-Premise
quality I-Premise
of I-Premise
life I-Premise
and I-Premise
arm I-Premise
functioning I-Premise
scores I-Premise
were I-Premise
statistically I-Premise
significantly I-Premise
better I-Premise
in I-Premise
the I-Premise
sentinel I-Premise
lymph I-Premise
node I-Premise
biopsy I-Premise
group I-Premise
throughout I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
or I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

The B-Premise
embolization I-Premise
group I-Premise
had I-Premise
a I-Premise
shorter I-Premise
median I-Premise
duration I-Premise
of I-Premise
hospitalization I-Premise
than I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
1 I-Premise
day I-Premise
vs. I-Premise
5 I-Premise
days I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
and I-Premise
a I-Premise
shorter I-Premise
time I-Premise
before I-Premise
returning I-Premise
to I-Premise
work I-Premise
( I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

During B-Premise
the I-Premise
first I-Premise
year I-Premise
of I-Premise
follow-up I-Premise
, I-Premise
there I-Premise
were I-Premise
13 I-Premise
major I-Premise
adverse I-Premise
events I-Premise
in I-Premise
the I-Premise
embolization I-Premise
group I-Premise
( I-Premise
12 I-Premise
% I-Premise
) I-Premise
and I-Premise
10 I-Premise
in I-Premise
the I-Premise
surgical I-Premise
group I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
( I-Premise
P=0.22 I-Premise
) I-Premise
, I-Premise
mostly I-Premise
related I-Premise
to I-Premise
the I-Premise
intervention I-Premise
. I-Premise

The B-Premise
level I-Premise
of I-Premise
CD3+ I-Premise
CD4+ I-Premise
and I-Premise
CD4+/CD8+ I-Premise
ratio I-Premise
increased I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
CD8+ I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
( I-Premise
P I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
while I-Premise
they I-Premise
showed I-Premise
insignificant I-Premise
change I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
18.2 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC-Top I-Premise
arm I-Premise
versus I-Premise
18.5 I-Premise
months I-Premise
in I-Premise
the I-Premise
TC I-Premise
arm I-Premise
( I-Premise
stratum-adjusted I-Premise
HR I-Premise
= I-Premise
0.97 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
0.85 I-Premise
to I-Premise
1.10 I-Premise
] I-Premise
";" I-Premise
P I-Premise
= I-Premise
.688 I-Premise
) I-Premise
. I-Premise

For B-Premise
the I-Premise
chemoradiation I-Premise
group I-Premise
, I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
was I-Premise
7.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
6.0 I-Premise
, I-Premise
9.0 I-Premise
) I-Premise
months I-Premise
compared I-Premise
with I-Premise
the I-Premise
mean I-Premise
QALM-24 I-Premise
of I-Premise
8.1 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
7.0 I-Premise
, I-Premise
10.0 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
no I-Premise
chemoradiation I-Premise
group I-Premise
. I-Premise

The B-Premise
primary I-Premise
outcome I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
( I-Premise
adjusted I-Premise
difference I-Premise
-16.8 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-28.34 I-Premise
to I-Premise
-5.3 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.006 I-Premise
) I-Premise
. I-Premise

Between-group B-Premise
differences I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcomes I-Premise
were I-Premise
not I-Premise
significant I-Premise
at I-Premise
12 I-Premise
months I-Premise
, I-Premise
and B-Premise
no I-Premise
significant I-Premise
effects I-Premise
emerged I-Premise
on I-Premise
the I-Premise
secondary I-Premise
end I-Premise
points I-Premise
. I-Premise

Haemoglobin B-Premise
response I-Premise
( I-Premise
increase I-Premise
in I-Premise
Hb I-Premise
> I-Premise
or=2 I-Premise
g/dL I-Premise
from I-Premise
baseline I-Premise
) I-Premise
was I-Premise
observed I-Premise
in I-Premise
78.3 I-Premise
% I-Premise
of I-Premise
patients I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
30,000 I-Premise
IU I-Premise
and I-Premise
66.7 I-Premise
% I-Premise
receiving I-Premise
epoetin I-Premise
beta I-Premise
20,000 I-Premise
IU I-Premise
. I-Premise

Patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise

No B-Premise
significant I-Premise
difference I-Premise
was I-Premise
observed I-Premise
in I-Premise
quality I-Premise
of I-Premise
life I-Premise
and I-Premise
adverse I-Premise
events I-Premise
between I-Premise
the I-Premise
treated I-Premise
groups I-Premise
and I-Premise
the I-Premise
placebo I-Premise
group I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800-mg/d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low- I-Premise
and I-Premise
high-dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160-mg/d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

Vinorelbine-treated B-Premise
patients I-Premise
scored I-Premise
better I-Premise
than I-Premise
control I-Premise
patients I-Premise
on I-Premise
QoL I-Premise
functioning I-Premise
scales I-Premise
, I-Premise
and I-Premise
they I-Premise
reported I-Premise
fewer I-Premise
lung I-Premise
cancer-related I-Premise
symptoms I-Premise
but I-Premise
reported I-Premise
worse I-Premise
toxicity-related I-Premise
symptoms I-Premise
. I-Premise

Eighteen B-Premise
patients I-Premise
receiving I-Premise
IFN5 I-Premise
and I-Premise
4 I-Premise
patients I-Premise
receiving I-Premise
IFN1 I-Premise
had I-Premise
dose I-Premise
reductions I-Premise
( I-Premise
P I-Premise
= I-Premise
.002 I-Premise
) I-Premise
. I-Premise

Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
hematologic I-Premise
toxicity I-Premise
did I-Premise
not I-Premise
exceed I-Premise
15 I-Premise
% I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
. I-Premise

At B-Premise
week I-Premise
12 I-Premise
, I-Premise
changes I-Premise
in I-Premise
TPV I-Premise
for I-Premise
degarelix I-Premise
and I-Premise
goserelin I-Premise
were I-Premise
similar I-Premise
( I-Premise
-37.2 I-Premise
% I-Premise
vs I-Premise
-39.0 I-Premise
% I-Premise
) I-Premise
and I-Premise
met I-Premise
the I-Premise
predefined I-Premise
non-inferiority I-Premise
criterion I-Premise
. I-Premise

The B-Premise
mean I-Premise
changes I-Premise
in I-Premise
the I-Premise
endpoints I-Premise
from I-Premise
baseline I-Premise
in I-Premise
the I-Premise
trial I-Premise
group I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
: I-Premise
in I-Premise
the I-Premise
primary I-Premise
endpoints I-Premise
, I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
fatigue I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
and I-Premise
in I-Premise
the I-Premise
secondary I-Premise
endpoints I-Premise
, I-Premise
grip I-Premise
strength I-Premise
( I-Premise
p I-Premise
= I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
Glasgow I-Premise
Prognostic I-Premise
Score I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
Eastern I-Premise
Cooperative I-Premise
Oncology I-Premise
Group I-Premise
performance I-Premise
status I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
, I-Premise
IL-6 I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
and I-Premise
tumor I-Premise
necrosis I-Premise
factor-α I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

The B-Premise
additional I-Premise
charge I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
was I-Premise
$ I-Premise
1,748 I-Premise
per I-Premise
patient I-Premise
randomized I-Premise
( I-Premise
$ I-Premise
1,194 I-Premise
the I-Premise
result I-Premise
of I-Premise
surgical I-Premise
instruments I-Premise
and I-Premise
$ I-Premise
554 I-Premise
the I-Premise
result I-Premise
of I-Premise
longer I-Premise
operative I-Premise
time I-Premise
) I-Premise
. I-Premise

Percentage B-Premise
transfused I-Premise
was I-Premise
significantly I-Premise
lower I-Premise
in I-Premise
the I-Premise
epoetin I-Premise
alfa I-Premise
group I-Premise
compared I-Premise
with I-Premise
SOC I-Premise
( I-Premise
8.6 I-Premise
% I-Premise
v I-Premise
22.9 I-Premise
% I-Premise
) I-Premise
. I-Premise

The B-Premise
improvement I-Premise
in I-Premise
overall I-Premise
survival I-Premise
did I-Premise
not I-Premise
reach I-Premise
significance I-Premise
( I-Premise
median I-Premise
, I-Premise
16.2 I-Premise
v I-Premise
14.7 I-Premise
months I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
12 I-Premise
) I-Premise
. I-Premise

Other B-Premise
grade I-Premise
3/4 I-Premise
toxic I-Premise
effects I-Premise
were I-Premise
rare I-Premise
( I-Premise
< I-Premise
5 I-Premise
% I-Premise
) I-Premise
. I-Premise

We B-Premise
observed I-Premise
no I-Premise
significant I-Premise
changes I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
. I-Premise

Docetaxel B-Premise
improved I-Premise
progression-free I-Premise
survival I-Premise
, I-Premise
response I-Premise
rate I-Premise
, I-Premise
and I-Premise
disease-related I-Premise
symptoms I-Premise
versus I-Premise
vinorelbine I-Premise
. I-Premise

Fatigue B-Premise
scores I-Premise
indicated I-Premise
less I-Premise
increase I-Premise
and I-Premise
physical I-Premise
well-being I-Premise
subscale I-Premise
scores I-Premise
showed I-Premise
less I-Premise
decline I-Premise
for I-Premise
the I-Premise
experimental I-Premise
group I-Premise
( I-Premise
p I-Premise
= I-Premise
0.008 I-Premise
and I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

When B-Premise
stent I-Premise
obstruction I-Premise
was I-Premise
not I-Premise
regarded I-Premise
as I-Premise
a I-Premise
major I-Premise
complication I-Premise
, I-Premise
no I-Premise
differences I-Premise
in I-Premise
complications I-Premise
were I-Premise
found I-Premise
( I-Premise
P I-Premise
= I-Premise
.4 I-Premise
) I-Premise
. I-Premise

The B-Premise
changes I-Premise
of I-Premise
BMD I-Premise
in I-Premise
group I-Premise
B I-Premise
patients I-Premise
were I-Premise
significantly I-Premise
greater I-Premise
than I-Premise
patients I-Premise
in I-Premise
group I-Premise
A I-Premise
( I-Premise
p=0.011 I-Premise
, I-Premise
CI=0.063-0.437 I-Premise
) I-Premise
, I-Premise
and I-Premise
group I-Premise
C I-Premise
( I-Premise
p=0.003 I-Premise
, I-Premise
CI=0.146-0.620 I-Premise
) I-Premise
. I-Premise

WHO B-Premise
grade I-Premise
3-4 I-Premise
toxicity I-Premise
occurred I-Premise
in I-Premise
13 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
of I-Premise
experimental I-Premise
arm I-Premise
and I-Premise
in I-Premise
8 I-Premise
% I-Premise
of I-Premise
cycles I-Premise
in I-Premise
control I-Premise
arm I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
was I-Premise
7.8 I-Premise
months I-Premise
( I-Premise
range I-Premise
, I-Premise
4-11.6 I-Premise
months I-Premise
) I-Premise
. I-Premise

Functionality B-Premise
was I-Premise
not I-Premise
greatly I-Premise
affected I-Premise
by I-Premise
treatment I-Premise
. I-Premise

The B-Premise
arms I-Premise
were I-Premise
comparable I-Premise
with I-Premise
respect I-Premise
to I-Premise
toxicity I-Premise
except I-Premise
for I-Premise
leucopenia I-Premise
, I-Premise
neutropenia I-Premise
, I-Premise
infection I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
. I-Premise

Intention-to-treat B-Premise
analyses I-Premise
indicated I-Premise
that I-Premise
AET I-Premise
resulted I-Premise
in I-Premise
a I-Premise
nonsignificant I-Premise
( I-Premise
P I-Premise
= I-Premise
0.16 I-Premise
) I-Premise
improvement I-Premise
in I-Premise
global I-Premise
sleep I-Premise
quality I-Premise
compared I-Premise
with I-Premise
usual I-Premise
care I-Premise
[ I-Premise
mean I-Premise
group I-Premise
difference I-Premise
= I-Premise
-0.64 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
( I-Premise
CI I-Premise
) I-Premise
, I-Premise
-1.56 I-Premise
to I-Premise
+0.27 I-Premise
] I-Premise
. I-Premise

Treatment-related B-Premise
toxicity I-Premise
was I-Premise
less I-Premise
in I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
and I-Premise
quality-of-life I-Premise
( I-Premise
QOL I-Premise
) I-Premise
analysis I-Premise
favored I-Premise
the I-Premise
single-agent I-Premise
arm I-Premise
. I-Premise

The B-Premise
female I-Premise
patients I-Premise
in I-Premise
the I-Premise
ORP I-Premise
group I-Premise
had I-Premise
significantly I-Premise
lower I-Premise
body I-Premise
image I-Premise
scores I-Premise
than I-Premise
the I-Premise
male I-Premise
patients I-Premise
( I-Premise
14.9 I-Premise
vs I-Premise
18.3 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
of I-Premise
the I-Premise
same I-Premise
period I-Premise
, I-Premise
the I-Premise
2-and I-Premise
3-year I-Premise
somatic I-Premise
functions I-Premise
, I-Premise
psychological I-Premise
functions I-Premise
, I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
2-year I-Premise
somatic I-Premise
functions I-Premise
and I-Premise
psychological I-Premise
functions I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
";" I-Premise
the B-Premise
3-year I-Premise
psychological I-Premise
functions I-Premise
and I-Premise
the I-Premise
general I-Premise
symptoms I-Premise
scores I-Premise
decreased I-Premise
in I-Premise
the I-Premise
treatment I-Premise
group I-Premise
, I-Premise
all I-Premise
with I-Premise
statistical I-Premise
difference I-Premise
( I-Premise
all I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Postoperative B-Premise
side I-Premise
effects I-Premise
were I-Premise
significantly I-Premise
less I-Premise
in I-Premise
the I-Premise
SLN I-Premise
group I-Premise
and I-Premise
there I-Premise
was I-Premise
no I-Premise
negative I-Premise
impact I-Premise
of I-Premise
the I-Premise
SLN I-Premise
procedure I-Premise
on I-Premise
psychologic I-Premise
well I-Premise
being I-Premise
. I-Premise

With B-Premise
a I-Premise
median I-Premise
follow-up I-Premise
time I-Premise
of I-Premise
12 I-Premise
months I-Premise
and I-Premise
382 I-Premise
deaths I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
clear I-Premise
survival I-Premise
benefit I-Premise
when I-Premise
comparing I-Premise
PCV I-Premise
with I-Premise
TMZ I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
, I-Premise
0.91 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.74 I-Premise
to I-Premise
1.11 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.350 I-Premise
) I-Premise
. I-Premise

By B-Premise
contrast I-Premise
, I-Premise
QoL I-Premise
was I-Premise
preserved I-Premise
in I-Premise
the I-Premise
rhTSH I-Premise
group I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
difference I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
in I-Premise
disease-free I-Premise
survival I-Premise
( I-Premise
DFS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
DFS I-Premise
79.8 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
76.4 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.527 I-Premise
) I-Premise
and I-Premise
overall I-Premise
survival I-Premise
( I-Premise
OS I-Premise
) I-Premise
( I-Premise
2-year I-Premise
OS I-Premise
83.1 I-Premise
% I-Premise
in I-Premise
the I-Premise
intervention I-Premise
arm I-Premise
and I-Premise
84.3 I-Premise
% I-Premise
in I-Premise
the I-Premise
control I-Premise
arm I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.925 I-Premise
) I-Premise
. I-Premise

Compared B-Premise
with I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
standard I-Premise
chemotherapy I-Premise
, I-Premise
patients I-Premise
who I-Premise
were I-Premise
treated I-Premise
with I-Premise
capecitabine I-Premise
had I-Premise
significantly I-Premise
better I-Premise
QoL I-Premise
, I-Premise
role I-Premise
function I-Premise
, I-Premise
and I-Premise
social I-Premise
function I-Premise
, I-Premise
fewer I-Premise
systemic I-Premise
adverse I-Premise
effects I-Premise
, I-Premise
less I-Premise
psychological I-Premise
distress I-Premise
, I-Premise
and I-Premise
less I-Premise
fatigue I-Premise
during I-Premise
and I-Premise
at I-Premise
the I-Premise
completion I-Premise
of I-Premise
treatment I-Premise
( I-Premise
P I-Premise
≤ I-Premise
.005 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
grade I-Premise
2 I-Premise
or I-Premise
above I-Premise
nausea I-Premise
was I-Premise
numerically I-Premise
higher I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
, I-Premise
but B-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
GE I-Premise
15.5 I-Premise
% I-Premise
, I-Premise
GP I-Premise
27.7 I-Premise
% I-Premise
, I-Premise
p I-Premise
= I-Premise
0.20 I-Premise
) I-Premise
. I-Premise

16 B-Premise
( I-Premise
29 I-Premise
% I-Premise
) I-Premise
patients I-Premise
in I-Premise
the I-Premise
open I-Premise
oesophagectomy I-Premise
group I-Premise
had I-Premise
pulmonary I-Premise
infection I-Premise
in I-Premise
the I-Premise
first I-Premise
2 I-Premise
weeks I-Premise
compared I-Premise
with I-Premise
five I-Premise
( I-Premise
9 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
minimally I-Premise
invasive I-Premise
group I-Premise
( I-Premise
relative I-Premise
risk I-Premise
[ I-Premise
RR I-Premise
] I-Premise
0·30 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·12-0·76 I-Premise
";" I-Premise
p=0·005 I-Premise
) I-Premise
. I-Premise

Intrusive B-Premise
thoughts I-Premise
also I-Premise
influenced I-Premise
the I-Premise
trajectory I-Premise
of I-Premise
pain I-Premise
, I-Premise
depressive I-Premise
symptoms I-Premise
, I-Premise
negative I-Premise
affect I-Premise
, I-Premise
and I-Premise
physical I-Premise
functioning I-Premise
over I-Premise
time I-Premise
";" I-Premise
women B-Premise
with I-Premise
higher I-Premise
intrusions I-Premise
at I-Premise
baseline I-Premise
started I-Premise
worse I-Premise
and I-Premise
improved I-Premise
over I-Premise
time I-Premise
, I-Premise
whereas I-Premise
those I-Premise
with I-Premise
lower I-Premise
intrusions I-Premise
remained I-Premise
at I-Premise
a I-Premise
constant I-Premise
, I-Premise
lower I-Premise
level I-Premise
over I-Premise
time I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
significant I-Premise
survival I-Premise
differences I-Premise
between I-Premise
the I-Premise
244 I-Premise
interferon-alfa-treated I-Premise
patients I-Premise
and I-Premise
248 I-Premise
noninterferon-alfa I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.00 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.81-1.24 I-Premise
) I-Premise
or I-Premise
between I-Premise
the I-Premise
247 I-Premise
interleukin-2 I-Premise
and I-Premise
245 I-Premise
noninterleukin-2-treated I-Premise
patients I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.07 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.87-1.33 I-Premise
";" I-Premise
log I-Premise
rank I-Premise
, I-Premise
0.99 I-Premise
and I-Premise
0.52 I-Premise
, I-Premise
respectively I-Premise
) I-Premise
. I-Premise

At B-Premise
study I-Premise
completion I-Premise
, I-Premise
participants I-Premise
in I-Premise
the I-Premise
IG I-Premise
were I-Premise
walking I-Premise
twice I-Premise
as I-Premise
far I-Premise
and I-Premise
were I-Premise
significantly I-Premise
more I-Premise
likely I-Premise
to I-Premise
have I-Premise
continued I-Premise
walking I-Premise
or I-Premise
another I-Premise
form I-Premise
of I-Premise
exercise I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
UCG I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
16 I-Premise
and I-Premise
21 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
C3 I-Premise
and I-Premise
C6 I-Premise
groups I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P=0.21 I-Premise
, I-Premise
HR I-Premise
0.86 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.68-1.08 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
allocated I-Premise
to I-Premise
oxaliplatin I-Premise
plus I-Premise
LV5FU2 I-Premise
had I-Premise
significantly I-Premise
longer I-Premise
progression-free I-Premise
survival I-Premise
( I-Premise
median I-Premise
, I-Premise
9.0 I-Premise
v I-Premise
6.2 I-Premise
months I-Premise
";" I-Premise
P I-Premise
=.0003 I-Premise
) I-Premise
and I-Premise
better I-Premise
response I-Premise
rate I-Premise
( I-Premise
50.7 I-Premise
% I-Premise
v I-Premise
22.3 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
when I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
arm I-Premise
. I-Premise

No B-Premise
unique I-Premise
safety I-Premise
observations I-Premise
were I-Premise
reported I-Premise
during I-Premise
open-label I-Premise
exposure I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
EBRT I-Premise
reported I-Premise
lower I-Premise
scores I-Premise
on I-Premise
the I-Premise
SF-36 I-Premise
scales I-Premise
" I-Premise
physical I-Premise
functioning I-Premise
" I-Premise
( I-Premise
P I-Premise
= I-Premise
.004 I-Premise
) I-Premise
and I-Premise
" I-Premise
role-physical I-Premise
" I-Premise
( I-Premise
P I-Premise
= I-Premise
.003 I-Premise
) I-Premise
. I-Premise

In B-Premise
contrast I-Premise
, I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
, I-Premise
endpoints I-Premise
with I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
from I-Premise
baseline I-Premise
included I-Premise
body I-Premise
weight I-Premise
( I-Premise
p I-Premise
< I-Premise
0.02 I-Premise
) I-Premise
and I-Premise
appetite I-Premise
( I-Premise
p I-Premise
= I-Premise
0.02 I-Premise
) I-Premise
. I-Premise

Significant B-Premise
improvements I-Premise
in I-Premise
self-reported I-Premise
anxiety I-Premise
, I-Premise
depression I-Premise
, I-Premise
interference I-Premise
of I-Premise
hot I-Premise
flashes I-Premise
on I-Premise
daily I-Premise
activities I-Premise
, I-Premise
and I-Premise
sleep I-Premise
were I-Premise
observed I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
the I-Premise
hypnosis I-Premise
intervention I-Premise
( I-Premise
P I-Premise
< I-Premise
.005 I-Premise
) I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
no I-Premise
treatment I-Premise
control I-Premise
group I-Premise
. I-Premise

Progression-free B-Premise
survival I-Premise
( I-Premise
PFS I-Premise
) I-Premise
of I-Premise
the I-Premise
patients I-Premise
in I-Premise
the I-Premise
Tomudex I-Premise
arm I-Premise
was I-Premise
statistically I-Premise
lower I-Premise
compared I-Premise
to I-Premise
that I-Premise
of I-Premise
patients I-Premise
treated I-Premise
with I-Premise
LV5FU2 I-Premise
or I-Premise
ldLV5FU2 I-Premise
( I-Premise
combined I-Premise
group I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.013 I-Premise
, I-Premise
log I-Premise
rank I-Premise
test I-Premise
) I-Premise
. I-Premise

Epoetin B-Premise
alfa I-Premise
recipients I-Premise
had I-Premise
less I-Premise
of I-Premise
a I-Premise
decrease I-Premise
in I-Premise
FACT-An I-Premise
subscale I-Premise
scores I-Premise
from I-Premise
baseline I-Premise
to I-Premise
cycle I-Premise
4 I-Premise
and I-Premise
improvement I-Premise
in I-Premise
FACT-An I-Premise
subscale I-Premise
scores I-Premise
at I-Premise
6-month I-Premise
follow-up I-Premise
assessment I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
. I-Premise

PF B-Premise
change I-Premise
scores I-Premise
were I-Premise
-3.9 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
-8.6 I-Premise
for I-Premise
BSC I-Premise
( I-Premise
P I-Premise
= I-Premise
.046 I-Premise
) I-Premise
at I-Premise
8 I-Premise
weeks I-Premise
and I-Premise
were I-Premise
-5.9 I-Premise
and I-Premise
-12.5 I-Premise
for I-Premise
cetuximab I-Premise
and I-Premise
BSC I-Premise
, I-Premise
respectively I-Premise
, I-Premise
( I-Premise
P I-Premise
= I-Premise
.027 I-Premise
) I-Premise
at I-Premise
16 I-Premise
weeks I-Premise
. I-Premise

Peripheral B-Premise
neuropathy I-Premise
and I-Premise
alopecia I-Premise
were I-Premise
more I-Premise
common I-Premise
with I-Premise
CVP I-Premise
. I-Premise

Patients B-Premise
who I-Premise
received I-Premise
EBRT I-Premise
reported I-Premise
significantly I-Premise
higher I-Premise
levels I-Premise
of I-Premise
diarrhea I-Premise
and I-Premise
bowel I-Premise
symptoms I-Premise
. I-Premise

Attrition B-Premise
rates I-Premise
did I-Premise
not I-Premise
vary I-Premise
significantly I-Premise
between I-Premise
study I-Premise
arms I-Premise
. I-Premise

There B-Premise
were I-Premise
also I-Premise
no I-Premise
differences I-Premise
in I-Premise
median I-Premise
survival I-Premise
( I-Premise
stent I-Premise
: I-Premise
56 I-Premise
days I-Premise
vs I-Premise
GJJ I-Premise
: I-Premise
78 I-Premise
days I-Premise
) I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise

A B-Premise
statistically I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
general I-Premise
health I-Premise
score I-Premise
in I-Premise
both I-Premise
homeopathy I-Premise
groups I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
on I-Premise
the I-Premise
SF-36 I-Premise
after I-Premise
1 I-Premise
year I-Premise
was I-Premise
found I-Premise
. I-Premise

Adjusted B-Premise
for I-Premise
baseline I-Premise
score I-Premise
, I-Premise
disease I-Premise
, I-Premise
and I-Premise
demographic I-Premise
covariates I-Premise
, I-Premise
the I-Premise
intervention I-Premise
group I-Premise
showed I-Premise
an I-Premise
estimated I-Premise
improvement I-Premise
at I-Premise
six I-Premise
weeks I-Premise
for I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
of I-Premise
-6.6 I-Premise
points I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
-12.3 I-Premise
to I-Premise
-0.9 I-Premise
, I-Premise
P=0.02 I-Premise
";" I-Premise
effect I-Premise
size=0.33 I-Premise
, I-Premise
0.04 I-Premise
to I-Premise
0.61 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
differences I-Premise
in I-Premise
patients I-Premise
' I-Premise
QOL I-Premise
outcomes I-Premise
over I-Premise
the I-Premise
study I-Premise
period I-Premise
. I-Premise

There B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
found I-Premise
in I-Premise
the I-Premise
primary I-Premise
outcome I-Premise
measure I-Premise
, I-Premise
the I-Premise
hot I-Premise
flash I-Premise
severity I-Premise
score I-Premise
, I-Premise
although B-Premise
there I-Premise
was I-Premise
a I-Premise
positive I-Premise
trend I-Premise
in I-Premise
the I-Premise
single I-Premise
remedy I-Premise
group I-Premise
during I-Premise
the I-Premise
first I-Premise
3 I-Premise
months I-Premise
of I-Premise
the I-Premise
study I-Premise
( I-Premise
p I-Premise
= I-Premise
0.1 I-Premise
) I-Premise
. I-Premise

Improvements B-Premise
in I-Premise
absolute I-Premise
OS I-Premise
rates I-Premise
were I-Premise
10 I-Premise
% I-Premise
at I-Premise
6 I-Premise
months I-Premise
and I-Premise
15 I-Premise
% I-Premise
at I-Premise
12 I-Premise
months I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
monotherapy I-Premise
arm I-Premise
. I-Premise

Three B-Premise
treatment-related I-Premise
deaths I-Premise
occurred I-Premise
: I-Premise
2 I-Premise
patients I-Premise
in I-Premise
the I-Premise
surgical I-Premise
arms I-Premise
( I-Premise
one I-Premise
late I-Premise
pulmonary I-Premise
toxicity I-Premise
and I-Premise
one I-Premise
pulmonary I-Premise
embolus I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
patient I-Premise
in I-Premise
the I-Premise
radiation I-Premise
arm I-Premise
( I-Premise
radiation I-Premise
pneumonitis I-Premise
) I-Premise
. I-Premise

The B-Premise
unadjusted I-Premise
relative I-Premise
risk I-Premise
for I-Premise
mortality I-Premise
in I-Premise
the I-Premise
octreotide I-Premise
group I-Premise
compared I-Premise
with I-Premise
patients I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
1.11 I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.76-1.63 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.59 I-Premise
) I-Premise
. I-Premise

Poor B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
between I-Premise
two I-Premise
groups I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
23.9 I-Premise
% I-Premise
vs. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
15.8 I-Premise
% I-Premise
vs. I-Premise
3.7 I-Premise
% I-Premise
) I-Premise
after I-Premise
chemotherapy I-Premise
. I-Premise

Patients B-Premise
carrying I-Premise
the I-Premise
GPX1-CC I-Premise
genotype I-Premise
had I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
the I-Premise
UNISCALE I-Premise
( I-Premise
odds I-Premise
ratio I-Premise
( I-Premise
OR I-Premise
) I-Premise
: I-Premise
7.5 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
total I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Lung I-Premise
score I-Premise
( I-Premise
OR I-Premise
: I-Premise
11.0 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
physical I-Premise
( I-Premise
OR I-Premise
: I-Premise
7.1 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.03 I-Premise
) I-Premise
, I-Premise
functional I-Premise
( I-Premise
OR I-Premise
: I-Premise
5.2 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
, I-Premise
and I-Premise
emotional I-Premise
well-being I-Premise
constructs I-Premise
( I-Premise
OR I-Premise
: I-Premise
23.8 I-Premise
";" I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Although B-Premise
there I-Premise
was I-Premise
a I-Premise
tendency I-Premise
for I-Premise
improved I-Premise
survival I-Premise
in I-Premise
grade I-Premise
III I-Premise
, I-Premise
no I-Premise
statistical I-Premise
significant I-Premise
differences I-Premise
were I-Premise
found I-Premise
between I-Premise
the I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
grade I-Premise
3-4 I-Premise
late I-Premise
radiation I-Premise
toxicities I-Premise
. I-Premise

The B-Premise
pectoral I-Premise
stretching I-Premise
program I-Premise
did I-Premise
not I-Premise
influence I-Premise
the I-Premise
outcomes I-Premise
measured I-Premise
because I-Premise
the I-Premise
symptoms I-Premise
reported I-Premise
by I-Premise
patients I-Premise
were I-Premise
not I-Premise
a I-Premise
consequence I-Premise
of I-Premise
contracture I-Premise
. I-Premise

Conversely B-Premise
, I-Premise
the I-Premise
nocturnal I-Premise
group I-Premise
exhibited I-Premise
a I-Premise
significant I-Premise
decrease I-Premise
in I-Premise
the I-Premise
occurrence I-Premise
of I-Premise
muscle I-Premise
cramps I-Premise
in I-Premise
the I-Premise
legs I-Premise
( I-Premise
P I-Premise
= I-Premise
0.014 I-Premise
) I-Premise
and I-Premise
significantly I-Premise
improved I-Premise
Fisher I-Premise
's I-Premise
ratio I-Premise
after I-Premise
3 I-Premise
months I-Premise
( I-Premise
P I-Premise
= I-Premise
0.04 I-Premise
) I-Premise
. I-Premise

After B-Premise
4 I-Premise
weeks I-Premise
of I-Premise
NHT I-Premise
, I-Premise
negative I-Premise
changes I-Premise
of I-Premise
FACT-B I-Premise
and I-Premise
FACT-G I-Premise
scores I-Premise
were I-Premise
found I-Premise
in I-Premise
group I-Premise
B I-Premise
and I-Premise
C I-Premise
patients I-Premise
, I-Premise
but B-Premise
there I-Premise
were I-Premise
positive I-Premise
changes I-Premise
in I-Premise
group I-Premise
A I-Premise
patients I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
between I-Premise
the I-Premise
two I-Premise
treatment I-Premise
arms I-Premise
in I-Premise
favor I-Premise
of I-Premise
the I-Premise
r-HuEPO-treated I-Premise
group I-Premise
. I-Premise

Linear B-Premise
mixed I-Premise
models I-Premise
( I-Premise
primary I-Premise
model I-Premise
) I-Premise
demonstrated I-Premise
no I-Premise
statistically I-Premise
significant I-Premise
overall I-Premise
difference I-Premise
between I-Premise
EVE I-Premise
+ I-Premise
EXE I-Premise
and I-Premise
PBO I-Premise
+ I-Premise
EXE I-Premise
for I-Premise
QL2 I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-1.91 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-4.61 I-Premise
, I-Premise
0.78 I-Premise
) I-Premise
, I-Premise
BRBS I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-0.18 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-1.98 I-Premise
, I-Premise
1.62 I-Premise
) I-Premise
, I-Premise
or I-Premise
BRAS I-Premise
( I-Premise
LSM I-Premise
difference I-Premise
= I-Premise
-0.42 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
-2.94 I-Premise
, I-Premise
2.10 I-Premise
) I-Premise
. I-Premise

With B-Premise
regard I-Premise
to I-Premise
the I-Premise
long-term I-Premise
quality I-Premise
of I-Premise
life I-Premise
there I-Premise
were I-Premise
no I-Premise
significant I-Premise
differences I-Premise
between I-Premise
the I-Premise
two I-Premise
groups I-Premise
. I-Premise

Only B-Premise
1 I-Premise
patient I-Premise
in I-Premise
each I-Premise
group I-Premise
had I-Premise
acute I-Premise
nonhematologic I-Premise
toxicity I-Premise
greater I-Premise
than I-Premise
Grade I-Premise
3 I-Premise
( I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significantly I-Premise
higher I-Premise
risk I-Premise
of I-Premise
death I-Premise
in I-Premise
the I-Premise
TMX120 I-Premise
group I-Premise
compared I-Premise
with I-Premise
the I-Premise
P I-Premise
group I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
1.39 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
, I-Premise
1.07-1.81 I-Premise
) I-Premise
. I-Premise

QOL B-Premise
decreased I-Premise
during I-Premise
the I-Premise
first I-Premise
8 I-Premise
weeks I-Premise
of I-Premise
treatment I-Premise
, I-Premise
and I-Premise
a I-Premise
partial I-Premise
recovery I-Premise
followed I-Premise
. I-Premise

Three B-Premise
years I-Premise
after I-Premise
radiotherapy I-Premise
, I-Premise
urinary I-Premise
incontinence I-Premise
was I-Premise
reported I-Premise
by I-Premise
35 I-Premise
% I-Premise
of I-Premise
patients I-Premise
, I-Premise
but I-Premise
only I-Premise
6 I-Premise
% I-Premise
required I-Premise
the I-Premise
use I-Premise
of I-Premise
a I-Premise
pad I-Premise
or I-Premise
other I-Premise
protective I-Premise
device I-Premise
. I-Premise

There B-Premise
was I-Premise
significant I-Premise
early I-Premise
attrition I-Premise
due I-Premise
to I-Premise
disease I-Premise
progression I-Premise
";" I-Premise
only I-Premise
61.5 I-Premise
% I-Premise
of I-Premise
patients I-Premise
were I-Premise
alive I-Premise
at I-Premise
2 I-Premise
months I-Premise
. I-Premise

That B-Premise
is I-Premise
, I-Premise
by I-Premise
specifically I-Premise
lowering I-Premise
intervention I-Premise
patients I-Premise
' I-Premise
distress I-Premise
at I-Premise
4 I-Premise
months I-Premise
, I-Premise
their I-Premise
health I-Premise
was I-Premise
improved I-Premise
at I-Premise
12 I-Premise
months I-Premise
( I-Premise
p I-Premise
< I-Premise
.05 I-Premise
) I-Premise
. I-Premise

There B-Premise
were I-Premise
three I-Premise
treatment-related I-Premise
deaths I-Premise
with I-Premise
CAF I-Premise
but B-Premise
none I-Premise
with I-Premise
the I-Premise
16-week I-Premise
regimen I-Premise
. I-Premise

All B-Premise
procedures I-Premise
were I-Premise
well I-Premise
tolerated I-Premise
by I-Premise
the I-Premise
patients I-Premise
. I-Premise

Global B-Premise
QOL I-Premise
, I-Premise
emotional/role I-Premise
functioning I-Premise
, I-Premise
nausea/vomiting I-Premise
, I-Premise
pain I-Premise
, I-Premise
swallowing I-Premise
, I-Premise
speech I-Premise
, I-Premise
social I-Premise
contact/eating I-Premise
, I-Premise
insomnia I-Premise
showed I-Premise
rapid I-Premise
recovery I-Premise
( I-Premise
< I-Premise
6months I-Premise
) I-Premise
while I-Premise
physical/cognitive I-Premise
functioning I-Premise
, I-Premise
dry I-Premise
mouth I-Premise
, I-Premise
sticky I-Premise
saliva I-Premise
, I-Premise
fatigue I-Premise
, I-Premise
senses I-Premise
showed I-Premise
delayed I-Premise
recovery I-Premise
( I-Premise
> I-Premise
6months I-Premise
) I-Premise
. I-Premise

Among B-Premise
the I-Premise
patients I-Premise
receiving I-Premise
treatment I-Premise
3 I-Premise
times I-Premise
weekly I-Premise
, I-Premise
16 I-Premise
of I-Premise
49 I-Premise
patients I-Premise
( I-Premise
32.7 I-Premise
% I-Premise
) I-Premise
achieved I-Premise
a I-Premise
clinical I-Premise
response I-Premise
at I-Premise
the I-Premise
end I-Premise
of I-Premise
the I-Premise
third I-Premise
treatment I-Premise
cycle I-Premise
( I-Premise
no I-Premise
CRs I-Premise
, I-Premise
1 I-Premise
PR I-Premise
, I-Premise
and I-Premise
15 I-Premise
SDs I-Premise
) I-Premise
. I-Premise

Complete B-Premise
resection I-Premise
was I-Premise
performed I-Premise
in I-Premise
73 I-Premise
% I-Premise
of I-Premise
26 I-Premise
patients I-Premise
undergoing I-Premise
thoracotomy I-Premise
. I-Premise

Both B-Premise
energy I-Premise
and I-Premise
protein I-Premise
intake I-Premise
decreased I-Premise
significantly I-Premise
in I-Premise
group I-Premise
3 I-Premise
( I-Premise
p I-Premise
< I-Premise
.01 I-Premise
) I-Premise
. I-Premise

A B-Premise
model I-Premise
measuring I-Premise
effectiveness I-Premise
of I-Premise
CCSP I-Premise
on I-Premise
QOL I-Premise
( I-Premise
total I-Premise
and I-Premise
subscale I-Premise
) I-Premise
at I-Premise
1-year I-Premise
follow-up I-Premise
showed I-Premise
that I-Premise
the I-Premise
CCSP I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
38 I-Premise
) I-Premise
had I-Premise
significant I-Premise
improvement I-Premise
in I-Premise
overall I-Premise
QOL I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
, I-Premise
health I-Premise
and I-Premise
functioning I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
, I-Premise
and I-Premise
socioeconomic I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
and I-Premise
psychological/spiritual I-Premise
well-being I-Premise
( I-Premise
p I-Premise
< I-Premise
0.01 I-Premise
) I-Premise
compared I-Premise
with I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
35 I-Premise
) I-Premise
. I-Premise

Regardless B-Premise
of I-Premise
treatment I-Premise
arm I-Premise
, I-Premise
participants I-Premise
reported I-Premise
high I-Premise
levels I-Premise
of I-Premise
QOL I-Premise
with I-Premise
few I-Premise
exceptions I-Premise
. I-Premise

Long-term B-Premise
benefits I-Premise
for I-Premise
older I-Premise
patients I-Premise
were I-Premise
seen I-Premise
in I-Premise
the I-Premise
anger-hostility I-Premise
scale I-Premise
at I-Premise
week I-Premise
27 I-Premise
( I-Premise
92.2 I-Premise
vs. I-Premise
84.2 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.027 I-Premise
) I-Premise
and I-Premise
week I-Premise
52 I-Premise
( I-Premise
96.3 I-Premise
vs. I-Premise
85.9 I-Premise
, I-Premise
p I-Premise
= I-Premise
0.005 I-Premise
) I-Premise
. I-Premise

A B-Premise
mean I-Premise
of I-Premise
10.6 I-Premise
units I-Premise
of I-Premise
PRBCs I-Premise
over I-Premise
5 I-Premise
months I-Premise
were I-Premise
administered I-Premise
to I-Premise
those I-Premise
who I-Premise
received I-Premise
epoetin I-Premise
alpha I-Premise
compared I-Premise
with I-Premise
13 I-Premise
units I-Premise
for I-Premise
those I-Premise
who I-Premise
did I-Premise
not I-Premise
receive I-Premise
epoetin I-Premise
( I-Premise
P I-Premise
= I-Premise
.04 I-Premise
) I-Premise
. I-Premise

No B-Premise
adverse I-Premise
effects I-Premise
were I-Premise
noted I-Premise
. I-Premise

However B-Premise
, I-Premise
subjective I-Premise
changes I-Premise
in I-Premise
QOL I-Premise
scores I-Premise
on I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
were I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
GP I-Premise
arm I-Premise
( I-Premise
p I-Premise
= I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

For B-Premise
astrocytoma I-Premise
grade I-Premise
III I-Premise
the I-Premise
median I-Premise
survival I-Premise
time I-Premise
was I-Premise
10.6 I-Premise
( I-Premise
1.3-92.7 I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
radiotherapy I-Premise
only I-Premise
group I-Premise
and I-Premise
17.3 I-Premise
( I-Premise
0.4-96.9+ I-Premise
) I-Premise
months I-Premise
for I-Premise
the I-Premise
estramustine I-Premise
+ I-Premise
radiotherapy I-Premise
group I-Premise
. I-Premise

At B-Premise
24-month I-Premise
follow-up I-Premise
, I-Premise
patients I-Premise
in I-Premise
the I-Premise
hysterectomy I-Premise
group I-Premise
were I-Premise
significantly I-Premise
more I-Premise
satisfied I-Premise
than I-Premise
those I-Premise
in I-Premise
the I-Premise
UAE I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
. I-Premise

In B-Premise
planned I-Premise
subgroup I-Premise
analyses I-Premise
, I-Premise
a I-Premise
significant I-Premise
interaction I-Premise
was I-Premise
noted I-Premise
( I-Premise
P I-Premise
= I-Premise
.01 I-Premise
) I-Premise
: I-Premise
limited-stage I-Premise
vandetanib I-Premise
patients I-Premise
had I-Premise
longer I-Premise
overall I-Premise
survival I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.45 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.07 I-Premise
) I-Premise
and I-Premise
extensive-stage I-Premise
vandetanib I-Premise
patients I-Premise
shorter I-Premise
survival I-Premise
compared I-Premise
with I-Premise
placebo I-Premise
( I-Premise
HR I-Premise
, I-Premise
2.27 I-Premise
";" I-Premise
one-sided I-Premise
P I-Premise
= I-Premise
.996 I-Premise
) I-Premise
. I-Premise

Quality B-Premise
of I-Premise
life I-Premise
was I-Premise
well I-Premise
preserved I-Premise
in I-Premise
the I-Premise
euthyroid I-Premise
group I-Premise
, I-Premise
compared I-Premise
with I-Premise
the I-Premise
hypothyroid I-Premise
group I-Premise
, I-Premise
as I-Premise
demonstrated I-Premise
by I-Premise
their I-Premise
lower I-Premise
pretreatment I-Premise
scores I-Premise
on I-Premise
the I-Premise
Billewicz I-Premise
scale I-Premise
for I-Premise
hypothyroid I-Premise
signs I-Premise
and I-Premise
symptoms I-Premise
, I-Premise
27 I-Premise
+/- I-Premise
7 I-Premise
vs. I-Premise
18 I-Premise
+/- I-Premise
4 I-Premise
( I-Premise
P I-Premise
< I-Premise
0.0001 I-Premise
) I-Premise
and I-Premise
their I-Premise
significantly I-Premise
higher I-Premise
Short I-Premise
Form-36 I-Premise
Health I-Premise
Assessment I-Premise
Scale I-Premise
scores I-Premise
in I-Premise
five I-Premise
of I-Premise
eight I-Premise
categories I-Premise
. I-Premise

There B-Premise
were I-Premise
no I-Premise
opportunistic I-Premise
infections I-Premise
. I-Premise

The B-Premise
mean I-Premise
length I-Premise
of I-Premise
hospital I-Premise
stay I-Premise
was I-Premise
10 I-Premise
( I-Premise
4.9 I-Premise
) I-Premise
days I-Premise
in I-Premise
the I-Premise
laparoscopic I-Premise
group I-Premise
and I-Premise
13.6 I-Premise
( I-Premise
10 I-Premise
) I-Premise
days I-Premise
in I-Premise
the I-Premise
open I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
0.004 I-Premise
) I-Premise
. I-Premise

The B-Premise
corresponding I-Premise
mean I-Premise
amounts I-Premise
of I-Premise
residual I-Premise
contrast-enhancing I-Premise
tumor I-Premise
tissue I-Premise
were I-Premise
29.2 I-Premise
and I-Premise
24.4 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Acupuncture B-Premise
had I-Premise
the I-Premise
additional I-Premise
benefit I-Premise
of I-Premise
increased I-Premise
sex I-Premise
drive I-Premise
in I-Premise
some I-Premise
women I-Premise
, I-Premise
and I-Premise
most I-Premise
reported I-Premise
an I-Premise
improvement I-Premise
in I-Premise
their I-Premise
energy I-Premise
, I-Premise
clarity I-Premise
of I-Premise
thought I-Premise
, I-Premise
and I-Premise
sense I-Premise
of I-Premise
well-being I-Premise
. I-Premise

Median B-Premise
survivals I-Premise
for I-Premise
marimastat I-Premise
and I-Premise
placebo I-Premise
patients I-Premise
were I-Premise
9.3 I-Premise
months I-Premise
and I-Premise
9.7 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
=.90 I-Premise
) I-Premise
. I-Premise

Reported B-Premise
adverse I-Premise
events I-Premise
were I-Premise
similar I-Premise
between I-Premise
groups I-Premise
. I-Premise

Clinic B-Premise
discussions I-Premise
were I-Premise
associated I-Premise
with I-Premise
severity I-Premise
of I-Premise
patient-reported I-Premise
symptoms I-Premise
but I-Premise
not I-Premise
with I-Premise
patient-reported I-Premise
functional I-Premise
concerns I-Premise
. I-Premise

The B-Premise
tumor I-Premise
progression I-Premise
duration I-Premise
in I-Premise
these I-Premise
two I-Premise
groups I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
5.6 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

In B-Premise
grade I-Premise
IV I-Premise
tumours I-Premise
the I-Premise
corresponding I-Premise
figures I-Premise
were I-Premise
5.1 I-Premise
and I-Premise
3.3 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

Adverse B-Premise
events I-Premise
were I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
immediate I-Premise
treatment I-Premise
group I-Premise
. I-Premise

There B-Premise
is I-Premise
a I-Premise
further I-Premise
significant I-Premise
reduction I-Premise
in I-Premise
both I-Premise
uterine I-Premise
volume I-Premise
and I-Premise
dominant I-Premise
fibroid I-Premise
diameter I-Premise
between I-Premise
6 I-Premise
months I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
UAE I-Premise
. I-Premise

QOL B-Premise
score I-Premise
changes I-Premise
per I-Premise
4-week I-Premise
period I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
showed I-Premise
overall I-Premise
less I-Premise
deterioration I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group-physical I-Premise
scores I-Premise
( I-Premise
-0.2 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
";" I-Premise
functional I-Premise
scores I-Premise
( I-Premise
+0.4 I-Premise
% I-Premise
versus I-Premise
-5.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.02 I-Premise
) I-Premise
";" I-Premise
psychologic I-Premise
scores I-Premise
( I-Premise
-0.7 I-Premise
% I-Premise
versus I-Premise
-2.4 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.11 I-Premise
) I-Premise
";" I-Premise
overall I-Premise
QOL I-Premise
score I-Premise
( I-Premise
+0.1 I-Premise
% I-Premise
versus I-Premise
-3.5 I-Premise
% I-Premise
";" I-Premise
P I-Premise
=.0001 I-Premise
) I-Premise
. I-Premise

After B-Premise
the I-Premise
exercise I-Premise
program I-Premise
, I-Premise
improvements I-Premise
were I-Premise
observed I-Premise
in I-Premise
Group I-Premise
1 I-Premise
in I-Premise
6-minute I-Premise
walk I-Premise
test I-Premise
, I-Premise
BDI I-Premise
, I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
functional I-Premise
, I-Premise
and I-Premise
EORTC I-Premise
QLQ-C30 I-Premise
BR23 I-Premise
functional I-Premise
scores I-Premise
( I-Premise
P I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

Initial B-Premise
costs I-Premise
were I-Premise
higher I-Premise
for I-Premise
GJJ I-Premise
compared I-Premise
to I-Premise
stent I-Premise
placement I-Premise
( I-Premise
euro8315 I-Premise
vs. I-Premise
euro4820 I-Premise
, I-Premise
P I-Premise
< I-Premise
0.001 I-Premise
) I-Premise
. I-Premise

Among B-Premise
responding I-Premise
patients I-Premise
, I-Premise
mean I-Premise
scores I-Premise
generally I-Premise
improved I-Premise
from I-Premise
time I-Premise
of I-Premise
response I-Premise
to I-Premise
end-of-treatment I-Premise
assessment I-Premise
, I-Premise
substantially I-Premise
driven I-Premise
by I-Premise
patients I-Premise
achieving I-Premise
complete I-Premise
response I-Premise
( I-Premise
CR I-Premise
) I-Premise
. I-Premise

The B-Premise
median I-Premise
OS I-Premise
for I-Premise
the I-Premise
vaccine I-Premise
group I-Premise
was I-Premise
31.9 I-Premise
months I-Premise
and I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
was I-Premise
15.0 I-Premise
months I-Premise
( I-Premise
P I-Premise
< I-Premise
0.002 I-Premise
) I-Premise
. I-Premise

There B-Premise
was I-Premise
a I-Premise
significant I-Premise
effect I-Premise
of I-Premise
group I-Premise
on I-Premise
women I-Premise
's I-Premise
perceptions I-Premise
of I-Premise
social I-Premise
support I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
being I-Premise
more I-Premise
satisfied I-Premise
with I-Premise
the I-Premise
emotional I-Premise
support I-Premise
they I-Premise
received I-Premise
( I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

ES B-Premise
scores I-Premise
and I-Premise
CES-D I-Premise
scores I-Premise
were I-Premise
similar I-Premise
in I-Premise
all I-Premise
treatment I-Premise
groups I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
was I-Premise
6.9 I-Premise
( I-Premise
4.6-10.1 I-Premise
) I-Premise
and I-Premise
9.2 I-Premise
( I-Premise
7.9-11.5 I-Premise
) I-Premise
months I-Premise
and I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
17.4 I-Premise
( I-Premise
12.6-23.0+ I-Premise
) I-Premise
and I-Premise
24.7 I-Premise
( I-Premise
16.3-26.4+ I-Premise
) I-Premise
months I-Premise
. I-Premise

Frequent B-Premise
grade I-Premise
3 I-Premise
to I-Premise
4 I-Premise
toxicities I-Premise
for I-Premise
DCF I-Premise
v I-Premise
CF I-Premise
were I-Premise
: I-Premise
neutropenia I-Premise
( I-Premise
82 I-Premise
% I-Premise
v I-Premise
57 I-Premise
% I-Premise
) I-Premise
, I-Premise
stomatitis I-Premise
( I-Premise
21 I-Premise
% I-Premise
v I-Premise
27 I-Premise
% I-Premise
) I-Premise
, I-Premise
diarrhea I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
8 I-Premise
% I-Premise
) I-Premise
, I-Premise
lethargy I-Premise
( I-Premise
19 I-Premise
% I-Premise
v I-Premise
14 I-Premise
% I-Premise
) I-Premise
. I-Premise

Beyond B-Premise
tumor I-Premise
and I-Premise
nodal I-Premise
stage I-Premise
, I-Premise
Karnofsky I-Premise
performance I-Premise
status I-Premise
, I-Premise
primary I-Premise
site I-Premise
, I-Premise
cigarette I-Premise
use I-Premise
, I-Premise
use I-Premise
of I-Premise
concurrent I-Premise
chemotherapy I-Premise
, I-Premise
and I-Premise
altered I-Premise
fractionation I-Premise
schedules I-Premise
, I-Premise
the I-Premise
FACT-H I-Premise
& I-Premise
amp I-Premise
";" I-Premise
N I-Premise
score I-Premise
was I-Premise
independently I-Premise
predictive I-Premise
of I-Premise
LRC I-Premise
( I-Premise
but I-Premise
not I-Premise
OS I-Premise
) I-Premise
, I-Premise
with I-Premise
p I-Premise
= I-Premise
0.0038 I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
HRQoL I-Premise
deterioration I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT-P I-Premise
total I-Premise
score I-Premise
( I-Premise
12·7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
11·1-14·0 I-Premise
] I-Premise
vs I-Premise
8·3 I-Premise
months I-Premise
[ I-Premise
7·4-10·6 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·66-0·92 I-Premise
";" I-Premise
p=0·003 I-Premise
) I-Premise
and I-Premise
by I-Premise
the I-Premise
score I-Premise
on I-Premise
its I-Premise
prostate-cancer-specific I-Premise
subscale I-Premise
( I-Premise
11·1 I-Premise
months I-Premise
[ I-Premise
8·6-13·8 I-Premise
] I-Premise
vs I-Premise
5·8 I-Premise
months I-Premise
[ I-Premise
5·5-8·3 I-Premise
] I-Premise
";" I-Premise
HR I-Premise
0·70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0·60-0·83 I-Premise
";" I-Premise
p I-Premise
< I-Premise
0·0001 I-Premise
) I-Premise
. I-Premise

Median B-Premise
time I-Premise
to I-Premise
progress I-Premise
for I-Premise
radiotherapy I-Premise
only I-Premise
and I-Premise
radiotherapy I-Premise
and I-Premise
estramustin I-Premise
group I-Premise
in I-Premise
grade I-Premise
III I-Premise
tumours I-Premise
was I-Premise
6.5 I-Premise
and I-Premise
10.1 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
. I-Premise

A B-Premise
non-significant I-Premise
trend I-Premise
towards I-Premise
delayed I-Premise
time I-Premise
to I-Premise
cough I-Premise
and I-Premise
time I-Premise
to I-Premise
dyspnoea I-Premise
( I-Premise
HR=0.77 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.49-1.21 I-Premise
] I-Premise
and I-Premise
HR=0.75 I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0.48-1.17 I-Premise
] I-Premise
, I-Premise
respectively I-Premise
) I-Premise
was I-Premise
also I-Premise
observed I-Premise
. I-Premise

Global B-Premise
QL I-Premise
scores I-Premise
were I-Premise
lower I-Premise
at I-Premise
both I-Premise
1 I-Premise
and I-Premise
6 I-Premise
weeks I-Premise
following I-Premise
treatment I-Premise
for I-Premise
patients I-Premise
treated I-Premise
by I-Premise
SEMSs I-Premise
( I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
1=-0.66 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
: I-Premise
-0.02 I-Premise
to I-Premise
-1.30 I-Premise
, I-Premise
P=0.04 I-Premise
";" I-Premise
mean I-Premise
difference I-Premise
QL I-Premise
index I-Premise
week I-Premise
6=-1.01 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
-0.30 I-Premise
to I-Premise
-1.72 I-Premise
, I-Premise
P=0.006 I-Premise
) I-Premise
. I-Premise

At B-Premise
6 I-Premise
months I-Premise
, I-Premise
there I-Premise
was I-Premise
a I-Premise
clinically I-Premise
relevant I-Premise
, I-Premise
but I-Premise
nonsignificant I-Premise
reduction I-Premise
in I-Premise
presentations I-Premise
to I-Premise
emergency I-Premise
departments I-Premise
( I-Premise
21 I-Premise
% I-Premise
vs I-Premise
33 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
1.41 I-Premise
, I-Premise
P I-Premise
= I-Premise
.23 I-Premise
) I-Premise
and I-Premise
readmission I-Premise
to I-Premise
the I-Premise
hospital I-Premise
( I-Premise
37 I-Premise
% I-Premise
vs I-Premise
47 I-Premise
% I-Premise
";" I-Premise
χ1 I-Premise
= I-Premise
0.82 I-Premise
, I-Premise
P I-Premise
= I-Premise
.37 I-Premise
) I-Premise
among I-Premise
intervention I-Premise
compared I-Premise
with I-Premise
control I-Premise
group I-Premise
participants I-Premise
. I-Premise

The B-Premise
sample I-Premise
size I-Premise
was I-Premise
small I-Premise
, I-Premise
and I-Premise
patients I-Premise
applied I-Premise
a I-Premise
small I-Premise
amount I-Premise
of I-Premise
imiquimod I-Premise
5 I-Premise
% I-Premise
cream I-Premise
( I-Premise
half I-Premise
a I-Premise
sachet I-Premise
) I-Premise
to I-Premise
a I-Premise
large I-Premise
surface I-Premise
area I-Premise
. I-Premise

Time B-Premise
to I-Premise
progression I-Premise
( I-Premise
TTP I-Premise
";" I-Premise
primary I-Premise
end I-Premise
point I-Premise
) I-Premise
and I-Premise
time I-Premise
to I-Premise
treatment I-Premise
failure I-Premise
( I-Premise
TTF I-Premise
) I-Premise
were I-Premise
significantly I-Premise
longer I-Premise
with I-Premise
AT I-Premise
than I-Premise
AC I-Premise
( I-Premise
median I-Premise
TTP I-Premise
, I-Premise
37.3 I-Premise
v I-Premise
31.9 I-Premise
weeks I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.014 I-Premise
";" I-Premise
median I-Premise
TTF I-Premise
, I-Premise
25.6 I-Premise
v I-Premise
23.7 I-Premise
weeks I-Premise
";" I-Premise
log-rank I-Premise
P I-Premise
=.048 I-Premise
) I-Premise
. I-Premise

Response B-Premise
was I-Premise
slightly I-Premise
higher I-Premise
at I-Premise
the I-Premise
175-mg/m2 I-Premise
dose I-Premise
( I-Premise
20 I-Premise
% I-Premise
) I-Premise
than I-Premise
at I-Premise
135 I-Premise
mg/m2 I-Premise
( I-Premise
15 I-Premise
% I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
statistically I-Premise
significant I-Premise
( I-Premise
P I-Premise
= I-Premise
.2 I-Premise
) I-Premise
. I-Premise

Patients B-Premise
treated I-Premise
with I-Premise
PB I-Premise
experienced I-Premise
more I-Premise
improvement I-Premise
in I-Premise
total I-Premise
FACT-B I-Premise
( I-Premise
Functional I-Premise
Assessment I-Premise
of I-Premise
Cancer I-Premise
Therapy-Breast I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
.021 I-Premise
) I-Premise
, I-Premise
FACT-B I-Premise
Social/Family I-Premise
Well-being I-Premise
( I-Premise
P I-Premise
= I-Premise
.041 I-Premise
) I-Premise
, I-Premise
and I-Premise
Breast I-Premise
Cancer-Additional I-Premise
Concerns I-Premise
( I-Premise
P I-Premise
= I-Premise
.008 I-Premise
) I-Premise
scores I-Premise
than I-Premise
patients I-Premise
treated I-Premise
with I-Premise
PB+G I-Premise
. I-Premise

Increased B-Premise
symptoms I-Premise
were I-Premise
reflected I-Premise
by I-Premise
the I-Premise
frequent I-Premise
use I-Premise
of I-Premise
incontinence I-Premise
materials I-Premise
after I-Premise
EBRT I-Premise
( I-Premise
day I-Premise
and I-Premise
night I-Premise
use I-Premise
, I-Premise
42.9 I-Premise
% I-Premise
v I-Premise
15.2 I-Premise
% I-Premise
for I-Premise
NAT I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

Kaplan-Meier B-Premise
survival I-Premise
analysis I-Premise
did I-Premise
not I-Premise
indicate I-Premise
an I-Premise
overall I-Premise
survival I-Premise
benefit I-Premise
for I-Premise
the I-Premise
IG I-Premise
. I-Premise

Self-reported B-Premise
severity I-Premise
of I-Premise
facial I-Premise
hair I-Premise
in I-Premise
the I-Premise
intervention I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
51 I-Premise
) I-Premise
fell I-Premise
from I-Premise
7.3 I-Premise
to I-Premise
3.6 I-Premise
over I-Premise
the I-Premise
6-month I-Premise
study I-Premise
period I-Premise
";" I-Premise
for I-Premise
the I-Premise
control I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
37 I-Premise
) I-Premise
the I-Premise
corresponding I-Premise
scores I-Premise
were I-Premise
7.1 I-Premise
and I-Premise
6.1 I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
> I-Premise
/= I-Premise
grade I-Premise
3 I-Premise
esophagitis I-Premise
was I-Premise
30 I-Premise
% I-Premise
with I-Premise
AM I-Premise
versus I-Premise
34 I-Premise
% I-Premise
without I-Premise
AM I-Premise
( I-Premise
P I-Premise
= I-Premise
.9 I-Premise
) I-Premise
. I-Premise

Neither B-Premise
group I-Premise
had I-Premise
a I-Premise
survival I-Premise
advantage I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
0.95 I-Premise
, I-Premise
0.73 I-Premise
to I-Premise
1.24 I-Premise
";" I-Premise
P=0.71 I-Premise
) I-Premise
. I-Premise

Fatigue B-Premise
was I-Premise
lower I-Premise
at I-Premise
1 I-Premise
year I-Premise
than I-Premise
before I-Premise
CTX I-Premise
";" I-Premise
no B-Premise
group I-Premise
effects I-Premise
were I-Premise
found I-Premise
. I-Premise

The B-Premise
median I-Premise
survival I-Premise
in I-Premise
the I-Premise
patients I-Premise
receiving I-Premise
induction I-Premise
chemotherapy I-Premise
only I-Premise
was I-Premise
8.9 I-Premise
months I-Premise
. I-Premise

However B-Premise
, I-Premise
this I-Premise
difference I-Premise
did I-Premise
not I-Premise
translate I-Premise
into I-Premise
a I-Premise
worse I-Premise
feeling I-Premise
of I-Premise
general I-Premise
well-being I-Premise
as I-Premise
measured I-Premise
by I-Premise
a I-Premise
simple I-Premise
visual I-Premise
analogue I-Premise
scale I-Premise
( I-Premise
5.8 I-Premise
vs I-Premise
5.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.3 I-Premise
) I-Premise
. I-Premise

Eligible O
patients O
were O
required O
to O
have O
NSCLC O
unsuitable O
for O
curative O
therapy O
and O
baseline O
hemoglobin O
( O
Hgb O
) O
levels O
less O
than O
121 O
g/L O
. O

Forty-two O
patients O
were O
randomized O
to O
receive O
misoprostol O
and O
41 O
to O
receive O
a O
placebo O
. O

The O
primary O
endpoint O
was O
investigator-assessed O
overall O
response O
rate O
( O
ORR O
) O
";" O
secondary O
endpoints O
were O
PFS O
, O
overall O
survival O
( O
OS O
) O
, O
safety O
, O
and O
quality O
of O
life O
. O

This O
study O
examined O
how O
PRO O
feedback O
had O
an O
impact O
on O
patient-physician O
communication O
over O
time O
to O
gain O
a O
better O
understanding O
of O
how O
it O
may O
influence O
patient O
care O
. O

A O
specifically O
designed O
questionnaire O
was O
administered O
at O
three O
months O
to O
assess O
time O
from O
the O
operation O
until O
the O
patient O
was O
able O
to O
walk O
, O
return O
to O
daily O
activities O
, O
or O
sit O
without O
pain O
, O
time O
to O
return O
to O
work O
or O
school O
, O
and O
time O
to O
healing O
. O

Endpoints O
included O
the O
QLQ-C30 O
Global O
Health O
Status O
( O
QL2 O
) O
scale O
, O
the O
QLQ-BR23 O
breast O
symptom O
( O
BRBS O
) O
, O
and O
arm O
symptom O
( O
BRAS O
) O
scales O
. O

Randomized O
controlled O
trial O
. O

We O
evaluated O
the O
effects O
of O
lanreotide O
, O
a O
somatostatin O
analogue O
, O
in O
patients O
with O
polycystic O
liver O
because O
of O
autosomal-dominant O
( O
AD O
) O
PKD O
or O
autosomal-dominant O
polycystic O
liver O
disease O
( O
PCLD O
) O
. O

Thyroid O
ablation O
was O
assessed O
8 O
months O
after O
radioiodine O
administration O
by O
neck O
ultrasonography O
and O
measurement O
of O
recombinant O
human O
thyrotropin-stimulated O
thyroglobulin O
. O

We O
compared O
initial O
costs O
and O
costs O
during O
follow-up O
. O

The O
purpose O
of O
this O
study O
was O
to O
examine O
the O
effects O
of O
live O
music O
therapy O
on O
quality O
of O
life O
indicators O
, O
amount O
of O
medications O
administered O
and O
length O
of O
stay O
for O
persons O
receiving O
elective O
surgical O
procedures O
of O
the O
brain O
. O

Men O
with O
metastatic O
prostate O
cancer O
( O
n O
= O
161 O
) O
were O
randomized O
to O
receive O
either O
daily O
prednisone O
alone O
or O
mitoxantrone O
( O
every O
3 O
weeks O
) O
plus O
prednisone O
. O

Pilates O
exercise O
sessions O
were O
performed O
three O
times O
a O
week O
for O
a O
period O
of O
eight O
weeks O
in O
the O
rehabilitation O
unit O
. O

Cognitive O
function O
was O
assessed O
by O
Executive O
Interview O
( O
EXIT25 O
) O
and O
Clock O
Drawing O
Tasks O
";" O
mood O
by O
Profile O
of O
Mood O
States O
";" O
anemia-related O
symptoms O
, O
including O
fatigue O
, O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anemia O
( O
FACT-An O
) O
subscale O
";" O
and O
QOL O
by O
Linear O
Analog O
Scale O
Assessment O
. O

Five O
, O
five O
, O
and O
four O
patients O
, O
treated O
with O
oral O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
, O
respectively O
, O
required O
opioid O
switching O
. O

At O
29 O
centers O
in O
the O
United O
Kingdom O
, O
we O
conducted O
a O
randomized O
noninferiority O
trial O
comparing O
low-dose O
and O
high-dose O
radioiodine O
, O
each O
in O
combination O
with O
either O
thyrotropin O
alfa O
or O
thyroid O
hormone O
withdrawal O
before O
ablation O
. O

Using O
KPS O
scores O
, O
changes O
in O
quality O
of O
life O
were O
compared O
before O
and O
after O
the O
treatment O
. O

This O
randomized O
controlled O
trial O
assessed O
the O
effect O
of O
a O
SMART O
( O
Stress O
Management O
and O
Resiliency O
Training O
) O
program O
among O
25 O
women O
diagnosed O
with O
breast O
cancer O
. O

Consequently O
, O
there O
are O
no O
guidelines O
available O
with O
regard O
to O
the O
exercises O
that O
can O
be O
recommended O
and O
difficulties O
are O
encountered O
in O
the O
clinical O
practice O
as O
to O
which O
exercise O
is O
more O
suitable O
to O
the O
patients O
. O

Secondary O
outcomes O
included O
additional O
QOL O
measures O
, O
patient O
satisfaction O
, O
safety O
and O
health O
economics O
. O

QoL O
was O
assessed O
in O
350 O
patients O
randomly O
assigned O
to O
either O
standard O
chemotherapy O
( O
cyclophosphamide O
, O
methotrexate O
, O
and O
fluorouracil O
[ O
CMF O
] O
or O
doxorubicin O
and O
cyclophosphamide O
[ O
AC O
] O
";" O
n O
= O
182 O
) O
or O
capecitabine O
( O
n O
= O
168 O
) O
. O

BT O
plans O
were O
revised O
before O
each O
CTX O
and O
30 O
, O
60 O
, O
and O
90 O
days O
after O
the O
last O
CTX O
and O
reinforced O
7 O
to O
9 O
days O
later O
. O

The O
CMA O
intervention O
, O
delivered O
by O
a O
nurse O
practitioner O
, O
focused O
on O
symptom O
assessment O
, O
education O
, O
counseling O
and O
, O
as O
appropriate O
, O
specific O
pharmacologic O
and O
behavioral O
interventions O
for O
each O
of O
the O
three O
target O
symptoms O
. O

A O
recent O
randomized O
trial O
to O
compare O
external O
beam O
radiation O
therapy O
( O
EBRT O
) O
to O
cryoablation O
for O
localized O
disease O
showed O
cryoablation O
to O
be O
noninferior O
to O
external O
beam O
EBRT O
in O
disease O
progression O
and O
overall O
and O
disease-specific O
survival O
. O

Mixed O
effects O
regressions O
were O
used O
to O
evaluate O
the O
intervention O
adjusting O
for O
patient O
, O
practice O
, O
and O
site O
characteristics O
. O

Assessments O
were O
performed O
before O
TRT O
and O
until O
week O
54 O
. O

Improvement O
in O
PCS O
score O
at O
24-month O
follow-up O
was O
significantly O
higher O
for O
patients O
who O
were O
employed O
at O
baseline O
( O
P O
= O
.035 O
) O
. O

Outcomes O
were O
compared O
between O
groups O
using O
analysis O
of O
covariance O
adjusted O
for O
baseline O
values O
. O

Survival O
status O
for O
all O
patients O
was O
determined O
from O
our O
own O
records O
and O
from O
three O
external O
sources O
: O
the O
Hamburg O
cancer O
registry O
, O
family O
doctors O
, O
and O
the O
general O
citizen O
registration O
offices O
. O

There O
were O
no O
differences O
in O
the O
intraoperative O
time O
and O
hospital O
stay O
. O

The O
mean O
age O
of O
the O
participants O
was O
58.8 O
years O
";" O
181 O
( O
65 O
% O
) O
were O
men O
and O
98 O
( O
35 O
% O
) O
were O
women O
. O

To O
explore O
the O
preference O
and O
compliance O
of O
elderly O
patients O
regarding O
p.o O
. O

OS O
and O
updated O
PFS O
data O
are O
presented O
using O
Kaplan-Meier O
curves O
and O
log-rank O
tests O
stratified O
for O
hormone O
receptor O
and O
visceral O
disease O
status O
. O

A O
total O
of O
111 O
colorectal O
cancer O
outpatients O
referred O
for O
radiotherapy O
, O
stratified O
by O
staging O
, O
were O
randomly O
assigned O
: O
group O
1 O
( O
G1 O
";" O
n O
= O
37 O
) O
, O
dietary O
counseling O
( O
regular O
foods O
) O
";" O
group O
2 O
( O
G2 O
";" O
n O
= O
37 O
) O
, O
protein O
supplements O
";" O
and O
group O
3 O
( O
G3 O
";" O
n O
= O
37 O
) O
, O
ad O
libitum O
intake O
. O

A O
total O
of O
497 O
patients O
with O
previously O
untreated O
metastatic O
colorectal O
cancer O
were O
randomly O
assigned O
to O
receive O
bolus O
FU O
425 O
mg/m2 O
intravenously O
+ O
LV O
20 O
mg/m2 O
on O
days O
1 O
to O
5 O
and O
repeated O
on O
day O
28 O
( O
FU O
+ O
LV O
) O
, O
or O
FU O
2600 O
mg/m2 O
as O
a O
24-hour O
infusion O
alone O
( O
FU24h O
) O
or O
in O
combination O
with O
500 O
mg/m2 O
LV O
( O
FU24h O
+ O
LV O
) O
-all O
given O
weekly O
x6 O
followed O
by O
a O
2-week O
rest O
period O
. O

The O
interdisciplinary O
teams O
( O
IDTs O
) O
caring O
for O
these O
dyads O
were O
randomly O
assigned O
to O
either O
experimental O
( O
n O
= O
338 O
) O
or O
control O
( O
n O
= O
371 O
) O
conditions O
. O

Few O
intervention O
studies O
have O
been O
conducted O
to O
help O
couples O
manage O
the O
effects O
of O
prostate O
cancer O
and O
maintain O
their O
quality O
of O
life O
. O

A O
total O
of O
1113 O
men O
were O
registered O
, O
of O
whom O
970 O
were O
randomly O
assigned O
, O
483 O
to O
short-term O
suppression O
and O
487 O
to O
long-term O
suppression O
. O

Although O
many O
of O
the O
adverse O
effects O
associated O
with O
exemestane O
and O
tamoxifen O
have O
been O
analysed O
, O
there O
are O
no O
comparative O
data O
concerning O
body O
weight O
and O
body O
composition O
. O

This O
study O
addressed O
the O
effects O
of O
pilates O
exercise O
, O
as O
a O
new O
approach O
, O
on O
functional O
capacity O
, O
fatigue O
, O
depression O
and O
quality O
of O
life O
in O
breast O
cancer O
patients O
in O
whom O
there O
are O
doubts O
regarding O
the O
efficacy O
and O
usefulness O
of O
the O
exercise O
. O

Consistent O
results O
are O
observed O
across O
subgroups O
of O
patients O
. O

This O
triple O
blinded O
study O
randomized O
220 O
HNC O
patients O
scheduled O
for O
CRT O
( O
three O
weekly O
Cisplatin O
+ O
RT O
= O
66 O
Gray O
( O
2 O
Gy/session O
) O
, O
five O
fractions/week O
for O
6.5 O
weeks O
, O
total O
33 O
fractions O
) O
into O
laser O
( O
110 O
) O
and O
placebo O
( O
110 O
) O
groups O
. O

The O
primary O
end O
point O
was O
time-to-progression O
( O
TTP O
) O
. O

Patients O
with O
lymphoma O
experience O
sleep O
problems O
that O
may O
be O
managed O
with O
aerobic O
exercise O
but O
no O
previous O
study O
has O
examined O
this O
issue O
. O

To O
determine O
the O
incremental O
cost O
utility O
of O
epoetin-alfa O
versus O
placebo O
in O
anaemic O
patients O
with O
stage O
IV O
breast O
cancer O
from O
a O
UK O
National O
Health O
Service O
perspective O
. O

Analysis O
was O
conducted O
after O
intervention O
for O
immediate O
effects O
on O
outcome O
variables O
and O
6 O
weeks O
later O
for O
maintenance O
of O
effects O
. O

There O
are O
few O
randomized O
controlled O
trials O
on O
the O
effectiveness O
of O
palliative O
care O
interventions O
to O
improve O
the O
care O
of O
patients O
with O
advanced O
cancer O
. O

108 O
, O
111 O
, O
and O
107 O
patients O
, O
respectively O
, O
were O
analysed O
. O

Following O
pretesting O
in O
313 O
patients O
, O
patients O
who O
needed O
district O
nursing O
and O
who O
did O
not O
need O
district O
nursing O
at O
home O
were O
randomly O
assigned O
to O
a O
control O
or O
intervention O
group O
. O

Patients O
were O
followed O
up O
per-protocol O
";" O
there O
were O
no O
deaths O
, O
and O
five O
patients O
had O
a O
total O
of O
six O
complications O
. O

Prespecified O
outcomes O
were O
three O
genitourinary O
symptoms O
( O
bowel O
function O
tenderness O
, O
frequent O
urination O
, O
and O
erectile O
dysfunction O
[ O
ED O
] O
) O
and O
measures O
of O
physical O
and O
emotional O
function O
. O

A O
total O
of O
420 O
patients O
were O
randomised O
and O
411 O
were O
analysed O
. O

Multivariate O
analyses O
were O
used O
to O
evaluate O
the O
association O
of O
the O
genotypes O
on O
the O
four O
endpoints O
. O

This O
randomised O
non-inferiority O
trial O
was O
designed O
to O
assess O
whether O
radiosurgery O
plus O
adjuvant O
whole O
brain O
radiotherapy O
( O
RS O
+ O
WBRT O
) O
is O
as O
effective O
as O
surgery O
plus O
whole O
brain O
radiotherapy O
( O
S O
+ O
WBRT O
) O
for O
cancer O
patients O
with O
a O
solitary O
brain O
metastasis O
, O
with O
respect O
to O
overall O
survival O
and O
quality O
of O
life O
. O

This O
article O
compares O
the O
impact O
on O
HRQOL O
of O
first-line O
treatment O
with O
cisplatin O
versus O
raltitrexed O
and O
cisplatin O
. O

Patients O
with O
GOO O
. O

The O
purpose O
of O
this O
pilot O
study O
was O
to O
examine O
the O
effects O
of O
a O
combined O
cardiorespiratory O
and O
resistance O
exercise O
training O
program O
of O
short O
duration O
on O
the O
cardiorespiratory O
fitness O
, O
strength O
endurance O
, O
task O
specific O
functional O
muscle O
capacity O
, O
body O
composition O
and O
quality O
of O
life O
( O
QOL O
) O
in O
women O
breast O
cancer O
survivors O
. O

For O
flare O
protection O
, O
goserelin-treated O
patients O
also O
received O
daily O
bicalutamide O
( O
50 O
mg O
) O
during O
the O
initial O
28 O
days O
. O

Relatively O
small O
patient O
population O
. O

A O
randomized O
Phase O
III O
trial O
for O
Stage O
IIIA O
( O
T1-T3N2M0 O
) O
non-small O
cell O
lung O
cancer O
was O
conducted O
by O
the O
Radiation O
Therapy O
Oncology O
Group O
( O
RTOG O
) O
and O
Eastern O
Cooperative O
Oncology O
Group O
between O
April O
1990 O
and O
April O
1994 O
. O

Few O
well-designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O

Primary O
-- O
patients O
alive O
and O
without O
moderate O
or O
severe O
cough O
, O
chest O
pain O
, O
haemoptysis O
, O
or O
dyspnoea O
six O
months O
from O
randomisation O
, O
as O
recorded O
by O
clinicians O
. O

A O
randomized O
, O
wait-listed O
, O
controlled O
trial O
was O
carried O
out O
in O
229 O
women O
after O
surgery O
, O
chemotherapy O
, O
and O
radiotherapy O
for O
breast O
cancer O
. O

According O
to O
the O
1997-American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
definition O
, O
the O
5-year O
biochemical O
relapse O
rate O
was O
39 O
% O
and O
28 O
% O
in O
the O
-70 O
and O
80-Gy O
arms O
, O
respectively O
( O
p O
= O
.036 O
) O
. O

To O
compare O
the O
efficacy O
of O
a O
standard O
anthracycline-based O
regimen O
to O
a O
dose-intensified O
anthracycline O
regimen O
in O
locally O
advanced O
breast O
cancer O
. O

Embolization O
was O
performed O
in O
a O
standardized O
manner O
. O

G O
responses O
: O
2 O
PR O
( O
5.3 O
% O
) O
and O
16 O
SD O
( O
42.1 O
% O
) O
";" O
DCR O
( O
47.4 O
% O
) O
. O

To O
determine O
whether O
palliation O
of O
chest O
symptoms O
from O
a O
10 O
Gy O
single O
fraction O
( O
regimen O
1 O
) O
was O
equivalent O
to O
that O
from O
30 O
Gy O
in O
10 O
fractions O
( O
regimen O
2 O
) O
. O

Supervised O
12 O
week O
group O
exercise O
programme O
in O
addition O
to O
usual O
care O
, O
compared O
with O
usual O
care O
. O

This O
double-blind O
, O
placebo-controlled O
study O
randomly O
assigned O
patients O
to O
placebo O
or O
epoetin O
alfa O
( O
Ortho O
Biotech O
, O
Bridgewater O
, O
NJ O
) O
40,000 O
U O
subcutaneous O
weekly O
for O
16 O
weeks O
. O

Fifty O
patients O
were O
randomized O
";" O
30 O
patients O
received O
epoetin O
beta O
30,000 O
IU O
once O
weekly O
and O
20 O
received O
20,000 O
IU O
once O
weekly O
. O

For O
those O
reporting O
sexual O
activity O
at O
baseline O
( O
N=41 O
) O
, O
sexual O
dysfunction O
was O
associated O
with O
a O
range O
of O
specific O
measures O
of O
psychological O
well-being O
, O
all O
in O
the O
hypothesized O
direction O
. O

The O
upper O
limit O
of O
the O
95 O
% O
confidence O
interval O
was O
less O
than O
the O
prespecified O
limit O
of O
< O
0.75 O
g/dL O
, O
supporting O
noninferiority O
of O
the O
EDS O
dosing O
schedule O
. O

The O
primary O
endpoint O
was O
survival O
, O
and O
HRQOL O
was O
a O
secondary O
endpoint O
. O

All O
patients O
who O
returned O
questionnaires O
at O
12 O
months O
and O
were O
still O
on O
study O
treatment O
were O
included O
in O
the O
analysis O
of O
the O
primary O
endpoint O
. O

The O
documented O
administration O
of O
postoperative O
pain O
medications O
";" O
the O
frequency O
, O
dosage O
, O
type O
, O
and O
how O
it O
was O
given O
was O
also O
compared O
between O
groups O
. O

Intensity O
of O
service O
was O
measured O
as O
the O
number O
of O
days O
in O
the O
hospital O
and O
in O
the O
intensive O
care O
unit O
( O
ICU O
) O
and O
the O
number O
of O
emergency O
department O
visits O
recorded O
in O
the O
electronic O
medical O
record O
. O

The O
effect O
of O
this O
intervention O
on O
a O
patient O
's O
general O
well-being O
was O
also O
investigated O
. O

Subjects O
were O
asked O
to O
document O
the O
frequency O
, O
duration O
, O
and O
intensity O
of O
all O
exercise O
participation O
on O
monthly O
calendars O
. O

Thirty-one O
posttreatment O
cancer O
survivors O
were O
randomized O
in O
groups O
of O
seven O
to O
nine O
to O
either O
the O
8-week O
III O
+ O
ISG O
intervention O
or O
the O
8-week O
III O
condition O
. O

Secondary O
end O
points O
included O
overall O
survival O
, O
response O
rate O
after O
reinitiation O
of O
imatinib O
, O
and O
quality O
of O
life O
. O

Paclitaxel O
and O
pegylated O
liposomal O
doxorubicin O
( O
PLD O
) O
are O
active O
cytotoxic O
agents O
for O
the O
treatment O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
-associated O
Kaposi O
sarcoma O
( O
KS O
) O
. O

Prospective O
outcomes O
included O
patient-reported O
symptoms O
and O
quality O
of O
life O
assessed O
with O
questionnaires O
from O
baseline O
to O
4 O
years O
after O
randomisation O
. O

Inclusion O
criteria O
were O
inoperable O
, O
disease O
too O
advanced O
for O
curative O
radiotherapy O
, O
and O
chest O
symptoms O
or O
central O
tumor O
threatening O
the O
airways O
. O

Patients O
completed O
the O
Lung O
Cancer O
Symptom O
Scale O
( O
LCSS O
) O
at O
baseline O
, O
after O
each O
cycle O
, O
and O
post-discontinuation O
. O

The O
association O
between O
intervention O
and O
survival O
was O
also O
assessed O
. O

After O
removing O
patients O
who O
did O
not O
complete O
the O
follow-up O
survey O
or O
censured O
cases O
, O
24 O
patients O
in O
the O
RY O
group O
and O
18 O
patients O
in O
the O
INT O
group O
were O
clinically O
available O
and O
their O
postoperative O
status O
was O
assessed O
. O

Endpoints O
were O
survival O
, O
safety O
, O
efficacy O
, O
and O
quality O
of O
life O
. O

The O
primary O
objective O
was O
to O
compare O
progression-free O
survival O
( O
PFS O
) O
. O

This O
open-label O
study O
was O
designed O
to O
compare O
the O
overall O
survival O
( O
OS O
) O
of O
patients O
randomly O
assigned O
to O
GEM O
alone O
or O
GEM O
plus O
capecitabine O
( O
GEM-CAP O
) O
. O

Wilcoxon O
test O
was O
used O
to O
analyse O
changes O
in O
IEF O
and O
in O
I-QoL O
score O
";" O
Fisher O
exact O
test O
was O
used O
to O
compare O
continent O
patients O
between O
the O
groups O
. O

Appetite O
, O
mood O
, O
and O
nausea O
were O
monitored O
daily O
with O
a O
visual O
analog O
scale O
( O
VAS O
) O
";" O
QOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
composite O
score O
: O
questions O
29 O
and O
30 O
) O
. O

The O
minimum O
follow-up O
time O
was O
5.2 O
years O
for O
the O
surviving O
patients O
. O

Thus O
, O
300 O
patients O
were O
assessable O
for O
toxicity O
and O
to O
determine O
time O
to O
disease O
progression O
( O
TTP O
) O
, O
TTF O
, O
and O
OS O
. O

The O
present O
study O
showed O
that O
ADT O
with O
the O
gonadotropin O
hormone-releasing O
hormone O
( O
GhRH O
) O
antagonist O
degarelix O
is O
non-inferior O
to O
combined O
treatment O
with O
the O
LHRH O
agonist O
goserelin O
and O
bicalutamide O
in O
terms O
of O
reducing O
prostate O
volume O
during O
the O
treatment O
period O
of O
3 O
months O
. O

A O
total O
of O
1308 O
patients O
with O
previously O
untreated O
ovarian O
cancer O
( O
International O
Federation O
of O
Gynecology O
and O
Obstetrics O
stages O
IIB-IV O
) O
were O
randomly O
assigned O
to O
receive O
six O
cycles O
of O
paclitaxel O
and O
carboplatin O
followed O
by O
either O
four O
cycles O
of O
topotecan O
( O
TC-Top O
";" O
658 O
patients O
) O
or O
surveillance O
( O
TC O
";" O
650 O
patients O
) O
on O
a O
3-week O
per O
cycle O
schedule O
. O

HRQoL O
was O
assessed O
with O
the O
EORTC O
Core O
QoL O
Questionnaire O
( O
QLQ-C30 O
) O
and O
the O
myeloma-specific O
module O
( O
QLQ-MY24 O
) O
at O
baseline O
and O
at O
predetermined O
intervals O
during O
treatment O
. O

Patients O
without O
prior O
chemotherapy O
for O
metastatic O
disease O
were O
randomly O
assigned O
to O
standard O
combination O
therapy O
with O
doxorubicin O
and O
paclitaxel O
( O
AT O
) O
or O
double O
HDCT O
with O
cyclophosphamide O
, O
mitoxantrone O
, O
and O
etoposide O
followed O
by O
peripheral-blood O
stem-cell O
transplantation O
. O

Methodology O
was O
similar O
to O
our O
recently O
published O
study O
( O
Gautam O
et O
al O
. O

A O
total O
of O
219 O
participants O
from O
12 O
oncology O
clinics O
were O
randomly O
assigned O
in O
a O
clinical O
trial O
. O

This O
study O
took O
place O
at O
the O
Royal O
Prince O
Alfred O
Hospital O
, O
Sydney O
, O
Australia O
. O

There O
were O
no O
differences O
in O
the O
two O
treatment O
groups O
at O
baseline O
. O

Secondary O
end O
points O
were O
progression-free O
and O
overall O
survival O
. O

A O
total O
of O
166 O
patients O
were O
randomized O
to O
receive O
intravenous O
5-FU O
( O
450 O
mg/m2/day O
) O
or O
oral O
doxifluridine O
( O
900 O
mg/m2/day O
) O
in O
combination O
with O
leucovorin O
( O
20 O
mg/m2/day O
) O
for O
depth O
of O
invasion O
, O
nodal O
status O
, O
metastasis O
( O
TNM O
) O
stage O
II O
and O
III O
patients O
between O
October O
1997 O
and O
February O
1999 O
. O

Outcomes O
were O
medical O
effects O
, O
quality O
of O
life O
, O
and O
costs O
. O

The O
exercise O
group O
followed O
a O
progressive O
, O
8-week O
upper-body O
exercise O
program O
consisting O
of O
resistance O
training O
plus O
aerobic O
exercise O
using O
a O
Monark O
Rehab O
Trainer O
arm O
ergometer O
. O

They O
were O
randomized O
to O
receive O
marimastat O
10 O
mg O
or O
placebo O
orally O
bid O
for O
up O
to O
2 O
years O
. O

The O
most O
likely O
advantage O
of O
LRP O
is O
the O
superior O
cosmetic O
result O
. O

This O
double-blind O
, O
randomised O
, O
phase O
3 O
trial O
was O
undertaken O
at O
37 O
clinics O
in O
Denmark O
, O
Norway O
, O
and O
Sweden O
. O

Overall O
278 O
patients O
were O
enrolled O
into O
the O
trial O
. O

Adjusted O
linear O
mixed-model O
analyses O
demonstrated O
that O
patient O
preference O
moderated O
QoL O
response O
( O
P= O
.005 O
) O
. O

Paclitaxel O
was O
administered O
as O
a O
3-hour O
intravenous O
infusion O
every O
3 O
weeks O
. O

Statistical O
significance O
was O
kept O
at O
p O
< O
0.05 O
. O

A O
phase O
III O
trial O
( O
Cancer O
and O
Leukemia O
Group O
B O
CALGB-49907 O
) O
was O
conducted O
to O
test O
whether O
older O
patients O
with O
early-stage O
breast O
cancer O
would O
have O
equivalent O
relapse-free O
and O
overall O
survival O
with O
capecitabine O
compared O
with O
standard O
chemotherapy O
. O

Haemoglobin O
levels O
, O
transfusion O
need O
and O
QoL O
[ O
Functional O
Assessment O
of O
Cancer O
Therapy-fatigue O
( O
FACT-F O
) O
subscale O
score O
] O
were O
assessed O
at O
regular O
intervals O
. O

Between O
April O
2010 O
and O
May O
2011 O
, O
patients O
undergoing O
elective O
LCR O
in O
two O
centres O
were O
randomized O
to O
analgesia O
via O
epidural O
or O
WIC O
. O

Previously O
untreated O
stage O
III O
to O
IVB O
NPC O
were O
randomly O
assigned O
to O
( O
1 O
) O
neoadjuvant O
docetaxel O
75 O
mg/m O
( O
2 O
) O
and O
cisplatin O
75 O
mg/m O
( O
2 O
) O
every O
3 O
weeks O
for O
two O
cycles O
, O
followed O
by O
cisplatin O
40 O
mg/m O
( O
2 O
) O
/wk O
concurrent O
with O
radiotherapy O
, O
or O
( O
2 O
) O
CRT O
alone O
. O

Analysis O
was O
completed O
with O
use O
of O
chi O
( O
2 O
) O
analysis O
, O
Fisher O
exact O
tests O
, O
Student O
t O
tests O
, O
and O
analysis O
of O
variance O
as O
appropriate O
. O

We O
obtained O
quality-of-life O
information O
from O
872 O
( O
99 O
% O
) O
of O
875 O
eligible O
men O
with O
locally O
advanced O
prostate O
cancer O
( O
T3 O
";" O
78 O
% O
) O
who O
were O
randomly O
assigned O
, O
between O
1996 O
and O
2002 O
, O
to O
3 O
months O
of O
total O
androgen O
blockade O
followed O
by O
continuous O
endocrine O
treatment O
( O
439 O
patients O
) O
or O
the O
same O
hormonal O
treatment O
with O
radiotherapy O
3 O
months O
after O
randomisation O
( O
436 O
patients O
) O
. O

Breast O
cancer O
patients O
who O
were O
initiating O
adjuvant O
chemotherapy O
( O
N=242 O
) O
were O
assigned O
randomly O
to O
receive O
usual O
care O
( O
UC O
) O
( O
n=82 O
) O
, O
resistance O
exercise O
training O
( O
RET O
) O
( O
n=82 O
) O
, O
or O
aerobic O
exercise O
training O
( O
AET O
) O
( O
n=78 O
) O
for O
the O
duration O
of O
chemotherapy O
. O

Treosulfan O
, O
an O
alkylating O
agent O
, O
has O
demonstrated O
activity O
in O
recurrent O
ovarian O
carcinoma O
. O

Outcomes O
measured O
were O
scores O
on O
a O
composite O
menopausal O
symptom O
scale O
, O
the O
RAND O
Short O
Form O
Health O
Survey O
Vitality O
Scale O
, O
and O
the O
Cancer O
Rehabilitation O
Evaluation O
System O
( O
CARES O
) O
Sexual O
Functioning O
Scale O
at O
baseline O
and O
at O
4-month O
follow-up O
. O

Each O
call O
was O
standardized O
, O
comprising O
the O
assessment O
of O
unmet O
need O
and O
the O
provision O
of O
information O
and O
emotional O
support O
. O

All O
statistical O
tests O
were O
two-sided O
. O

The O
majority O
of O
pain O
topics O
had O
to O
be O
discussed O
. O

We O
investigated O
the O
role O
of O
tamoxifen O
and O
radiotherapy O
( O
RT O
) O
for O
the O
prevention O
and O
treatment O
of O
gynecomastia O
and O
breast O
pain O
during O
adjuvant O
bicalutamide O
monotherapy O
after O
radical O
prostatectomy O
( O
RP O
) O
in O
patients O
with O
prostate O
cancer O
. O

They O
had O
also O
received O
morphine O
or O
transdermal O
fentanyl O
patches O
for O
at O
least O
1 O
week O
. O

Group O
1 O
received O
20 O
mg O
of O
CRO O
, O
group O
2 O
received O
10 O
mg O
of O
CRO O
, O
and O
group O
3 O
received O
a O
placebo O
at O
1 O
hour O
before O
transarterial O
chemoembolization O
( O
T O
( O
0 O
) O
) O
and O
12 O
( O
T O
( O
12 O
) O
) O
and O
24 O
( O
T O
( O
24 O
) O
) O
hours O
after O
T O
( O
0 O
) O
. O

The O
aim O
of O
the O
study O
was O
to O
compare O
clinical O
outcomes O
and O
quality O
of O
life O
in O
patients O
undergoing O
surgery O
for O
pilonidal O
disease O
with O
unroofing O
and O
marsupialization O
( O
UM O
) O
or O
rhomboid O
excision O
and O
Limberg O
flap O
( O
RELP O
) O
procedures O
. O

This O
randomized O
phase O
II O
study O
compared O
two O
treatment O
schedules O
of O
gemcitabine O
in O
patients O
with O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
and O
impaired O
Karnofsky O
performance O
status O
( O
KP O
) O
. O

Control O
subjects O
received O
routine O
hospital O
care O
without O
any O
music O
therapy O
intervention O
. O

HRQL O
primary O
end O
points O
assessed O
by O
the O
EORTC O
QLQ-C30 O
were O
physical O
function O
( O
PF O
) O
and O
global O
health O
status O
( O
GHS O
) O
";" O
mean O
changes O
from O
baseline O
to O
8 O
and O
16 O
weeks O
were O
assessed O
. O

The O
primary O
end O
point O
was O
progression-free O
survival O
. O

The O
purpose O
of O
this O
study O
was O
to O
test O
the O
efficacy O
of O
a O
comprehensive O
menopausal O
assessment O
( O
CMA O
) O
intervention O
program O
in O
achieving O
relief O
of O
symptoms O
, O
the O
improvement O
in O
quality O
of O
life O
( O
QOL O
) O
, O
and O
sexual O
functioning O
in O
breast O
cancer O
survivors O
. O

Changes O
in O
mean O
scores O
from O
baseline O
to O
eight O
weeks O
and O
the O
prognostic O
value O
of O
the O
EQ-5D O
were O
evaluated O
. O

Ninety-seven O
patients O
being O
offered O
outpatient-based O
cancer O
treatment O
were O
randomised O
to O
treatment O
delivered O
in O
a O
hospital O
day O
unit O
, O
at O
the O
patient O
's O
home O
or O
in O
local O
general O
practice O
( O
GP O
) O
surgeries O
. O

235 O
patients O
completed O
follow-up O
. O

After O
the O
first O
and O
second O
IAD O
cycle O
92 O
% O
and O
46 O
% O
, O
respectively O
, O
had O
a O
normalized O
testosterone O
. O

Physical O
symptoms O
, O
symptom-induced O
stress O
, O
and O
self-assessed O
quality O
of O
life O
were O
evaluated O
with O
a O
study-specific O
questionnaire O
. O

This O
study O
compared O
the O
effect O
of O
two O
doses O
of O
pamidronate O
on O
health-related O
quality O
of O
life O
and O
skeletal O
morbidity O
in O
patients O
with O
newly O
diagnosed O
multiple O
myeloma O
. O

To O
determine O
if O
the O
type O
of O
embolic O
material O
used O
for O
uterine O
artery O
embolization O
( O
UAE O
) O
for O
leiomyomas O
has O
an O
impact O
on O
short-term O
recovery O
or O
the O
effectiveness O
of O
embolization O
. O

We O
aimed O
to O
identify O
the O
effects O
of O
an O
established O
antidepressant O
on O
these O
symptoms O
and O
survival O
in O
patients O
with O
advanced O
cancer O
who O
did O
not O
have O
major O
depression O
as O
assessed O
by O
clinicians O
. O

Twenty-six O
patients O
with O
head O
and O
neck O
cancer O
receiving O
CRT O
. O

Between O
May O
5 O
, O
2009 O
, O
and O
Aug O
27 O
, O
2010 O
, O
96 O
women O
were O
randomly O
allocated O
to O
group O
CBT O
( O
n=47 O
) O
or O
usual O
care O
( O
n=49 O
) O
. O

Overall O
urinary O
morbidity O
was O
worst O
at O
1 O
month O
after O
the O
implant O
. O

All O
patients O
had O
stage O
IV O
or O
relapsed O
disease O
and O
a O
performance O
score O
of O
0 O
or O
1 O
. O

Transfusion O
data O
were O
available O
for O
79 O
of O
81 O
evaluable O
patients O
( O
98 O
% O
) O
who O
completed O
the O
treatment/observation O
period O
. O

All O
statistical O
tests O
were O
two-sided O
. O

Participants O
were O
randomly O
assigned O
to O
receive O
a O
10-month O
program O
of O
mailed O
print O
materials O
on O
diet O
and O
PA O
available O
in O
the O
public O
domain O
or O
a O
10-month O
program O
of O
tailored O
materials O
designed O
to O
increase O
fruit O
and O
vegetable O
( O
F O
& O
V O
) O
intake O
, O
decrease O
fat O
intake O
, O
and/or O
increase O
PA. O
Changes O
in O
self-efficacy O
for O
F O
& O
V O
intake O
and O
fat O
restriction O
were O
analyzed O
as O
potential O
mediators O
of O
the O
intervention O
's O
effects O
on O
diet O
at O
2-year O
follow-up O
. O

The O
objective O
of O
this O
study O
is O
to O
explore O
the O
inflammatory O
modulation O
effect O
of O
glutamine-enriched O
total O
parenteral O
nutrition O
( O
TPN O
) O
by O
investigating O
the O
alterations O
of O
inflammation-related O
cytokines O
in O
gastrointestinal O
( O
GI O
) O
cancer O
patients O
postoperatively O
. O

Consenting O
patients O
( O
N O
= O
271 O
) O
with O
a O
preliminary O
diagnosis O
of O
cancer O
of O
the O
esophagus O
, O
stomach O
, O
liver/gallbladder O
, O
pancreas O
, O
or O
colon/rectum O
were O
stratified O
by O
sex O
and O
randomly O
assigned O
to O
a O
control O
group O
that O
received O
standard O
care O
as O
provided O
on O
the O
surgical O
wards O
, O
or O
to O
an O
experimental O
group O
that O
received O
formal O
psychotherapeutic O
support O
in O
addition O
to O
routine O
care O
during O
the O
hospital O
stay O
. O

Patients O
were O
randomly O
assigned O
( O
1:1 O
) O
to O
receive O
oral O
abiraterone O
( O
1 O
g O
daily O
) O
plus O
prednisone O
( O
5 O
mg O
twice O
daily O
) O
or O
placebo O
plus O
prednisone O
in O
continuous O
4-week O
cycles O
. O

Mucositis O
was O
scored O
using O
a O
validated O
mucositis O
scoring O
system O
. O

Participants O
were O
randomised O
to O
follow-up O
care O
as O
usual O
( O
3-monthly O
outpatient O
clinic O
visits O
) O
, O
nurse-led O
telephone O
follow-up O
, O
or O
the O
former O
strategies O
combined O
with O
an O
educational O
group O
programme O
. O

The O
combination O
of O
radiotherapy O
plus O
long-term O
medical O
suppression O
of O
androgens O
( O
> O
or O
= O
2 O
years O
) O
improves O
overall O
survival O
in O
patients O
with O
locally O
advanced O
prostate O
cancer O
. O

Patients O
with O
stable O
or O
responding O
disease O
were O
then O
randomized O
to O
observation O
or O
four O
cycles O
of O
topotecan O
( O
1.5 O
mg/m O
( O
2 O
) O
/d O
for O
5 O
days O
, O
every O
3 O
weeks O
";" O
step O
2 O
) O
. O

Opioids O
, O
on O
their O
own O
, O
do O
not O
control O
this O
type O
of O
pain O
well O
enough O
, O
and O
co-analgesics O
are O
necessary O
. O

Compare O
GJJ O
and O
stent O
placement O
. O

The O
aim O
of O
the O
project O
was O
to O
identify O
clinical O
and O
quality O
of O
life O
( O
QL O
) O
factors O
that O
together O
predict O
survival O
and O
response O
to O
chemotherapy O
in O
advanced O
breast O
cancer O
. O

Aqua O
lymphatic O
therapy O
( O
ALT O
) O
is O
a O
novel O
treatment O
for O
limb O
volume O
reduction O
. O

The O
relationship O
between O
change O
in O
self-efficacy O
and O
long-term O
physical O
activity O
( O
PA O
) O
also O
was O
examined O
. O

We O
randomised O
149 O
patients O
and O
analysed O
74 O
in O
each O
arm O
. O

One O
hundred O
seven O
patients O
were O
randomly O
assigned O
to O
AM O
( O
n O
= O
54 O
) O
or O
PM O
( O
n O
= O
53 O
) O
dosing O
and O
on O
study O
for O
a O
median O
8.3 O
months O
. O

Studies O
on O
quality O
of O
life O
( O
QOL O
) O
among O
women O
with O
endometrial O
cancer O
have O
shown O
that O
patients O
who O
undergo O
pelvic O
radiotherapy O
report O
lower O
role O
functioning O
and O
more O
diarrhea O
and O
fatigue O
. O

From O
November O
1999 O
to O
October O
2003 O
, O
1031 O
patients O
were O
randomly O
assigned O
to O
undergo O
sentinel O
lymph O
node O
biopsy O
( O
n O
= O
515 O
) O
or O
standard O
axillary O
surgery O
( O
n O
= O
516 O
) O
. O

Patients O
completed O
the O
Short O
Form O
36-item O
Health O
Survey O
( O
SF-36 O
) O
and O
the O
Menopause O
Specific O
Quality O
of O
Life O
Questionnaire O
( O
MENQOL O
) O
at O
baseline O
, O
6 O
months O
, O
and O
annually O
. O

317 O
patients O
( O
218 O
from O
the O
abatacept O
and O
99 O
from O
the O
placebo O
group O
) O
entered O
and O
222 O
( O
70 O
% O
) O
completed O
18 O
months O
of O
long-term O
extension O
treatment O
. O

Primary O
outcome O
was O
general O
fatigue O
at O
6 O
weeks O
, O
measured O
with O
the O
Multidimensional O
Fatigue O
Inventory O
( O
MFI O
) O
. O

Their O
median O
age O
was O
65 O
years O
, O
30 O
% O
had O
PS O
2 O
and O
76 O
% O
stage O
IV O
disease O
. O

Eligible O
patients O
with O
complete O
response O
( O
CR O
) O
or O
partial O
response O
( O
PR O
) O
to O
combination O
chemotherapy O
( O
+/- O
thoracic O
or O
prophylactic O
cranial O
radiation O
) O
received O
oral O
vandetanib O
300 O
mg/d O
or O
matched O
placebo O
. O

The O
interventions O
offered O
dyads O
information O
and O
support O
. O

Patients O
in O
Group O
1 O
performed O
pilates O
and O
home O
exercises O
and O
patients O
in O
group O
2 O
performed O
only O
home O
exercises O
. O

The O
aim O
of O
this O
study O
was O
to O
examine O
whether O
ALT O
is O
a O
safe O
method O
and O
whether O
there O
are O
differences O
in O
adherence O
, O
limb O
volume O
, O
and O
quality O
of O
life O
between O
women O
who O
perform O
only O
self-management O
treatment O
and O
women O
who O
participate O
as O
well O
in O
ALT O
. O

The O
study O
was O
conducted O
in O
the O
palliative O
care O
and O
hospice O
ward O
of O
a O
public O
hospital O
in O
Hong O
Kong O
. O

Early O
stopping O
rules O
in O
cases O
of O
rapid O
progression O
of O
disease O
were O
defined O
, O
with O
preplanned O
interim O
analyses O
. O

Increased O
attention O
has O
focused O
on O
exercise O
as O
a O
quality O
of O
life O
intervention O
for O
breast O
cancer O
survivors O
during O
and O
after O
adjuvant O
therapy O
. O

Statistical O
tests O
were O
two-sided O
. O

Biopsies O
( O
n=168 O
) O
were O
taken O
without O
complications O
. O

The O
primary O
endpoint O
was O
progression-free O
survival O
( O
PFS O
) O
. O

Patients O
with O
measurable/evaluable O
HER2-positive O
LR/MBC O
who O
had O
not O
received O
trastuzumab O
or O
chemotherapy O
for O
LR/MBC O
were O
stratified O
by O
prior O
adjuvant O
trastuzumab O
, O
prior O
( O
neo O
) O
adjuvant O
taxane O
, O
hormone O
receptor O
status O
, O
and O
measurable O
disease O
and O
were O
randomly O
assigned O
to O
receive O
docetaxel O
100 O
mg/m O
( O
2 O
) O
plus O
trastuzumab O
8 O
mg/kg O
loading O
dose O
followed O
by O
6 O
mg/kg O
either O
with O
bevacizumab O
15 O
mg/kg O
or O
without O
bevacizumab O
, O
all O
administered O
every O
3 O
weeks O
. O

The O
primary O
efficacy O
data O
have O
been O
reported O
previously O
. O

A O
10-point O
change O
in O
QOL O
scores O
from O
baseline O
was O
considered O
clinically O
significant O
. O

There O
were O
6 O
partial O
responses O
( O
18.2 O
% O
) O
( O
95 O
% O
confidence O
interval O
[ O
CI O
] O
+/- O
13.2 O
) O
in O
Study O
A O
and O
7 O
partial O
responses O
( O
21.9 O
% O
) O
( O
95 O
% O
CI O
+/- O
14.3 O
) O
in O
Study O
B O
. O

Baseline O
global O
health O
status O
scores O
were O
found O
to O
be O
similar O
between O
treatment O
groups O
( O
64.7 O
vs O
65.3 O
) O
. O

Patients O
in O
the O
temozolomide O
+ O
radiotherapy O
arm O
received O
concomitant O
temozolomide O
( O
75 O
mg/m2 O
) O
once O
daily O
for O
the O
duration O
of O
radiation O
therapy O
( O
42-49 O
days O
) O
. O

In O
the O
delayed O
treatment O
group O
, O
48/115 O
( O
42 O
% O
) O
patients O
received O
thoracic O
radiotherapy O
( O
29 O
received O
one O
of O
the O
recommended O
regimens O
) O
";" O
64 O
( O
56 O
% O
) O
died O
without O
receiving O
thoracic O
radiotherapy O
";" O
the O
remaining O
three O
( O
3 O
% O
) O
were O
alive O
at O
the O
end O
of O
the O
study O
without O
having O
received O
the O
treatment O
. O

Swallowing O
AUC O
analyses O
were O
calculated O
from O
patient O
diaries O
and O
PDLs O
. O

The O
primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
. O

The O
Active O
After O
Cancer O
Trial O
( O
AACT O
) O
was O
a O
multicenter O
pilot O
study O
evaluating O
the O
feasibility O
of O
a O
telephone-based O
exercise O
intervention O
in O
a O
cooperative O
group O
setting O
. O

We O
also O
investigated O
the O
relationship O
between O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT O
) O
scale O
scores O
and O
EQ-5D O
utilities O
. O

They O
were O
questioned O
on O
the O
topics O
of O
( O
i O
) O
severity O
of O
pain O
, O
( O
ii O
) O
ease O
of O
swallowing O
, O
( O
iii O
) O
satisfaction O
of O
daily O
activities O
, O
( O
iv O
) O
dependence O
on O
medications O
, O
( O
v O
) O
working O
ability O
, O
( O
vi O
) O
fatigue O
, O
( O
vii O
) O
appetite O
, O
( O
viii O
) O
sociality O
, O
( O
ix O
) O
happiness O
and O
( O
x O
) O
self O
respect O
, O
in O
the O
third O
, O
sixth O
and O
twelfth O
month O
. O

Data O
come O
from O
the O
Moving O
Beyond O
Cancer O
psychoeducational O
intervention O
trial O
, O
aimed O
at O
easing O
the O
transition O
from O
patient O
to O
survivor O
. O

The O
primary O
endpoint O
was O
overall O
survival O
, O
and O
secondary O
endpoints O
were O
progression-free O
survival O
, O
response O
rate O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

Eighty O
percent O
of O
patients O
had O
stage O
IV O
NSCLC O
, O
with O
squamous O
cell O
( O
n=21 O
) O
, O
adenocarcinoma O
( O
n=12 O
) O
, O
and O
undifferentiated O
( O
n=7 O
) O
histologies O
. O

The O
effect O
of O
treatment O
was O
measured O
using O
a O
" O
Well-Being O
scale O
" O
, O
with O
the O
difference O
of O
the O
average O
score O
of O
the O
" O
Well-Being O
scale O
" O
on O
day O
10 O
being O
defined O
as O
primary O
and O
that O
on O
day O
5 O
as O
secondary O
endpoint O
. O

Thirty-six O
patients O
were O
treated O
. O

Patients O
receiving O
adjuvant O
RT O
reported O
worse O
bowel O
function O
( O
through O
approximately O
2 O
years O
) O
and O
worse O
urinary O
function O
. O

" O
Washout O
" O
patients O
discontinued O
anti-TNF O
therapy O
2 O
months O
or O
longer O
pre-screening O
";" O
" O
direct-switch O
100" O
patients O
began O
abatacept O
( O
approximately O
10 O
mg/kg O
) O
at O
their O
next O
scheduled O
anti-TNF O
therapy O
dose O
. O

We O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
HRQoL O
. O

The O
sample O
of O
patients O
( O
n O
= O
709 O
) O
newly O
admitted O
to O
hospice O
home O
care O
in O
2 O
hospices O
had O
designated O
family O
caregivers O
. O

All O
patients O
were O
randomly O
assigned O
to O
two O
groups O
, O
the O
55 O
patients O
in O
the O
treated O
group O
were O
treated O
with O
radiotherapy O
combined O
with O
the O
TCM O
therapy O
, O
and O
the O
53 O
in O
the O
control O
group O
were O
given O
radiotherapy O
alone O
. O

An O
interim O
analysis O
showed O
futility O
, O
and O
the O
results O
are O
presented O
with O
an O
adjusted O
one-sided O
alpha O
level O
of O
0.0429 O
. O

With O
the O
exception O
of O
previous O
chemotherapy O
, O
the O
treatment O
groups O
were O
well O
balanced O
, O
both O
regarding O
treatment- O
and O
patient-related O
factors O
. O

This O
study O
examined O
factors O
associated O
with O
attrition O
from O
a O
randomized O
controlled O
trial O
comparing O
meaning-centered O
group O
psychotherapy O
( O
MCGP O
) O
, O
an O
intervention O
designed O
to O
help O
advanced O
cancer O
patients O
sustain O
or O
enhance O
their O
sense O
of O
meaning O
to O
the O
supportive O
group O
psychotherapy O
( O
SGP O
) O
, O
a O
standardized O
support O
group O
. O

The O
current O
study O
examined O
the O
effect O
of O
recombinant O
human O
deoxyribonuclease O
( O
rhDNase O
) O
on O
quality O
of O
life O
( O
QOL O
) O
measures O
, O
clinical O
improvement O
, O
and O
DNA O
content O
of O
thick O
oropharyngeal O
secretions O
( O
OPS O
) O
in O
patients O
with O
head-and-neck O
( O
H O
& O
N O
) O
cancers O
. O

To O
describe O
the O
Food O
and O
Drug O
Administration O
( O
FDA O
) O
review O
and O
approval O
of O
erlotinib O
( O
Tarceva O
, O
OSI O
Pharmaceuticals O
, O
Melville O
, O
NY O
) O
for O
treatment O
of O
patients O
with O
locally O
advanced O
or O
metastatic O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
after O
failure O
of O
at O
least O
one O
prior O
chemotherapy O
regimen O
. O

Palliation O
was O
defined O
as O
an O
improvement O
of O
one O
point O
or O
more O
in O
the O
categorical O
scale O
. O

Patients O
with O
stage O
IIIB O
or O
IV O
NSCLC O
and O
WHO O
performance O
status O
( O
PS O
) O
0-2 O
were O
randomised O
to O
receive O
three O
( O
C3 O
) O
or O
six O
( O
C6 O
) O
courses O
of O
carboplatin O
( O
area O
under O
the O
curve O
( O
AUC O
) O
4 O
, O
Chatelut O
's O
formula O
, O
equivalent O
to O
Calvert O
's O
AUC O
5 O
) O
on O
day O
1 O
and O
vinorelbine O
25 O
mg O
m O
( O
-2 O
) O
on O
days O
1 O
and O
8 O
of O
a O
3-week O
cycle O
. O

The O
primary O
endpoint O
was O
increase O
in O
arm O
volume O
from O
baseline O
to O
the O
average O
of O
measurements O
at O
6 O
and O
12 O
months O
. O

We O
designed O
a O
trial O
to O
investigate O
the O
effects O
of O
epoetin O
alfa O
therapy O
on O
the O
QOL O
of O
anemic O
patients O
with O
advanced O
non-small-cell O
carcinoma O
of O
the O
lung O
( O
NSCLC O
) O
. O

The O
aim O
of O
the O
present O
trial O
was O
to O
evaluate O
the O
effects O
of O
chemotherapy O
on O
the O
quality O
of O
life O
and O
survival O
of O
patients O
with O
advanced O
non-small O
cell O
lung O
cancer O
( O
NSCLC O
) O
( O
stage O
IIIB O
or O
IV O
) O
. O

One O
thousand O
two O
hundred O
ninety-nine O
patients O
were O
randomly O
assigned O
. O

Eighty-nine O
chemotherapy-naïve O
patients O
were O
randomized O
either O
to O
gemcitabine O
( O
1,000 O
mg/m2 O
, O
30-min O
infusion O
on O
days O
1 O
, O
8 O
and O
15 O
) O
and O
oral O
etoposide O
( O
50 O
mg O
, O
days O
1-14 O
";" O
GE O
group O
) O
or O
gemcitabine O
at O
the O
same O
schedule O
and O
cisplatin O
( O
75 O
mg/m2 O
on O
day O
15 O
";" O
GP O
group O
) O
. O

QOL O
was O
assessed O
with O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
and O
a O
trial-specific O
checklist O
at O
baseline O
and O
at O
weeks O
5 O
and O
9 O
for O
those O
who O
received O
chemotherapy O
and O
at O
follow-up O
months O
3 O
, O
6 O
, O
9 O
, O
12 O
, O
18 O
, O
24 O
, O
30 O
and O
36 O
. O

All O
patients O
were O
followed O
for O
a O
median O
of O
48 O
( O
6-108 O
) O
months O
. O

Article O
from O
the O
Special O
issue O
on O
Targeted O
Inhibitors O
. O

After O
chemotherapy O
those O
in O
the O
treatment O
group O
took O
modified O
FJD O
. O

Treatment O
arms O
were O
balanced O
with O
respect O
to O
performance O
status O
grade O
0-1 O
( O
83 O
% O
versus O
86 O
% O
, O
respectively O
) O
and O
the O
presence O
of O
metastases O
( O
92 O
% O
versus O
89 O
% O
, O
respectively O
) O
. O

This O
phase O
III O
study O
was O
performed O
to O
determine O
the O
superiority O
of O
doxorubicin O
( O
DOX O
) O
and O
vinorelbine O
( O
VNB O
) O
( O
arm O
1 O
) O
versus O
DOX O
alone O
( O
arm O
2 O
) O
in O
metastatic O
breast O
cancer O
( O
MBC O
) O
for O
overall O
survival O
( O
OS O
) O
, O
time O
to O
treatment O
failure O
( O
TTF O
) O
, O
toxicity O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

We O
evaluated O
the O
impact O
of O
response O
and/or O
clinical O
benefit O
on O
quality O
of O
life O
( O
QL O
) O
in O
postmenopausal O
patients O
under O
second-line O
endocrine O
treatment O
after O
failure O
of O
tamoxifen O
. O

QOL O
outcomes O
were O
analyzed O
at O
a O
median O
follow-up O
of O
2 O
years O
. O

203 O
women O
entered O
the O
study O
";" O
177 O
completed O
the O
six O
month O
follow-up O
. O

Primary O
end O
point O
was O
overall O
survival O
( O
OS O
) O
";" O
secondary O
end O
points O
included O
overall O
response O
rate O
( O
ORR O
) O
and O
progression-free O
survival O
( O
PFS O
) O
. O

This O
trial O
is O
registered O
with O
the O
Netherlands O
Trial O
Register O
, O
NTR O
TC O
2452 O
. O

Sixteen O
advanced O
cancer O
patients O
with O
neuropathic O
pain O
on O
systemic O
morphine O
therapy O
, O
no O
longer O
receiving O
oncologic O
treatment O
, O
presenting O
moderate O
pain O
( O
about O
4 O
or O
more O
, O
but O
less O
than O
7 O
, O
on O
a O
numerical O
scale O
of O
0-10 O
) O
in O
the O
last O
week O
, O
and O
given O
a O
stable O
morphine O
dose O
in O
the O
last O
2 O
days O
were O
admitted O
to O
the O
study O
. O

Based O
on O
this O
safety O
analysis O
, O
the O
next O
step O
of O
study O
recruitment O
was O
continued O
. O

One O
hundred O
ninety O
patients O
with O
extremity O
STS O
were O
randomized O
after O
stratification O
by O
tumor O
size O
dichotomized O
at O
10 O
cm O
. O

Data O
of O
299 O
patients O
were O
available O
for O
evaluation O
. O

Androgen O
treatment O
for O
prostate O
cancer O
can O
adversely O
affect O
functional O
domains O
of O
quality O
of O
life O
. O

To O
compare O
the O
toxicities O
, O
tumor O
control O
, O
survival O
, O
and O
quality O
of O
life O
of O
nasopharyngeal O
cancer O
( O
NPC O
) O
patients O
treated O
with O
sequential O
neoadjuvant O
chemotherapy O
followed O
by O
concurrent O
cisplatin-radiotherapy O
( O
CRT O
) O
or O
CRT O
alone O
. O

MA.17 O
was O
conducted O
to O
determine O
whether O
letrozole O
improves O
outcome O
after O
discontinuation O
of O
tamoxifen O
. O

Dysuria O
was O
evaluated O
on O
a O
0-10 O
scale O
, O
before O
brachytherapy O
and O
then O
at O
1 O
, O
3 O
, O
6 O
and O
12 O
months O
afterward O
, O
with O
a O
median O
of O
four O
dysuria O
questionnaires O
per O
patient O
. O

Patients O
completed O
a O
comprehensive O
battery O
of O
QOL O
questionnaires O
at O
random O
assignment O
to O
treatment O
and O
at O
1 O
, O
3 O
, O
and O
6 O
months O
later O
. O

Seventy-two O
women O
were O
evaluable O
at O
the O
end O
of O
the O
study O
period O
. O

The O
goal O
of O
this O
study O
was O
to O
assess O
the O
impact O
of O
neuronavigation O
on O
the O
cytoreductive O
treatment O
of O
solitary O
contrast-enhancing O
intracerebral O
tumors O
and O
outcomes O
of O
this O
treatment O
in O
cases O
in O
which O
neuronavigation O
was O
preoperatively O
judged O
to O
be O
redundant O
. O

All O
patients O
were O
to O
receive O
WBRT O
( O
30 O
Gy O
in O
10 O
fractions O
) O
. O

We O
investigated O
whether O
cognitive O
behavioural O
therapy O
( O
CBT O
) O
can O
help O
breast O
cancer O
survivors O
to O
effectively O
manage O
HFNS O
. O

The O
training O
group O
followed O
an O
8-week O
exercise O
program O
consisting O
of O
3 O
weekly O
sessions O
of O
90-min O
duration O
, O
supervised O
by O
an O
experienced O
investigator O
and O
divided O
into O
resistance O
exercises O
and O
aerobic O
training O
. O

We O
report O
a O
phase O
III O
trial O
comparing O
DOX O
with O
DPPE O
plus O
DOX O
in O
metastatic O
or O
recurrent O
breast O
cancer O
. O

QOL O
was O
assessed O
by O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
and O
the O
lung O
cancer O
module O
QLQ-LC13 O
. O

Enzastaurin O
( O
E O
) O
inhibits O
PKCβ O
and O
PI3K/AKT O
signaling O
pathways O
with O
a O
dose-dependent O
effect O
on O
growth O
of O
pancreatic O
carcinoma O
xenografts O
. O

This O
phase O
III O
, O
double-blind O
, O
randomized O
, O
multicenter O
study O
evaluated O
the O
efficacy O
, O
pharmacodynamics O
, O
and O
safety O
of O
the O
oral O
aromatase O
inactivator O
exemestane O
( O
EXE O
) O
versus O
megestrol O
acetate O
( O
MA O
) O
in O
postmenopausal O
women O
with O
progressive O
advanced O
breast O
cancer O
who O
experienced O
failure O
of O
tamoxifen O
. O

A O
hot O
flash O
score O
was O
calculated O
at O
each O
time O
point O
. O

77 O
adult O
patients O
with O
cancer O
receiving O
moderately O
or O
highly O
emetogenic O
chemotherapy O
agents O
. O

These O
differences O
all O
resolved O
by O
12 O
months O
. O

The O
median O
dose O
intensity O
delivered O
for O
C O
and O
E O
reached O
, O
respectively O
, O
85 O
% O
and O
87 O
% O
of O
that O
planned O
in O
the O
CEF O
arm O
and O
96 O
% O
and O
95 O
% O
of O
that O
planned O
in O
the O
EC O
arm O
. O

For O
the O
last O
six O
months O
, O
all O
received O
the O
1 O
+ O
2.5 O
dosage O
. O

Spiritual O
well-being O
and O
sense O
of O
meaning O
are O
important O
concerns O
for O
clinicians O
who O
care O
for O
patients O
with O
cancer O
. O

Fifty O
eight O
of O
the O
60 O
randomized O
patients O
who O
filled O
the O
QOL O
questionnaire O
at O
least O
at O
one O
time O
point O
were O
included O
in O
the O
analysis O
. O

Median O
adherence O
to O
the O
supervised O
exercise O
program O
was O
92 O
% O
. O

This O
study O
aimed O
to O
determine O
the O
effectiveness O
of O
a O
nurse-delivered O
telephone O
supportive O
intervention O
( O
the O
" O
CONNECT O
" O
intervention O
) O
. O

This O
non-inferiority O
design O
trial O
aimed O
to O
determine O
whether O
the O
combination O
of O
gemcitabine O
and O
carboplatin O
( O
GC O
) O
results O
in O
similar O
survival O
but O
is O
less O
toxic O
with O
better O
quality O
of O
life O
. O

Greater O
levels O
of O
anxiety O
, O
depression O
, O
and O
hostility O
at O
baseline O
were O
related O
to O
nausea O
and O
vomiting O
, O
quality O
of O
life O
, O
and O
perceived O
control O
over O
decision O
making O
. O

Analyses O
of O
covariance O
were O
used O
to O
study O
the O
long-term O
effectiveness O
of O
CBT O
. O

A O
randomised O
controlled O
trial O
( O
RCT O
) O
demonstrated O
that O
cognitive O
behaviour O
therapy O
( O
CBT O
) O
for O
fatigue O
during O
curative O
cancer O
treatment O
was O
effective O
shortly O
after O
cancer O
treatment O
. O

The O
regimens O
were O
compared O
with O
regard O
to O
effects O
on O
survival O
, O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
. O

All O
patients O
were O
randomized O
to O
receive O
half O
of O
a O
sachet O
of O
imiquimod O
5 O
% O
cream O
twice O
weekly O
on O
half O
of O
their O
face O
and O
two O
sessions O
of O
PDT O
with O
20 O
% O
solution O
of O
ALA O
applied O
for O
1 O
hour O
to O
the O
other O
side O
of O
the O
face O
. O

Regularly O
collecting O
patient-reported O
outcomes O
( O
PROs O
) O
of O
health-related O
quality O
of O
life O
with O
feedback O
to O
oncologists O
may O
assist O
in O
eliciting O
and O
monitoring O
patients O
' O
problems O
during O
cancer O
treatment O
. O

In O
a O
prospective O
, O
randomized O
, O
double-blind O
, O
placebo-controlled O
trial O
, O
407 O
melanoma O
patients O
in O
stage O
IIA O
( O
301 O
patients O
) O
and O
IIB O
( O
106 O
patients O
) O
were O
randomly O
assigned O
to O
either O
IFNalpha O
and O
isotretinoin O
( O
isotretinoin O
group O
";" O
206 O
patients O
) O
or O
IFNalpha O
and O
placebo O
( O
placebo O
group O
";" O
201 O
patients O
) O
after O
excision O
of O
the O
primary O
tumor O
. O

The O
current O
study O
evaluated O
the O
cost-effectiveness O
of O
the O
capecitabine/docetaxel O
combination O
versus O
docetaxel O
monotherapy O
, O
comparing O
the O
gain O
in O
quality-adjusted O
survival O
with O
associated O
health O
care O
costs O
. O

From O
July O
2000 O
to O
December O
2004 O
, O
a O
total O
of O
81 O
patients O
were O
enrolled O
into O
the O
study O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
efficacy O
and O
safety O
of O
association O
of O
duloxetine O
and O
rehabilitation O
compared O
with O
rehabilitation O
alone O
in O
men O
with O
SUI O
after O
radical O
retropubic O
prostatectomy O
( O
RRP O
) O
, O
and O
to O
compare O
continence O
rate O
even O
after O
planned O
duloxetine O
suspension O
. O

After O
stratification O
by O
estrogen O
receptor O
( O
ER O
) O
status O
, O
patients O
were O
randomly O
assigned O
to O
receive O
three O
28-day O
courses O
of O
" O
classical O
" O
adjuvant O
CMF O
chemotherapy O
( O
cyclophosphamide O
at O
100 O
mg/m O
( O
2 O
) O
on O
days O
1-14 O
, O
orally O
";" O
methotrexate O
at O
40 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
";" O
and O
5-fluorouracil O
at O
600 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
, O
intravenously O
) O
followed O
by O
tamoxifen O
( O
20 O
mg/day O
, O
orally O
for O
57 O
months O
) O
( O
CMF O
-- O
> O
tamoxifen O
) O
or O
to O
receive O
tamoxifen O
alone O
( O
20 O
mg/day O
, O
orally O
for O
60 O
months O
) O
. O

Satisfaction O
was O
assessed O
with O
a O
seven-point O
Likert O
scale O
. O

Our O
primary O
end O
point O
was O
patient-rated O
physical O
functioning O
assessed O
by O
the O
Trial O
Outcome O
Index-Anemia O
. O

From O
November O
2002 O
to O
November O
2004 O
, O
65 O
eligible O
patients O
were O
randomly O
assigned O
to O
neoadjuvant O
chemotherapy O
followed O
by O
CRT O
( O
n O
= O
34 O
) O
or O
CRT O
alone O
( O
n O
= O
31 O
) O
. O

The O
16-week O
regimen O
features O
greater O
doxorubicin O
and O
5-FU O
dose-intensity O
than O
CAF O
and O
improved O
scheduling O
of O
antimetabolites O
with O
sequential O
methotrexate O
and O
5-FU O
, O
as O
well O
as O
infusion O
5-FU O
. O

Future O
trials O
should O
be O
designed O
so O
that O
the O
CR/PR O
and O
SD O
( O
6m O
) O
groups O
are O
investigated O
separately O
. O

This O
was O
followed O
, O
4 O
weeks O
later O
, O
by O
six O
cycles O
of O
temozolomide O
, O
150 O
or O
200 O
mg/m2 O
daily O
for O
5 O
days O
, O
every O
4 O
weeks O
. O

To O
facilitate O
the O
transition O
to O
recovery O
, O
we O
conducted O
the O
Moving O
Beyond O
Cancer O
( O
MBC O
) O
trial O
, O
a O
multisite O
, O
randomized O
, O
controlled O
trial O
of O
psychoeducational O
interventions O
for O
breast O
cancer O
patients O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
analgesic O
and O
adverse O
effects O
, O
doses O
, O
as O
well O
as O
cost O
of O
opioid O
drugs O
, O
supportive O
drug O
therapy O
and O
other O
analgesic O
drugs O
in O
patients O
treated O
with O
oral O
sustained-release O
morphine O
, O
transdermal O
fentanyl O
, O
and O
oral O
methadone O
. O

The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O

Baseline O
neutrophils O
over-ride O
nadir O
counts O
in O
prognostic O
significance O
. O

The O
4 O
arms O
were O
well O
balanced O
for O
sex O
ratio O
, O
age O
, O
WHO O
performance O
status O
, O
the O
primary O
tumour O
site O
and O
prior O
adjuvant O
chemotherapy O
. O

Patients O
had O
metastatic O
CRC O
and O
one O
of O
the O
following O
characteristics O
: O
age O
> O
or O
= O
65 O
years O
, O
Eastern O
Cooperative O
Oncology O
Group O
performance O
status O
1 O
or O
2 O
, O
serum O
albumin O
< O
or O
= O
3.5 O
g/dL O
, O
or O
prior O
abdominal/pelvic O
radiotherapy O
. O

In O
the O
randomized O
, O
multinational O
phase O
II/III O
trial O
( O
V325 O
) O
of O
untreated O
advanced O
gastric O
cancer O
patients O
, O
the O
phase O
II O
part O
selected O
docetaxel O
, O
cisplatin O
, O
and O
fluorouracil O
( O
DCF O
) O
over O
docetaxel O
and O
cisplatin O
for O
comparison O
against O
cisplatin O
and O
fluorouracil O
( O
CF O
";" O
reference O
regimen O
) O
in O
the O
phase O
III O
part O
. O

A O
total O
of O
103 O
patients O
with O
gastric O
cancer O
were O
prospectively O
randomly O
divided O
into O
groups O
for O
RY O
( O
n O
= O
51 O
) O
or O
INT O
reconstruction O
( O
n O
= O
52 O
) O
after O
total O
gastrectomy O
. O

One O
hundred O
twenty O
untreated O
patients O
with O
histologically O
confirmed O
HCC O
were O
randomized O
to O
receive O
either O
long-acting O
octreotide O
( O
Sandostation O
LAR O
30 O
mg O
) O
intramuscularly O
every O
4 O
weeks O
or O
placebo O
. O

A O
total O
of O
558 O
patients O
( O
mean O
age O
= O
56.9 O
years O
) O
were O
enrolled O
in O
the O
study O
between O
July O
1 O
, O
1999 O
, O
and O
June O
30 O
, O
2002 O
. O

One O
hundred O
fifty-five O
patients O
with O
far-advanced O
CRC O
including O
at O
least O
one O
measurable O
lesion O
were O
enrolled O
in O
a O
prospective O
randomized O
clinical O
trial O
funded O
by O
the O
Japanese O
Foundation O
for O
Multidisciplinary O
Treatment O
of O
Cancer O
. O

Only O
37 O
% O
of O
the O
patients O
completed O
protocol O
treatment O
. O

RECIST-defined O
objective O
response O
rate O
( O
ORR O
) O
was O
the O
primary O
end O
point O
. O

SNB O
had O
sensitivity O
94.5 O
% O
, O
false-negative O
rate O
5.5 O
% O
, O
and O
negative O
predictive O
value O
98 O
% O
. O

Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O

The O
140 O
patients O
included O
were O
in O
a O
good O
clinical O
condition O
with O
a O
median O
age O
of O
55 O
years O
( O
range O
22-87 O
) O
. O

Low-level O
laser O
therapy O
( O
LLLT O
) O
showed O
some O
preventive O
and O
curative O
effects O
against O
clinically O
reported O
objective O
measures O
of O
OM O
in O
few O
trials O
including O
our O
recently O
published O
study O
. O

Hospital O
anxiety O
and O
depression O
scale O
scores O
were O
consistent O
with O
the O
primary O
outcome O
measure O
. O

Resilience O
, O
perceived O
stress O
, O
anxiety O
, O
and O
quality O
of O
life O
improved O
at O
12 O
weeks O
in O
the O
active O
but O
not O
the O
control O
arm O
. O

A O
multi-method O
approach O
was O
used O
in O
which O
verbal O
instruction O
, O
written O
material O
, O
an O
audio O
cassette O
tape O
, O
and O
the O
use O
of O
a O
pain O
diary O
were O
combined O
to O
inform O
and O
instruct O
patients O
about O
pain O
and O
pain O
management O
. O

Four O
weeks O
of O
therapy O
constituted O
1 O
cycle O
";" O
patients O
could O
receive O
up O
to O
8 O
cycles O
and O
those O
who O
completed O
8 O
cycles O
were O
given O
the O
option O
of O
receiving O
extended O
therapy O
. O

Older O
breast O
cancer O
survivors O
( O
BCSs O
) O
are O
at O
risk O
for O
late O
and O
long-term O
treatment O
effects O
on O
quality O
of O
life O
( O
QOL O
) O
, O
including O
lower O
physical O
functioning O
and O
fear O
of O
recurrence O
. O

Breast O
cancer O
outcomes O
included O
recurrence O
as O
well O
as O
disease-free O
and O
overall O
survival O
. O

The O
mean O
number O
of O
hot O
flashes O
per O
day O
was O
reduced O
from O
8.7 O
( O
standard O
deviation O
[ O
SD O
] O
, O
3.9 O
) O
to O
6.2 O
( O
SD O
, O
4.2 O
) O
in O
the O
TRUE O
acupuncture O
group O
and O
from O
10.0 O
( O
SD O
, O
6.1 O
) O
to O
7.6 O
( O
SD O
, O
5.7 O
) O
in O
the O
sham O
group O
. O

We O
compared O
the O
combination O
of O
docetaxel-carboplatin O
with O
the O
combination O
of O
paclitaxel-carboplatin O
as O
first-line O
chemotherapy O
for O
stage O
Ic-IV O
epithelial O
ovarian O
or O
primary O
peritoneal O
cancer O
. O

A O
total O
of O
419 O
women O
were O
randomized O
to O
one O
of O
four O
treatments O
: O
once-daily O
1 O
mg O
E2V/2.5 O
mg O
MPA O
( O
1 O
+ O
2.5 O
group O
) O
";" O
1 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
1 O
+ O
5 O
group O
) O
";" O
2 O
mg O
E2V/2.5 O
mg O
MPA O
daily O
( O
2 O
+ O
2.5 O
group O
) O
";" O
2 O
mg O
E2V/5 O
mg O
MPA O
daily O
( O
2 O
+ O
5 O
group O
) O
( O
Indivina O
, O
Orion O
Pharma O
) O
. O

Secondary O
endpoints O
were O
the O
proportions O
of O
women O
with O
at O
least O
15 O
% O
increase O
in O
arm O
volume O
or O
early O
axillary O
morbidity O
, O
and O
average O
scores O
for O
arm O
symptoms O
, O
dysfunctions O
, O
and O
disabilities O
assessed O
at O
6 O
and O
12 O
months O
by O
patients O
with O
the O
SNAC O
Study-Specific O
Scales O
and O
other O
quality-of-life O
instruments O
. O

This O
study O
is O
registered O
, O
ISRCTN87786644 O
. O

Eighty-one O
pamidronate O
patients O
and O
80 O
control O
patients O
were O
monitored O
for O
a O
median O
of O
18 O
and O
21 O
months O
, O
respectively O
, O
for O
events O
of O
skeletal O
morbidity O
and O
the O
radiologic O
course O
of O
metastatic O
bone O
disease O
. O

In O
the O
absence O
of O
an O
overall O
survival O
benefit O
of O
using O
HDC O
for O
high-risk O
breast O
cancer O
patients O
, O
QOL O
studies O
with O
a O
longer O
follow-up O
play O
an O
important O
role O
in O
informing O
the O
complex O
trade-off O
implied O
by O
HDC O
between O
higher O
toxicity O
, O
reduced O
risk O
of O
relapse O
, O
and O
QOL O
decrease O
after O
the O
active O
phase O
of O
treatment O
. O

Patients O
with O
acute O
lymphoblastic O
leukemia O
( O
ALL O
) O
, O
lymphoblastic O
lymphoma O
( O
LL O
) O
, O
or O
Burkitt O
lymphoma O
( O
BL O
) O
who O
were O
receiving O
frontline O
myelosuppressive O
chemotherapy O
were O
randomized O
to O
receive O
epoetin O
alpha O
or O
no O
epoetin O
during O
the O
first O
6 O
cycles O
of O
their O
planned O
chemotherapy O
. O

Discharged O
patients O
were O
followed-up O
in O
the O
outpatient O
clinic O
. O

At O
baseline O
, O
groups O
were O
comparable O
for O
age O
( O
mean O
, O
61 O
years O
) O
, O
sex O
( O
54 O
% O
men O
) O
, O
weight O
loss O
( O
32 O
% O
> O
or O
= O
10 O
% O
) O
, O
PS O
( O
13 O
% O
ECOG O
= O
2 O
) O
, O
antineoplastic O
treatment O
( O
50 O
% O
) O
, O
appetite O
( O
mean O
VAS O
score O
, O
31/100 O
mm O
) O
, O
and O
QOL O
( O
mean O
score O
, O
30/100 O
) O
. O

The O
setting O
was O
in O
a O
hydrotherapy O
pool O
, O
1.2 O
m O
depth O
, O
and O
a O
temperature O
of O
32-33 O
degrees O
capital O
ES O
, O
Cyrillic O
. O

Patients O
with O
stage O
IIIb O
and O
IV O
NSCLC O
and O
KP O
< O
/= O
70 O
were O
randomly O
assigned O
to O
receive O
gemcitabine O
1,000 O
mg/m O
( O
2 O
) O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
each O
28-day O
cycle O
( O
3w4 O
) O
or O
gemcitabine O
1,500 O
mg/m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
of O
each O
21-day O
cycle O
( O
2w3 O
) O
, O
both O
for O
up O
to O
six O
cycles O
. O

Subjects O
were O
88 O
women O
with O
facial O
hirsutism O
due O
to O
PCOS O
recruited O
from O
hospital O
outpatient O
clinics O
and O
a O
patient O
support O
group O
in O
2001-2002 O
. O

One O
hundred O
forty O
consecutive O
patients O
with O
pilonidal O
sinus O
were O
randomly O
assigned O
to O
receive O
either O
UM O
or O
RELP O
procedures O
. O

After O
documentation O
of O
N2 O
disease O
by O
mediastinoscopy O
or O
anterior O
mediastinotomy O
, O
patients O
received O
induction O
chemotherapy O
with O
cisplatin O
, O
vinblastine O
, O
and O
mitomycin-C. O
Mitomycin-C O
was O
later O
dropped O
from O
the O
induction O
regimen O
. O

Intervention O
group O
patients O
received O
5 O
calls O
from O
a O
specialist O
colorectal O
nurse O
in O
the O
6 O
months O
after O
hospital O
discharge O
. O

Of O
the O
analyzable O
patients O
, O
90 O
% O
had O
a O
Karnofsky O
performance O
score O
of O
90-100 O
, O
18 O
% O
had O
weight O
loss O
> O
5 O
% O
, O
37 O
% O
had O
squamous O
cell O
histologic O
features O
, O
and O
54 O
% O
had O
bulky O
N2 O
disease O
. O

The O
aims O
of O
the O
present O
prospective O
randomized O
study O
were O
to O
evaluate O
the O
impact O
of O
TSH O
stimulation O
procedure O
( O
hypothyroidism O
vs. O
rhTSH O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RRA O
and O
to O
evaluate O
efficacy O
of O
both O
procedures O
. O

Secondary O
end O
points O
were O
progression-free O
survival O
and O
need O
of O
palliative O
radiotherapy O
. O

Patients O
with O
advanced O
HIV-associated O
KS O
were O
randomly O
assigned O
to O
receive O
paclitaxel O
at O
a O
dose O
of O
100 O
mg/m2 O
intravenously O
( O
iv O
) O
every O
2 O
weeks O
or O
PLD O
at O
a O
dose O
of O
20 O
mg/m2 O
iv O
every O
3 O
weeks O
. O

The O
primary O
endpoint O
was O
changes O
in O
oral O
calorie O
intake O
, O
and O
the O
secondary O
endpoints O
were O
chemotherapy-related O
adverse O
events O
";" O
appetite O
visual O
analog O
scale O
( O
VAS O
) O
scores O
";" O
changes O
in O
gastrointestinal O
hormones O
and O
nutritional O
status O
, O
including O
rapid O
turnover O
proteins O
, O
and O
quality O
of O
life O
( O
QoL O
) O
estimated O
with O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QoL O
core O
questionnaire O
( O
QLQ-C30 O
) O
. O

General O
practices O
in O
UK O
( O
384 O
) O
, O
Australia O
( O
91 O
) O
, O
and O
New O
Zealand O
( O
24 O
) O
. O

Primary O
outcomes O
were O
assessed O
as O
follows O
: O
CRF O
using O
the O
Visual O
Analogue O
Scale-Global O
Fatigue O
";" O
physical O
functioning O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality-of-Life O
Core O
30 O
Questionnaire O
, O
and O
CRF-associated O
distress O
using O
the O
Fatigue O
Outcome O
Measure O
. O

Symptoms O
were O
categorized O
as O
none O
, O
mild O
, O
moderate O
, O
or O
severe O
. O

We O
report O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
at O
a O
mean O
of O
5.3 O
years O
for O
168 O
trial-eligible O
men O
who O
either O
chose O
or O
were O
randomly O
assigned O
to O
RP O
or O
BT O
following O
a O
multidisciplinary O
educational O
session O
. O

Kruskall-Wallis O
methodology O
was O
used O
to O
compare O
scores O
between O
older O
and O
younger O
adult O
patients O
randomized O
to O
the O
intervention O
. O

Radiation-induced O
mucositis O
is O
an O
acute O
reaction O
of O
the O
mucosa O
of O
patients O
undergoing O
head O
and O
neck O
radiotherapy O
. O

SLNs O
were O
identified O
in O
662 O
of O
697 O
patients O
( O
95 O
% O
) O
and O
positive O
SLNs O
were O
found O
in O
189 O
of O
662 O
patients O
( O
28.5 O
% O
) O
. O

bolus O
( O
arm O
B O
) O
";" O
or O
MTX O
, O
750 O
mg/m2 O
i.v O
. O

The O
control O
group O
received O
no O
advice O
about O
exercise O
. O

QOL O
was O
assessed O
using O
FACT-Cx O
, O
consisting O
of O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
( O
FACT-G O
) O
plus O
a O
cervix O
cancer-specific O
subscale O
, O
the O
Brief O
Pain O
Inventory-Short O
Form O
( O
BPI-SF O
) O
, O
and O
a O
neurotoxicity O
subscale O
. O

Patients O
were O
interviewed O
by O
telephone O
before O
treatment O
( O
baseline O
) O
, O
midtreatment O
, O
within O
1 O
month O
post-treatment O
, O
and O
at O
12 O
, O
18 O
, O
and O
24 O
months O
postbaseline O
by O
using O
questionnaires O
from O
the O
European O
Organisation O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
, O
a O
breast O
systemic O
adverse O
effects O
scale O
( O
EORTC O
BR23 O
) O
, O
and O
the O
Hospital O
Anxiety O
and O
Depression O
Scale O
( O
HADS O
) O
. O

Most O
patients O
had O
visceral O
metastases O
, O
43 O
% O
had O
a O
disease-free O
interval O
less O
than O
12 O
months O
, O
and O
85 O
% O
had O
measurable O
disease O
. O

The O
primary O
end O
point O
of O
the O
study O
was O
the O
time O
to O
development O
of O
severe O
mucositis O
from O
the O
start O
of O
radiotherapy O
. O

They O
completed O
assessments O
of O
psychosocial O
, O
spiritual O
, O
and O
physical O
well-being O
pretreatment O
, O
midtreatment O
, O
and O
2 O
months O
post-treatment O
. O

The O
levels O
of O
VEGF O
and O
carcinoembryonic O
antigen O
( O
CEA O
) O
in O
the O
pleural O
fluid O
were O
determined O
by O
ELISA O
. O

The O
primary O
end O
points O
were O
body O
image O
and O
cosmesis O
. O

From O
February O
2006 O
to O
March O
2007 O
, O
291 O
patients O
were O
enrolled O
and O
randomized O
, O
after O
total O
thyroidectomy O
: O
( O
1 O
) O
withdrawal O
of O
levothyroxine O
( O
LT4 O
) O
for O
4 O
weeks O
( O
T4-WD O
Group O
, O
n O
= O
89 O
) O
, O
( O
2 O
) O
withdrawal O
of O
LT4 O
for O
4 O
weeks O
plus O
2 O
weeks O
on O
and O
then O
2 O
weeks O
off O
liothyronine O
( O
LT3 O
) O
( O
T3-WD O
Group O
, O
n O
= O
133 O
) O
, O
and O
( O
3 O
) O
rhTSH O
administration O
( O
rhTSH O
Group O
, O
n O
= O
69 O
) O
. O

Patients O
aged O
70 O
years O
and O
older O
, O
enrolled O
between O
December O
1997 O
and O
November O
2000 O
, O
were O
randomly O
assigned O
to O
receive O
intravenous O
vinorelbine O
( O
30 O
mg/m O
( O
2 O
) O
of O
body O
surface O
area O
) O
, O
gemcitabine O
( O
1200 O
mg/m O
( O
2 O
) O
) O
, O
or O
vinorelbine O
( O
25 O
mg/m O
( O
2 O
) O
) O
plus O
gemcitabine O
( O
1000 O
mg/m O
( O
2 O
) O
) O
. O

The O
starting O
dosage O
was O
60 O
mg/m O
( O
2 O
) O
, O
which O
was O
escalated O
to O
90 O
mg/m O
( O
2 O
) O
and O
then O
120 O
mg/m O
( O
2 O
) O
if O
the O
drug O
was O
well O
tolerated O
( O
< O
or= O
Grade O
2 O
toxicities O
[ O
according O
to O
the O
Southwest O
Oncology O
Group O
toxicity O
scale O
] O
) O
. O

406 O
eligible O
patients O
were O
entered O
into O
the O
trial O
. O

Randomized O
, O
double-blinded O
, O
placebo-controlled O
trial O
. O

The O
feasibility O
of O
measuring O
Bcl-2 O
protein O
in O
a O
cooperative O
group O
setting O
is O
hypothesis O
generating O
and O
supports O
further O
study O
as O
a O
marker O
for O
Bcl-2 O
targeted O
therapy O
. O

Of O
the O
186 O
total O
patients O
, O
113 O
had O
initial O
treatment O
with O
platinum O
therapy O
and O
DNA O
samples O
of O
whom O
46 O
also O
had O
QOL O
data O
. O

Despite O
premature O
trial O
closure O
, O
our O
data O
provided O
valuable O
insights O
. O

After O
catheter O
removal O
, O
112 O
patients O
were O
randomized O
to O
receive O
rehabilitation O
and O
duloxetine O
( O
group O
A O
) O
or O
rehabilitation O
alone O
( O
group O
B O
) O
, O
for O
16 O
wk O
. O

Eighty O
participants O
completed O
all O
follow-ups O
. O

241 O
patients O
( O
121 O
GC O
, O
120 O
PE O
) O
were O
recruited O
, O
of O
which O
216 O
( O
90 O
% O
) O
had O
died O
. O

Endpoints O
included O
MD O
Anderson O
Symptom O
Inventory-Head O
and O
Neck O
( O
MDASI-HN O
) O
and O
Functional O
Assessment O
of O
Cancer O
Therapy-Head O
and O
Neck O
( O
FACT-NH O
) O
scores O
, O
along O
with O
clinical O
assessment O
and O
DNA O
concentration O
of O
OPS O
. O

Primary O
outcome O
measures O
assessed O
spiritual O
well-being O
and O
quality O
of O
life O
";" O
secondary O
outcomes O
included O
anxiety O
, O
depression O
, O
hopelessness O
, O
symptom O
burden O
, O
and O
symptom-related O
distress O
. O

For O
this O
randomized O
controlled O
trial O
, O
60 O
patients O
with O
cancer O
were O
recruited O
and O
received O
either O
usual O
care O
or O
the O
intervention O
. O

Both O
gemcitabine O
( O
GEM O
) O
and O
fluoropyrimidines O
are O
valuable O
treatment O
for O
advanced O
pancreatic O
cancer O
. O

The O
purpose O
of O
this O
blinded O
, O
randomized O
clinical O
trial O
was O
to O
compare O
two O
topical O
agents O
( O
Calendula O
Weleda O
cream O
vs. O
Essex O
cream O
) O
in O
reducing O
the O
risk O
of O
severe O
acute O
radiation O
skin O
reactions O
( O
ARSR O
) O
in O
relation O
to O
adjuvant O
radiotherapy O
( O
RT O
) O
for O
breast O
cancer O
. O

In O
all O
, O
55 O
patients O
( O
27 O
on O
tamoxifen O
and O
28 O
on O
exemestane O
) O
completed O
the O
1-year O
study O
period O
. O

Patients O
were O
randomly O
assigned O
to O
fulvestrant O
500 O
mg O
( O
500 O
mg O
intramuscularly O
[ O
IM O
] O
on O
day O
0 O
, O
then O
500 O
mg O
IM O
on O
days O
14 O
and O
28 O
and O
every O
28 O
days O
thereafter O
) O
or O
250 O
mg O
every O
28 O
days O
. O

ORR O
was O
20 O
% O
with O
a O
7.2-month O
median O
response O
duration O
. O

Experimental O
subjects O
live O
and O
interactive O
music O
therapy O
sessions O
, O
including O
a O
pre-operative O
session O
and O
continuing O
with O
daily O
sessions O
until O
the O
patient O
was O
discharged O
home O
. O

Sixty O
female O
breast O
cancer O
survivors O
with O
hot O
flashes O
were O
randomly O
assigned O
to O
receive O
hypnosis O
intervention O
( O
five O
weekly O
sessions O
) O
or O
no O
treatment O
. O

Anthracycline-naive O
women O
with O
measurable O
metastatic O
disease O
were O
randomly O
assigned O
to O
receive O
, O
every O
21 O
days O
, O
either O
DOX O
60 O
mg/m O
( O
2 O
) O
intravenously O
or O
DOX O
during O
the O
last O
20 O
minutes O
of O
an O
80-minute O
infusion O
of O
DPPE O
( O
5.3 O
mg/kg O
) O
, O
in O
both O
cases O
to O
cumulative O
DOX O
doses O
of O
450 O
mg/m O
( O
2 O
) O
. O

At O
early O
closure O
of O
the O
trial O
, O
56,583 O
had O
been O
screened O
, O
8980 O
entered O
run-in O
, O
and O
5692 O
( O
26 O
% O
of O
target O
of O
22,300 O
) O
started O
treatment O
. O

The O
majority O
of O
the O
patient O
loss O
was O
because O
of O
patient O
preference O
( O
45 O
% O
of O
enrolled O
patients O
) O
. O

However O
, O
the O
survival O
and O
quality-of-life O
( O
QOL O
) O
benefits O
of O
paclitaxel O
used O
as O
a O
single O
agent O
compared O
with O
supportive O
care O
alone O
have O
not O
been O
assessed O
in O
a O
randomized O
clinical O
trial O
. O

The O
mean O
follow-up O
period O
was O
53.6 O
months O
. O

There O
were O
fewer O
patients O
with O
a O
performance O
status O
of O
0 O
( O
n O
= O
11 O
v O
20 O
) O
, O
and O
fewer O
had O
CR O
to O
initial O
therapy O
( O
n O
= O
4 O
v O
8 O
) O
in O
the O
vandetanib O
arm O
. O

Self-report O
questionnaires O
were O
completed O
at O
baseline O
, O
12 O
weeks O
, O
and O
6 O
months O
. O

Two O
million O
people O
across O
the O
U.K. O
are O
living O
with O
cancer O
, O
often O
experienced O
as O
a O
long-term O
condition O
. O

Data O
were O
collected O
from O
both O
groups O
of O
dyads O
using O
standardized O
assessments O
on O
admission O
and O
1 O
week O
after O
each O
of O
the O
first O
2 O
IDT O
meetings O
in O
which O
these O
dyads O
were O
discussed O
. O

The O
primary O
endpoint O
was O
change O
in O
hemoglobin O
from O
baseline O
to O
Week O
13 O
. O

Cross-over O
single-blind O
random O
clinical O
trial O
. O

Sensitivity O
analyses O
were O
also O
performed O
for O
selected O
QOL O
domains O
and O
items O
, O
using O
other O
types O
of O
summary O
measures O
and O
statistics O
. O

Group-wise O
randomization O
was O
implemented O
by O
assigning O
one O
half O
of O
the O
patients O
to O
the O
complete O
program O
while O
the O
other O
half O
were O
allowed O
to O
choose O
which O
program O
components O
they O
considered O
relevant O
. O

Forty O
patients O
were O
assessable O
for O
toxicity O
and O
32 O
for O
treatment O
response O
. O

Minimum O
followup O
was O
12 O
months O
. O

Tumour O
tissue O
was O
obtained O
from O
168 O
patients O
with O
mCRC O
for O
relative O
thymidylate O
synthase O
( O
TS O
) O
mRNA O
quantitation O
. O

HQL O
was O
assessed O
before O
treatment O
initiation O
and O
then O
every O
3 O
weeks O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality-of-Life O
Questionnaire O
C30 O
( O
EORTC O
QLQ-C30 O
) O
and O
the O
Quality O
of O
Life O
Module-Prostate O
14 O
( O
QOLM-P14 O
) O
, O
a O
trial-specific O
module O
developed O
for O
this O
study O
. O

Lung O
expansion O
was O
evaluated O
through O
chest O
CT O
scans O
obtained O
0 O
, O
1 O
, O
3 O
and O
6 O
months O
after O
pleurodesis O
. O

There O
is O
a O
modest O
dose O
effect O
with O
longer O
time O
to O
progression O
at O
175 O
mg/m2 O
. O

Primary O
end O
point O
was O
overall O
survival O
, O
secondary O
end O
points O
were O
objective O
response O
rate O
( O
ORR O
) O
, O
safety O
, O
symptom O
improvement O
, O
and O
quality O
of O
life O
( O
QOL O
) O
. O

This O
randomised O
multicentre O
trial O
was O
conducted O
to O
establish O
the O
optimal O
duration O
of O
palliative O
chemotherapy O
in O
advanced O
non-small-cell O
lung O
cancer O
( O
NSCLC O
) O
. O

We O
aimed O
to O
assess O
the O
effectiveness O
of O
acupuncture O
for O
cancer-related O
fatigue O
( O
CRF O
) O
in O
patients O
with O
breast O
cancer O
. O

This O
double-blind O
phase O
III O
trial O
randomly O
assigned O
731 O
patients O
with O
NSCLC O
who O
had O
progressed O
after O
prior O
chemotherapy O
to O
erlotinib O
150 O
mg O
daily O
or O
placebo O
, O
with O
survival O
as O
the O
primary O
study O
outcome O
. O

Those O
who O
received O
prednisone O
alone O
could O
have O
mitoxantrone O
added O
after O
6 O
weeks O
if O
there O
was O
no O
improvement O
in O
pain O
. O

We O
developed O
Individual O
Meaning-Centered O
Psychotherapy O
( O
IMCP O
) O
to O
address O
the O
need O
for O
brief O
interventions O
targeting O
spiritual O
well-being O
and O
meaning O
for O
patients O
with O
advanced O
cancer O
. O

Pneumocystis O
carinii O
pneumonia O
prophylaxis O
was O
required O
during O
temozolomide O
+ O
radiotherapy O
treatment O
and O
was O
continued O
until O
recovery O
of O
lymphocytopenia O
( O
Common O
Toxicity O
Criteria O
grade O
< O
1 O
) O
. O

Thirty O
patients O
finalized O
treatment O
. O

Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
2-year O
functional O
performance O
and O
quality O
of O
life O
in O
patients O
with O
operable O
squamous O
cell O
carcinoma O
of O
the O
esophagus O
, O
who O
have O
received O
either O
surgery O
or O
definitive O
chemoradiation O
( O
CRT O
) O
. O

The O
proposed O
sample O
size O
was O
300 O
patients O
. O

A O
cycle O
of O
BEP O
consisted O
of O
etoposide O
500 O
mg/m O
( O
2 O
) O
, O
administered O
at O
either O
100 O
mg/m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
165 O
mg/m O
( O
2 O
) O
days O
1 O
through O
3 O
, O
cisplatin O
100 O
mg/m O
( O
2 O
) O
, O
administered O
at O
either O
20 O
mg/m O
( O
2 O
) O
days O
1 O
through O
5 O
or O
50 O
mg/m O
( O
2 O
) O
days O
1 O
and O
2 O
. O

Patients O
were O
randomized O
to O
receive O
epoetin O
alfa O
40,000 O
U O
subcutaneously O
once O
weekly O
or O
placebo O
at O
the O
beginning O
of O
4 O
cycles O
of O
chemotherapy O
administered O
over O
12 O
weeks O
. O

Time-to-event O
data O
were O
analyzed O
using O
the O
Kaplan-Meier O
method O
, O
and O
a O
stratified O
log-rank O
test O
was O
used O
to O
compare O
distributions O
between O
treatment O
groups O
. O

Patients O
were O
randomly O
assigned O
to O
FU/LV/placebo O
( O
n O
= O
105 O
) O
or O
FU/LV/bevacizumab O
( O
n O
= O
104 O
) O
. O

Patients O
with O
sentinel O
lymph O
node O
metastases O
proceeded O
to O
delayed O
axillary O
clearance O
or O
received O
axillary O
radiotherapy O
( O
depending O
on O
the O
protocol O
at O
the O
treating O
institution O
) O
. O

Patients O
with O
cancer O
are O
characterized O
by O
a O
profound O
impairment O
of O
glucose O
utilization O
, O
with O
lipids O
being O
the O
preferred O
metabolic O
fuel O
. O

Serum O
CA125 O
concentration O
often O
rises O
several O
months O
before O
clinical O
or O
symptomatic O
relapse O
in O
women O
with O
ovarian O
cancer O
. O

To O
determine O
the O
efficacy O
, O
impact O
on O
quality-of-life O
( O
QoL O
) O
and O
tolerability O
of O
two O
different O
irinotecan O
administration O
schedules O
in O
combination O
with O
capecitabine O
as O
first-line O
treatment O
of O
metastatic O
colorectal O
cancer O
. O

QoL O
was O
assessed O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
QLQ-C30 O
questionnaire O
. O

157 O
patients O
in O
the O
90 O
mg O
group O
and O
156 O
in O
the O
30 O
mg O
group O
were O
included O
in O
the O
primary O
analysis O
. O

Only O
patients O
over O
5 O
years O
of O
age O
with O
parameningeal O
disease O
and O
patients O
over O
12 O
years O
with O
tumours O
at O
any O
site O
were O
given O
systematic O
irradiation O
. O

Patients O
randomized O
to O
combination O
therapy O
were O
given O
oral O
13-CRA O
1 O
mg/kg/d O
plus O
IFNalpha2a O
. O

Oestrogen O
only O
therapy O
( O
conjugated O
equine O
oestrogens O
0.625 O
mg O
orally O
daily O
) O
or O
combined O
hormone O
therapy O
( O
conjugated O
equine O
oestrogens O
plus O
medroxyprogesterone O
acetate O
2.5/5.0 O
mg O
orally O
daily O
) O
. O

This O
study O
tested O
the O
efficacy O
of O
a O
caregiver-assisted O
CST O
protocol O
in O
a O
sample O
of O
patients O
with O
lung O
cancer O
. O

This O
prospective O
, O
randomized O
, O
multicentric O
phase O
III O
study O
was O
designed O
to O
compare O
continuous O
( O
CONT O
) O
compared O
with O
interrupted O
( O
INT O
) O
imatinib O
beyond O
1 O
year O
of O
treatment O
in O
patients O
with O
advanced O
GIST O
. O

Gynecomastia O
, O
breast O
pain O
, O
prostate O
specific O
antigen O
, O
QOL O
, O
sexual O
function O
and O
hormonal O
levels O
were O
assessed O
. O

Caloric O
intake O
, O
body O
composition O
( O
dual-energy O
x-ray O
absorptiometry O
) O
, O
and O
respiratory O
gas O
exchanges O
at O
rest O
and O
during O
exercise O
were O
measured O
including O
health-related O
quality O
of O
life O
. O

We O
then O
compared O
the O
FACT-An O
data O
from O
the O
Internet O
survey O
with O
the O
QOL O
data O
of O
a O
375-patient O
randomized O
, O
double-blind O
clinical O
trial O
evaluating O
epoetin O
alfa O
versus O
placebo O
in O
anemic O
cancer O
patients O
. O

Baseline O
LCSS O
scores O
were O
low O
, O
indicating O
low O
symptom O
burden O
for O
patients O
without O
disease O
progression O
after O
completion O
of O
first-line O
treatment O
. O

The O
primary O
outcome O
was O
patient-perceived O
benefits O
, O
using O
the O
emotional O
function O
domain O
of O
the O
EORTC O
quality O
of O
life O
( O
QOL O
) O
QLQC30 O
questionnaire O
evaluated O
after O
12 O
weeks O
. O

Days O
1 O
, O
8 O
, O
and O
15 O
in O
28-day O
cycles O
";" O
G O
arm O
: O
G O
as O
in O
GE O
. O

An O
overall O
intent-to-treat O
analysis O
was O
performed O
. O

Both O
interventions O
were O
carried O
out O
for O
3 O
weeks O
. O

Mixed-effects O
models O
and O
multivariate O
regressions O
were O
used O
to O
examine O
the O
longitudinal O
impact O
of O
the O
intervention O
on O
patient-physician O
communication O
, O
dynamics O
of O
patient-physician O
interaction O
, O
and O
the O
association O
between O
PROs O
and O
the O
content O
of O
clinic O
discussion O
. O

Assessment O
of O
depression O
added O
to O
usual O
care O
probably O
had O
an O
effect O
because O
it O
is O
not O
normally O
a O
focus O
of O
hospice O
staff O
. O

Supportive O
care O
included O
palliative O
radiotherapy O
and O
supportive O
therapy O
with O
corticosteroids O
, O
antibiotics O
, O
analgesics O
, O
antiemetics O
, O
transfusions O
, O
and O
other O
symptomatic O
therapy O
as O
required O
. O

However O
, O
these O
guidelines O
can O
be O
questioned O
with O
regard O
to O
the O
extent O
of O
efficacy O
as O
well O
as O
the O
rationale O
for O
not O
using O
strong O
opioids O
as O
first-line O
treatment O
, O
especially O
in O
terminal O
cancer O
patients O
. O

Outcomes O
included O
safety O
and O
tolerance O
of O
the O
exercise O
program O
, O
physical O
function O
, O
physical O
activity O
level O
, O
body O
composition O
, O
fatigue O
, O
quality O
of O
life O
and O
psychological O
distress O
. O

Treatment O
effect O
was O
assessed O
using O
paired O
t-test O
. O

The O
aim O
of O
this O
study O
was O
to O
compare O
the O
toxicity O
and O
efficacy O
of O
radiation O
therapy O
( O
RT O
) O
for O
localized O
carcinoma O
of O
the O
prostate O
, O
using O
a O
hypofractionated O
( O
55 O
Gy/20 O
fractions/4 O
weeks O
) O
vs. O
a O
conventionally O
fractionated O
( O
64 O
Gy/32 O
fractions/6.5 O
weeks O
) O
dose O
schedule O
. O

The O
primary O
outcome O
, O
Fatigue O
score O
( O
CRF O
) O
, O
was O
evaluated O
by O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Anaemia O
Questionnaire O
( O
FACT-An- O
) O
( O
FACT-G O
score O
& O
FACT-An O
Anemia O
subscale O
) O
. O

Data O
from O
161 O
patients O
have O
been O
analyzed O
. O

Two O
hundred O
thirty-three O
lung O
cancer O
patients O
and O
their O
caregivers O
were O
randomly O
assigned O
to O
receive O
14 O
telephone-based O
sessions O
of O
either O
caregiver-assisted O
CST O
or O
education/support O
involving O
the O
caregiver O
. O

In O
addition O
, O
our O
study O
was O
to O
determine O
whether O
a O
disease-specific O
module O
has O
greater O
sensitivity O
to O
group O
differences O
than O
a O
generic O
QOL O
questionnaire O
and O
to O
determine O
the O
most O
pragmatic O
approach O
to O
treating O
epidemic O
Kaposi O
's O
sarcoma O
( O
EKS O
) O
in O
Zimbabwe O
. O

The O
success O
of O
blinding O
was O
assessed O
using O
a O
mixed-methods O
approach O
. O

To O
test O
the O
hypothesis O
that O
modulation O
of O
Bcl-2 O
with O
13-cis O
retinoic O
acid O
( O
CRA O
) O
/interferon-alpha2b O
( O
IFN O
) O
with O
paclitaxel O
( O
TAX O
) O
, O
or O
mitoxantrone O
, O
estramustine O
and O
vinorelbine O
( O
MEV O
) O
will O
have O
clinical O
activity O
in O
men O
with O
metastatic O
castrate-resistant O
prostate O
cancer O
( O
CRPC O
) O
. O

By O
March O
2007 O
, O
data O
on O
310 O
additional O
deaths O
were O
obtained O
( O
total O
= O
867 O
deaths O
) O
. O

Herein O
, O
we O
report O
results O
of O
an O
open-label O
, O
multicenter O
phase O
II O
mRCC O
study O
of O
sunitinib O
administered O
on O
a O
continuous O
once-daily O
dosing O
regimen O
. O

1046 O
patients O
were O
treated O
( O
449 O
washout O
, O
597 O
direct-switch O
";" O
baseline O
characteristics O
were O
similar O
between O
groups O
) O
. O

Bootstrap O
simulations O
( O
10,000 O
iterations O
) O
were O
conducted O
to O
account O
for O
uncertainty O
, O
and O
sensitivity O
analyses O
were O
conducted O
to O
establish O
robustness O
. O

This O
study O
aimed O
to O
compare O
quality O
of O
life O
( O
QOL O
) O
, O
functional O
outcome O
, O
body O
image O
, O
and O
cosmesis O
after O
hand-assisted O
laparoscopic O
( O
LRP O
) O
versus O
open O
restorative O
proctocolectomy O
( O
ORP O
) O
. O

Gemcitabine O
for O
advanced O
pancreatic O
cancer O
( O
APC O
) O
is O
palliative O
and O
the O
prognosis O
is O
poor O
, O
making O
health-related O
quality O
of O
life O
( O
HRQOL O
) O
particularly O
important O
. O

EORTC O
QLQ-C30 O
was O
administered O
at O
screening O
, O
on O
day O
1 O
of O
each O
cycle O
, O
at O
the O
end-of-treatment O
visit O
, O
and O
every O
8 O
wk O
until O
progression O
. O

Survival O
curves O
were O
calculated O
by O
the O
Kaplan-Meier O
method O
, O
and O
hazard O
ratios O
were O
estimated O
with O
the O
Cox O
proportional O
hazards O
model O
. O

This O
study O
was O
registered O
on O
ClinicalTrials.gov O
. O

One O
hundred O
and O
two O
candidates O
with O
CACS O
were O
randomly O
assigned O
to O
two O
treatment O
groups O
( O
trial O
group O
and O
control O
group O
) O
: O
the O
trial O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
plus O
thalidomide O
( O
50 O
mg O
po O
, O
bid O
) O
, O
while O
the O
control O
group O
received O
MA O
( O
160 O
mg O
po O
, O
bid O
) O
alone O
. O

Training O
efficacy O
was O
not O
modified O
by O
patient O
characteristics O
. O

The O
2-year O
risk O
of O
progression O
for O
baseline O
PSA O
< O
50 O
ng/ml O
, O
50 O
to O
< O
500 O
ng/ml O
, O
and O
≥ O
500 O
ng/ml O
was O
25 O
% O
, O
55 O
% O
, O
and O
76 O
% O
( O
P O
= O
0.03 O
) O
in O
CAD O
, O
and O
38 O
% O
, O
64 O
% O
, O
and O
85 O
% O
( O
P O
= O
0.006 O
) O
in O
IAD O
, O
respectively O
. O

Stimulated O
whole O
( O
SWS O
) O
and O
parotid O
( O
SPS O
) O
saliva O
flow O
were O
measured O
and O
Medical O
Outcomes O
Short O
Form O
36 O
( O
SF-36 O
) O
, O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
( O
EORTC O
) O
core O
quetionnaire O
, O
and O
EORTC O
head-and-neck O
module O
( O
QLQ-H O
& O
amp O
";" O
N35 O
) O
were O
completed O
at O
baseline O
and O
2 O
, O
6 O
, O
and O
12 O
months O
after O
radiotherapy O
. O

Analysis O
of O
the O
primary O
endpoint O
was O
done O
by O
modified O
intention O
to O
treat O
. O

Intention-to-treat O
analyses O
of O
data O
at O
1 O
, O
3 O
, O
6 O
, O
and O
12 O
months O
after O
surgery O
are O
presented O
. O

Safety O
and O
efficacy O
( O
American O
College O
of O
Rheumatology O
( O
ACR O
) O
criteria O
responses O
, O
DAS28 O
( O
C-reactive O
protein O
) O
, O
HAQ-DI O
, O
SF-36 O
, O
Medical O
Outcomes O
Study O
Sleep O
Problems O
Index O
, O
fatigue O
VAS O
) O
were O
assessed O
through O
2 O
years O
. O

Group O
CBT O
comprised O
one O
90 O
min O
session O
a O
week O
for O
6 O
weeks O
, O
and O
included O
psycho-education O
, O
paced O
breathing O
, O
and O
cognitive O
and O
behavioural O
strategies O
to O
manage O
HFNS O
. O

The O
aim O
of O
this O
multicenter O
, O
double-blind O
, O
prospective O
, O
randomized O
trial O
was O
to O
evaluate O
the O
clinical O
efficacy O
of O
an O
economically O
viable O
antimicrobial O
lozenge O
( O
bacitracin O
, O
clotrimazole O
, O
and O
gentamicin O
[ O
BcoG O
] O
) O
in O
the O
alleviation O
of O
radiation-induced O
mucositis O
in O
patients O
with O
head O
and O
neck O
cancer O
. O

To O
determine O
the O
feasibility O
of O
administering O
a O
flavonoid-rich O
adjunctive O
treatment O
( O
Concord O
grape O
juice O
) O
for O
the O
management O
of O
chemotherapy-induced O
nausea O
and O
vomiting O
( O
CINV O
) O
";" O
to O
evaluate O
the O
usefulness O
of O
existing O
measures O
for O
assessing O
CINV O
frequency O
and O
severity O
, O
quality O
of O
life O
, O
control O
over O
life O
events O
, O
and O
psychological O
state O
";" O
to O
identify O
any O
actual O
or O
potential O
adverse O
events O
associated O
with O
frequent O
grape O
juice O
intake O
";" O
and O
to O
provide O
preliminary O
data O
concerning O
the O
effect O
of O
Concord O
grape O
juice O
on O
CINV O
, O
quality O
of O
life O
, O
perceived O
control O
over O
life O
events O
, O
and O
psychological O
state O
. O

Patients O
with O
histologically-proven O
unresectable O
MPM O
, O
not O
pretreated O
with O
chemotherapy O
were O
randomly O
assigned O
to O
receive O
cisplatin O
80 O
mg/m2 O
intravenously O
on O
day O
1 O
, O
with O
or O
without O
preceding O
infusion O
of O
raltitrexed O
3 O
mg/m2 O
. O

Patient O
QOL O
was O
assessed O
using O
the O
Functional O
Assessment O
of O
Cancer O
Therapy-Lung O
and O
the O
UNISCALE O
QOL O
questionnaires O
. O

Patients O
aged O
18-75 O
years O
, O
undergoing O
an O
elective O
laparotomy O
and O
with O
a O
preoperative O
suspicion O
of O
gynecologic O
malignancy O
, O
were O
eligible O
. O

Patients O
undergoing O
UAE O
were O
randomly O
assigned O
to O
receive O
TAGMs O
or O
PVA O
. O

Although O
initial O
pre-trial O
interviews O
revealed O
concerns O
among O
health-care O
professionals O
and O
some O
patients O
regarding O
community O
treatment O
, O
opinions O
were O
largely O
more O
favourable O
in O
post-trial O
interviews O
. O

Promising O
results O
in O
a O
randomized O
phase O
II O
trial O
with O
the O
hypoxic O
cytotoxin O
tirapazamine O
( O
TPZ O
) O
combined O
with O
cisplatin O
( O
CIS O
) O
and O
radiation O
led O
to O
this O
phase O
III O
trial O
. O

A O
further O
aim O
was O
to O
investigate O
the O
role O
of O
high-dose O
chemotherapy O
in O
young O
patients O
with O
parameningeal O
primary O
tumours O
. O

In O
addition O
, O
we O
also O
evaluated O
the O
impact O
of O
rhTSH O
( O
rhTSH O
vs. O
conventional O
thyroid O
hormone O
withdrawal O
) O
on O
quality O
of O
life O
( O
QoL O
) O
of O
thyroid O
cancer O
patients O
undergoing O
RI O
ablation O
. O

This O
includes O
cross-sectional O
comparisons O
, O
together O
with O
a O
global O
test O
for O
the O
QOL O
response O
rate O
. O

To O
assess O
the O
efficacy O
of O
prophylactic O
swallowing O
exercises O
on O
swallowing O
function O
in O
patients O
undergoing O
chemoradiation O
therapy O
( O
CRT O
) O
for O
head O
and O
neck O
cancer O
. O

Patients O
( O
age O
range O
, O
16 O
to O
80 O
years O
) O
had O
tumor O
stage O
T1 O
to O
T3 O
, O
with O
possible O
spread O
to O
nearby O
lymph O
nodes O
but O
without O
metastasis O
. O

The O
study O
was O
designed O
to O
detect O
a O
15 O
% O
improvement O
";" O
that O
is O
, O
from O
50 O
% O
to O
65 O
% O
in O
median O
progression-free O
survival O
( O
PFS O
) O
in O
favor O
of O
the O
dose-intensified O
regimen O
. O

The O
primary O
endpoint O
is O
toxicity O
, O
and O
secondary O
endpoints O
include O
response O
rate O
, O
survival O
outcome O
and O
quality O
of O
life O
( O
QOL O
) O
. O

However O
, O
there O
were O
no O
significant O
differences O
in O
total O
response O
rates O
, O
tumor O
progression O
duration O
, O
and O
median O
survival O
rates O
of O
1 O
and O
2 O
years O
. O

The O
aim O
of O
this O
multicenter O
randomized O
trial O
was O
to O
assess O
the O
efficacy O
and O
safety O
of O
sentinel O
lymph O
node O
( O
SLN O
) O
biopsy O
compared O
with O
axillary O
lymph O
node O
dissection O
( O
ALND O
) O
. O

Patients O
received O
LV O
200 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
followed O
by O
FU O
400 O
mg/m O
( O
2 O
) O
( O
bolus O
) O
and O
FU O
600 O
mg/m O
( O
2 O
) O
( O
22-hour O
continuous O
infusion O
) O
on O
days O
1 O
and O
2 O
every O
14 O
days O
( O
LV5FU2 O
";" O
arm O
A O
) O
, O
LV5FU2 O
plus O
cisplatin O
50 O
mg/m O
( O
2 O
) O
( O
1-hour O
infusion O
) O
on O
day O
1 O
or O
2 O
( O
arm O
B O
) O
, O
or O
LV5FU2 O
plus O
irinotecan O
180 O
mg/m O
( O
2 O
) O
( O
2-hour O
infusion O
) O
on O
day O
1 O
( O
arm O
C O
) O
. O

V325 O
represents O
the O
largest O
trial O
with O
the O
longest O
prospectively O
controlled O
evaluations O
of O
QOL O
during O
protocol O
chemotherapy O
and O
follow-up O
in O
patients O
with O
advanced O
gastric O
or O
gastroesophageal O
junction O
cancer O
. O

Functional O
outcome O
and O
health O
status O
of O
extremity O
STS O
patients O
randomized O
in O
a O
phase O
III O
trial O
comparing O
preoperative O
versus O
postoperative O
RT O
is O
described O
. O

Quality-of-life O
data O
were O
prospectively O
collected O
. O

Patients O
watched O
a O
video O
followed O
by O
about O
20 O
min O
of O
manual-standardized O
training O
with O
an O
oncology O
nurse O
focused O
on O
reviewing O
the O
printed O
material O
and O
adapted O
to O
individual O
concerns O
of O
patients O
. O

All O
parties O
, O
except O
for O
the O
randomisation O
centre O
, O
were O
blinded O
for O
TS O
status O
. O

The O
purpose O
of O
this O
2-group O
randomized O
controlled O
pilot O
feasibility O
study O
was O
to O
test O
short-term O
effects O
of O
a O
12-week O
Mindful O
Movement O
Program O
( O
MMP O
) O
intervention O
combining O
mindfulness O
with O
self-directed O
movement O
on O
QOL O
and O
mindfulness O
in O
female O
BCSs O
50 O
years O
or O
older O
and O
at O
12 O
months O
or O
more O
following O
treatment O
. O

Dose O
escalation O
was O
achieved O
in O
77 O
% O
of O
patients O
who O
had O
≥1 O
cycle O
. O

Sham O
procedures O
were O
used O
to O
blind O
surgeons O
, O
patients O
and O
outcome O
assessors O
. O

Of O
260 O
eligible O
patients O
, O
104 O
( O
40 O
% O
) O
agreed O
to O
participate O
, O
and O
93 O
were O
randomised O
. O

Both O
cross-sectional O
single-time O
and O
change O
from O
baseline O
assessments O
were O
run O
at O
day O
2 O
, O
week O
2 O
, O
month O
2 O
, O
and O
month O
18 O
postoperatively O
in O
an O
intention-to-treat O
analysis O
using O
Wilcoxon O
rank-sum O
tests O
. O

The O
Pain O
Education O
Program O
was O
tailored O
to O
the O
needs O
of O
the O
individual O
patient O
and O
consisted O
of O
three O
elements O
: O
( O
1 O
) O
educating O
patients O
about O
the O
basic O
principles O
regarding O
pain O
and O
pain O
management O
";" O
( O
2 O
) O
instructing O
patients O
how O
to O
report O
their O
pain O
in O
a O
pain O
diary O
";" O
and O
( O
3 O
) O
instructing O
patients O
how O
to O
communicate O
about O
pain O
and O
how O
to O
contact O
health O
care O
providers O
. O

As O
health O
economic O
aspects O
have O
only O
been O
studied O
in O
general O
terms O
, O
we O
estimated O
the O
cost O
of O
GJJ O
and O
that O
of O
stent O
placement O
in O
such O
patients O
. O

All O
living O
Swedish O
and O
Finnish O
men O
( O
400 O
of O
695 O
) O
randomly O
assigned O
to O
radical O
prostatectomy O
or O
watchful O
waiting O
in O
SPCG-4 O
from O
1989 O
to O
1999 O
were O
included O
in O
our O
analysis O
. O

Seventy-two O
patients O
with O
malignant O
ascites O
were O
divided O
into O
two O
study O
groups O
. O

Analysis O
was O
by O
intention O
to O
treat O
. O

Pragmatic O
randomised O
controlled O
prospective O
open O
trial O
. O

After O
written O
informed O
consent O
was O
obtained O
, O
210 O
patients O
with O
liver O
cancer O
were O
randomized O
into O
three O
groups O
of O
70 O
patients O
. O

We O
randomly O
assigned O
patients O
who O
had O
completed O
primary O
cancer O
treatment O
within O
the O
past O
24 O
months O
in O
any O
of O
four O
Korean O
hospitals O
and O
had O
reported O
moderate O
to O
severe O
fatigue O
for O
at O
least O
1 O
week O
to O
participate O
in O
a O
12-week O
, O
Internet-based O
, O
individually O
tailored O
CRF O
education O
program O
or O
to O
receive O
routine O
care O
. O

In O
addition O
, O
tumor B-Claim
response I-Claim
was I-Claim
shown I-Claim
to I-Claim
have I-Claim
a I-Claim
beneficial I-Claim
effect I-Claim
on I-Claim
QoL I-Claim
indicators I-Claim
. I-Claim

Whereas O
patients B-Claim
with I-Claim
early I-Claim
alternating I-Claim
chemotherapy I-Claim
achieve I-Claim
a I-Claim
better I-Claim
subjective I-Claim
adjustment I-Claim
, I-Claim
late B-Claim
alternating I-Claim
chemotherapy I-Claim
allows I-Claim
for I-Claim
a I-Claim
higher I-Claim
RDI I-Claim
of I-Claim
cisplatin I-Claim
, I-Claim
adriamycin I-Claim
and I-Claim
etoposide I-Claim
, I-Claim
which I-Claim
results I-Claim
in I-Claim
a I-Claim
significantly I-Claim
longer I-Claim
median I-Claim
survival I-Claim
of I-Claim
patients I-Claim
with I-Claim
extensive I-Claim
disease I-Claim
. I-Claim

We O
conclude O
that O
three B-Claim
cycles I-Claim
of I-Claim
BEP I-Claim
, I-Claim
with I-Claim
etoposide I-Claim
at I-Claim
500 I-Claim
mg/m I-Claim
( I-Claim
2 I-Claim
) I-Claim
, I-Claim
is I-Claim
sufficient I-Claim
therapy I-Claim
in I-Claim
good-prognosis I-Claim
germ I-Claim
cell I-Claim
cancer I-Claim
and O
that O
the B-Claim
administration I-Claim
of I-Claim
the I-Claim
chemotherapy I-Claim
in I-Claim
3 I-Claim
days I-Claim
has I-Claim
no I-Claim
detrimental I-Claim
effect I-Claim
on I-Claim
the I-Claim
effectiveness I-Claim
of I-Claim
the I-Claim
BEP I-Claim
regimen I-Claim
. I-Claim

At O
present O
, O
the B-Claim
J-pouch I-Claim
remains I-Claim
the I-Claim
benchmark I-Claim
for I-Claim
routine I-Claim
clinical I-Claim
practice I-Claim
, I-Claim
and O
due B-Claim
care I-Claim
( I-Claim
including I-Claim
defunctioning I-Claim
stoma I-Claim
) I-Claim
should I-Claim
be I-Claim
exercised I-Claim
in I-Claim
situations I-Claim
requiring I-Claim
CP I-Claim
. I-Claim

However O
, O
there B-Claim
was I-Claim
a I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
secondary I-Claim
endpoints I-Claim
of I-Claim
clinically I-Claim
assessed I-Claim
OPS I-Claim
and I-Claim
DNA I-Claim
concentration I-Claim
compared I-Claim
with I-Claim
placebo I-Claim
in I-Claim
H I-Claim
& I-Claim
N I-Claim
cancer I-Claim
patients I-Claim
treated I-Claim
with I-Claim
CRT I-Claim
. I-Claim

Given O
the O
substantial O
survival O
benefit O
of O
combined O
treatment O
, O
the B-Claim
increase I-Claim
of I-Claim
symptoms I-Claim
seems I-Claim
acceptable I-Claim
and I-Claim
has I-Claim
little I-Claim
extra I-Claim
effect I-Claim
on I-Claim
quality I-Claim
of I-Claim
life I-Claim
after I-Claim
4 I-Claim
years I-Claim
compared I-Claim
with I-Claim
endocrine I-Claim
treatment I-Claim
alone I-Claim
. I-Claim

Nonetheless B-Claim
, I-Claim
it I-Claim
is I-Claim
apparent I-Claim
that I-Claim
these I-Claim
first-generation I-Claim
regimens I-Claim
must I-Claim
be I-Claim
applied I-Claim
judiciously I-Claim
, I-Claim
and O
thus B-Claim
we I-Claim
view I-Claim
efforts I-Claim
at I-Claim
better I-Claim
patient I-Claim
selection I-Claim
and I-Claim
the I-Claim
development I-Claim
of I-Claim
more I-Claim
tolerable I-Claim
therapies I-Claim
as I-Claim
higher I-Claim
priorities I-Claim
than I-Claim
carrying I-Claim
either I-Claim
of I-Claim
these I-Claim
regimens I-Claim
to I-Claim
phase I-Claim
III I-Claim
evaluation I-Claim
in I-Claim
the I-Claim
cooperative I-Claim
group I-Claim
setting I-Claim
. I-Claim

The B-Premise
quality I-Premise
of I-Premise
life I-Premise
was I-Premise
almost I-Premise
the I-Premise
same I-Premise
between I-Premise
the I-Premise
arms I-Premise
. O

Pain B-Premise
and I-Premise
analgesic I-Premise
scores I-Premise
increased I-Premise
more I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
placebo I-Premise
than I-Premise
in I-Premise
patients I-Premise
who I-Premise
received I-Premise
zoledronic I-Premise
acid I-Premise
, I-Premise
but O
there B-Premise
were I-Premise
no I-Premise
differences I-Premise
in I-Premise
disease I-Premise
progression I-Premise
, I-Premise
performance I-Premise
status I-Premise
, I-Premise
or I-Premise
quality-of-life I-Premise
scores I-Premise
among I-Premise
the I-Premise
groups I-Premise
. I-Premise

Adverse B-Premise
drug I-Premise
reactions I-Premise
were I-Premise
reported I-Premise
in I-Premise
3 I-Premise
% I-Premise
( I-Premise
9 I-Premise
patients I-Premise
) I-Premise
, I-Premise
and O
8 B-Premise
patients I-Premise
were I-Premise
lost I-Premise
to I-Premise
follow-up I-Premise
. I-Premise

Also O
, O
the B-Premise
Kaplan-Meier I-Premise
survival I-Premise
curves I-Premise
of I-Premise
these I-Premise
two I-Premise
groups I-Premise
were I-Premise
not I-Premise
significantly I-Premise
different I-Premise
by I-Premise
log-rank I-Premise
test I-Premise
( I-Premise
p=0.286 I-Premise
) I-Premise
. I-Premise

However O
, O
when B-Premise
compared I-Premise
with I-Premise
sham I-Premise
acupuncture I-Premise
, I-Premise
the I-Premise
reduction I-Premise
by I-Premise
the I-Premise
acupuncture I-Premise
regimen I-Premise
as I-Premise
provided I-Premise
in I-Premise
the I-Premise
current I-Premise
study I-Premise
did I-Premise
not I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
. I-Premise

Moreover O
, O
the B-Premise
meta-analysis I-Premise
of I-Premise
two I-Premise
additional I-Premise
studies I-Premise
involving I-Premise
935 I-Premise
patients I-Premise
showed I-Premise
a I-Premise
significant I-Premise
survival I-Premise
benefit I-Premise
in I-Premise
favor I-Premise
of I-Premise
GEM-CAP I-Premise
( I-Premise
HR I-Premise
, I-Premise
0.86 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0.75 I-Premise
to I-Premise
0.98 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
with I-Premise
no I-Premise
intertrial I-Premise
heterogeneity I-Premise
. I-Premise

Median B-Premise
progression-free I-Premise
survival I-Premise
was I-Premise
9.2 I-Premise
months I-Premise
( I-Premise
FU/LV/bevacizumab I-Premise
) I-Premise
and I-Premise
5.5 I-Premise
months I-Premise
( I-Premise
FU/LV/placebo I-Premise
) I-Premise
";" I-Premise
hazard B-Premise
ratio I-Premise
was I-Premise
0.50 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.0002 I-Premise
. O

Thus O
, O
elderly B-Claim
patients I-Claim
in I-Claim
need I-Claim
of I-Claim
intensified I-Claim
chemotherapy I-Claim
may I-Claim
receive I-Claim
FLOT I-Claim
without I-Claim
compromising I-Claim
patient-reported I-Claim
outcome I-Claim
parameters I-Claim
. I-Claim

In O
contrast O
, O
no B-Premise
significant I-Premise
improvement I-Premise
was I-Premise
observed I-Premise
in I-Premise
Group I-Premise
2 I-Premise
after I-Premise
the I-Premise
exercise I-Premise
program I-Premise
in I-Premise
any I-Premise
of I-Premise
parameters I-Premise
in I-Premise
comparison I-Premise
to I-Premise
the I-Premise
pre-exercise I-Premise
period I-Premise
( I-Premise
P I-Premise
> I-Premise
0.05 I-Premise
) I-Premise
. I-Premise

These B-Claim
results I-Claim
suggest I-Claim
that I-Claim
sexual I-Claim
functioning I-Claim
may I-Claim
require I-Claim
focused I-Claim
assessment I-Claim
by I-Claim
providers I-Claim
, I-Claim
beyond I-Claim
broad I-Claim
QOL I-Claim
assessments I-Claim
, I-Claim
and O
that O
attention B-Claim
to I-Claim
Sexual/Relationship I-Claim
Satisfaction I-Claim
may I-Claim
be I-Claim
critical I-Claim
in I-Claim
the I-Claim
development I-Claim
and I-Claim
implementation I-Claim
of I-Claim
interventions I-Claim
for I-Claim
this I-Claim
cohort I-Claim
of I-Claim
patients I-Claim
. I-Claim

This B-Claim
toxicity I-Claim
profile I-Claim
of I-Claim
GE I-Claim
is I-Claim
similar I-Claim
to I-Claim
GP I-Claim
, I-Claim
but B-Claim
the I-Claim
apparent I-Claim
inferior I-Claim
efficacy I-Claim
may I-Claim
discourage I-Claim
further I-Claim
investigation I-Claim
. O

Expression B-Premise
of I-Premise
somatostatin I-Premise
receptors I-Premise
is I-Premise
found I-Premise
in I-Premise
HCCs I-Premise
, I-Premise
but O
the B-Claim
efficacy I-Claim
of I-Claim
the I-Claim
somatostatin I-Claim
analogue I-Claim
octreotide I-Claim
remains I-Claim
controversial I-Claim
. I-Claim

Thus O
, O
the B-Premise
rate I-Premise
of I-Premise
efficacy I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
combined I-Premise
treatment I-Premise
group I-Premise
( I-Premise
85.36 I-Premise
% I-Premise
";" I-Premise
p I-Premise
< I-Premise
0.05 I-Premise
vs. I-Premise
control I-Premise
group I-Premise
) I-Premise
. I-Premise

In O
addition O
to O
known O
clinical O
factors O
, O
patient-assessed B-Claim
QL I-Claim
variables I-Claim
appear I-Claim
to I-Claim
be I-Claim
prognostic I-Claim
for I-Claim
survival I-Claim
and I-Claim
response I-Claim
to I-Claim
chemotherapy I-Claim
in I-Claim
women I-Claim
with I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
. I-Claim

Systematic B-Claim
assessment I-Claim
is I-Claim
vital I-Claim
to I-Claim
palliative I-Claim
care I-Claim
, O
but O
documentation O
confirming O
completion O
of O
systematic O
assessment O
in O
hospice O
settings O
is O
often O
inadequate O
or O
absent O
. O

The O
decreased O
risk O
occurred O
in O
women O
aged O
49 O
years O
or O
younger O
( O
44 O
% O
) O
, O
50-59 O
years O
( O
51 O
% O
) O
, O
and O
60 O
years O
or O
older O
( O
55 O
% O
) O
";" O
risk B-Premise
was I-Premise
also I-Premise
reduced I-Premise
in I-Premise
women I-Premise
with I-Premise
a I-Premise
history I-Premise
of I-Premise
lobular I-Premise
carcinoma I-Premise
in I-Premise
situ I-Premise
( I-Premise
56 I-Premise
% I-Premise
) I-Premise
or I-Premise
atypical I-Premise
hyperplasia I-Premise
( I-Premise
86 I-Premise
% I-Premise
) I-Premise
and I-Premise
in I-Premise
those I-Premise
with I-Premise
any I-Premise
category I-Premise
of I-Premise
predicted I-Premise
5-year I-Premise
risk I-Premise
. I-Premise

Particularly O
, O
there B-Premise
was I-Premise
no I-Premise
significant I-Premise
difference I-Premise
regarding I-Premise
time I-Premise
to I-Premise
definitive I-Premise
deterioration I-Premise
of I-Premise
global I-Premise
health I-Premise
status/quality I-Premise
of I-Premise
life I-Premise
from I-Premise
baseline I-Premise
( I-Premise
primary I-Premise
endpoint I-Premise
) I-Premise
. I-Premise

Symptom B-Premise
distress I-Premise
was I-Premise
significantly I-Premise
worse I-Premise
for I-Premise
the I-Premise
RP+RT I-Premise
arm I-Premise
compared I-Premise
with I-Premise
the I-Premise
RP I-Premise
alone I-Premise
arm I-Premise
, O
but B-Premise
the I-Premise
treatment I-Premise
arms I-Premise
did I-Premise
not I-Premise
differ I-Premise
with I-Premise
respect I-Premise
to I-Premise
other I-Premise
general I-Premise
measures I-Premise
of I-Premise
HRQL I-Premise
. I-Premise

In O
view O
of O
the O
improvements O
in O
overall O
and O
progression-free O
survival O
noted O
with O
pemetrexed O
maintenance O
therapy O
, O
such B-Claim
treatment I-Claim
is I-Claim
an I-Claim
option I-Claim
for I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non-squamous I-Claim
NSCLC I-Claim
who I-Claim
have I-Claim
not I-Claim
progressed I-Claim
after I-Claim
platinum-based I-Claim
induction I-Claim
therapy I-Claim
. I-Claim

For B-Premise
BT I-Premise
versus I-Premise
RP I-Premise
, I-Premise
there I-Premise
was I-Premise
no I-Premise
difference I-Premise
in I-Premise
bowel I-Premise
or I-Premise
hormonal I-Premise
domains I-Premise
, I-Premise
but O
men B-Premise
treated I-Premise
with I-Premise
BT I-Premise
scored I-Premise
better I-Premise
in I-Premise
urinary I-Premise
( I-Premise
91.8 I-Premise
v I-Premise
88.1 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.02 I-Premise
) I-Premise
and I-Premise
sexual I-Premise
( I-Premise
52.5 I-Premise
v I-Premise
39.2 I-Premise
";" I-Premise
P I-Premise
= I-Premise
.001 I-Premise
) I-Premise
domains I-Premise
, I-Premise
and I-Premise
in I-Premise
patient I-Premise
satisfaction I-Premise
( I-Premise
93.6 I-Premise
v I-Premise
76.9 I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. I-Premise

The B-Premise
rate I-Premise
of I-Premise
stable I-Premise
disease I-Premise
was I-Premise
, I-Premise
however I-Premise
, I-Premise
greater I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
( I-Premise
60.2 I-Premise
% I-Premise
v I-Premise
40.2 I-Premise
% I-Premise
";" I-Premise
P I-Premise
< I-Premise
.001 I-Premise
) I-Premise
. O

Patients B-Premise
on I-Premise
Arm I-Premise
B I-Premise
reported I-Premise
a I-Premise
clinically I-Premise
significant I-Premise
decline I-Premise
in I-Premise
QOL I-Premise
between I-Premise
baseline I-Premise
and I-Premise
week I-Premise
9/10 I-Premise
( I-Premise
.71 I-Premise
s.d I-Premise
. I-Premise
) O
, I-Premise
and I-Premise
a I-Premise
significantly I-Premise
lower I-Premise
level I-Premise
of I-Premise
QOL I-Premise
than I-Premise
Arm I-Premise
A I-Premise
( I-Premise
p I-Premise
= I-Premise
0.01 I-Premise
) I-Premise
. I-Premise

Moreover O
, O
compared B-Premise
with I-Premise
participants I-Premise
reporting I-Premise
no I-Premise
regular I-Premise
exercise I-Premise
during I-Premise
the I-Premise
follow-up I-Premise
period I-Premise
, I-Premise
those I-Premise
reporting I-Premise
regular I-Premise
aerobic I-Premise
and I-Premise
resistance I-Premise
exercise I-Premise
also I-Premise
reported I-Premise
better I-Premise
patient-rated I-Premise
outcomes I-Premise
, I-Premise
including I-Premise
quality I-Premise
of I-Premise
life I-Premise
( I-Premise
adjusted I-Premise
mean I-Premise
difference I-Premise
, I-Premise
9.5 I-Premise
";" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1.2-17.8 I-Premise
";" I-Premise
P I-Premise
= I-Premise
0.025 I-Premise
) I-Premise
. I-Premise

However O
, O
we B-Premise
reported I-Premise
a I-Premise
response I-Premise
rate I-Premise
of I-Premise
43.1 I-Premise
and I-Premise
38.6 I-Premise
% I-Premise
, I-Premise
respectively I-Premise
, I-Premise
in I-Premise
MVP I-Premise
and I-Premise
MVC I-Premise
arm I-Premise
( I-Premise
P=0.59 I-Premise
) I-Premise
and I-Premise
a I-Premise
median I-Premise
survival I-Premise
of I-Premise
10.2 I-Premise
and I-Premise
7.2 I-Premise
months I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
cisplatin I-Premise
and I-Premise
carboplatin I-Premise
arm I-Premise
( I-Premise
P=0.39 I-Premise
) I-Premise
. I-Premise

